<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2606222257
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SAXENDA 6 mg/ml sloution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LIRAGLUTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        887.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BX07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Saxenda<sup>&reg;</sup> is</p><p>Saxenda<sup>&reg;</sup> is a weight loss medicine that contains the active substance liraglutide. It is similar to a natural occurring hormone called GLP-1 that is released from the intestine after a meal. Saxenda<sup>&reg;</sup> works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry. This may help you eat less food and reduce your body weight.</p><p>&nbsp;</p><p>What Saxenda<sup>&reg;</sup> is used for</p><p>Saxenda<sup>&reg;</sup> is used for weight loss in addition to diet and exercise in adults aged 18 and above who have:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a BMI of 30 or greater (obese) or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a BMI of 27 and less than 30 (overweight) and weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood or breathing problems during sleep called &lsquo;obstructive sleep apnoea&rsquo;).</p><p>BMI (Body Mass Index) is a measure of your weight in relation to your height.</p><p>&nbsp;</p><p>You should only continue using Saxenda<sup>&reg;</sup> if you have lost at least 5% of your initial body weight after 12 weeks on the 3 mg/day dose (see section 3 <em>How to use Saxenda<sup>&reg;</sup></em>). Consult your doctor before you continue.</p><p>&nbsp;</p><p>Saxenda can be used in adolescents from the age of 12 to below 18 years with obesity as diagnosed by your doctor.</p><p>&nbsp;</p><p>Consult with your doctor for the use of Saxenda in adolescents aged 12 to below 18 years.</p><p>&nbsp;</p><p>Diet and exercise</p><p>Your doctor will start you on a diet and exercise programme. Stay on this programme while you are using Saxenda<sup>&reg;</sup>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Saxenda<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8ccbd051-6ed5-4ff0-9b6a-5cbafe423fba \* MERGEFORMAT <span
style='mso-element:field-separator'></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to liraglutide or any of the other ingredients of this medicine (listed in section 6 <em>Contents of the pack and other information</em>).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_abd85b17-aa65-4208-a0f4-612365279eeb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Talk to your doctor, pharmacist or nurse before using Saxenda<sup>&reg;</sup>.</p><p>&nbsp;</p><p>The use of Saxenda<sup>&reg;</sup> is not recommended if you have severe heart failure.</p><p>&nbsp;</p><p>There is little experience with this medicine in patients of 75 years and older. It is not recommended if you are 75 years or older.</p><p>&nbsp;</p><p>There is little experience with this medicine in patients with kidney problems. If you have kidney disease or are on dialysis, consult your doctor.</p><p>&nbsp;</p><p>There is little experience with this medicine in patients with liver problems. If you have liver problems, consult your doctor.</p><p>&nbsp;</p><p>This medicine is not recommended if you have a severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease.</p><p>&nbsp;</p><p>If you know that you are due to have surgery where you will be under anesthesia (sleeping), please tell your doctor that you are taking Saxenda&reg;.</p><p>&nbsp;</p><p><strong><em>People with diabetes</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:normal'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2ebde692-c8c6-4446-9c8e-6f39f49e108c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>If you have diabetes, do not use Saxenda<sup>&reg;</sup> as a replacement for insulin.</p><p>&nbsp;</p><p><strong><em>Inflammation of the pancreas</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:normal'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_90cd21b1-777d-4a58-b464-479fcd3e8ca9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Talk to your doctor if you have or have had a disease of the pancreas.</p><p>&nbsp;</p><p><strong><em>Gallbladder Problems: </em></strong></p><p>Saxenda&reg; may cause gallbladder problems including gallstones. Some gallbladder problems need surgery. Call your healthcare provider if you have any of the following symptoms:</p><p>&nbsp;</p><ul><li>pain in your upper stomach (abdomen)</li><li>fever</li><li>yellowing of your skin or eyes (jaundice)</li><li>Clay-colored stools</li></ul><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Inflamed gall bladder and gallstones</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:
normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4e841624-0154-4af2-a327-3cbd262f6ae6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>If you lose substantial weight, you are at a risk of gallstones and thereby inflamed gall bladder. Stop taking Saxenda<sup>&reg;</sup> and contact a doctor immediately if you experience severe pain in your upper abdomen, usually worst on the right side under the ribs. The pain may be felt through to your back or right shoulder. See section 4 <em>Possible side effects.</em></p><p><em>&nbsp;</em></p><p><strong><em>Thyroid disease</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_616873af-543e-4230-bbdd-2e425b385314 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>If you have thyroid disease, including thyroid nodules and enlargement of the thyroid gland, consult your doctor.</p><p>&nbsp;</p><p><strong><em>Heart rate</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_59476314-88a5-4a5f-8d93-d21360502431 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Talk to your doctor if you have palpitations (you feel aware of your heartbeat) or if you have feelings of a racing heartbeat while at rest during Saxenda<sup>&reg;</sup> treatment.</p><p>&nbsp;</p><p><strong><em>Kidney Problems (Kidney Failure):</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9fbc37a2-f7c7-4c74-bc18-bbb5a43ad824 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Saxenda<sup>&reg;</sup> may cause diarrhea, nausea and vomiting leading to loss of fluids (dehydration). Dehydration may cause kidney failure which can lead to the need for dialysis. This can happen in people who have never had kidney problems before. Drinking plenty of fluids may reduce your chance of dehydration. Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away, or if you cannot drink liquids by mouth<strong><em>.</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7ad909ad-055a-457d-9f67-da8e0be0ccdf \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p><em>&nbsp;</em></p><p><strong><em>Loss of fluid and dehydration</em></strong><!--[if supportFields]><b><i style='mso-bidi-font-style:
normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b7302bd5-565d-4185-a054-c1683311c8d2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>When starting treatment with Saxenda<sup>&reg;</sup>, you may lose body fluid or become dehydrated. This may be due to feeling sick (nausea), being sick (vomiting) and diarrhoea. It is important to avoid dehydration by drinking plenty of fluids. Talk to your doctor, pharmacist or nurse if you have any questions or concerns. See section 4 <em>Possible side effects.</em></p><p><em>&nbsp;</em></p><p><strong><em>Depression or thoughts of suicide:</em></strong></p><p>You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings.</p><p>Call your health care provider right away if you have any mental changes that are new, worse, or worry you.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><strong>Children and adolescents</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bd02c4c4-a04e-4938-a67e-6e9e6d6cc1ba \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>The safety and efficacy of Saxenda&reg; in children below 12&nbsp;years of age has not been studied.</p><p>&nbsp;</p><p><strong>Other medicines and Saxenda<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1d69626e-9580-412b-8308-4f82e06ae8b3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor, pharmacist or nurse if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking medicines for diabetes called &lsquo;sulfonylurea&rsquo; (such as glimepiride or glibenclamide) or if you are taking insulin &ndash; you may get low blood sugar (hypoglycaemia) when you use these medicines with Saxenda<sup>&reg;</sup>. Your doctor may adjust the dose of your diabetes medicine to prevent you from getting low blood sugar. See section 4 <em>Possible side effects </em>for the warning signs of low blood sugar. If you adjust your insulin dose your doctor may recommend you to monitor your blood sugar more frequently.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking warfarin or other medicines by mouth that reduce your blood clotting (anticoagulants). More frequent blood testing to determine the ability of your blood to clot may be required.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8b242bc3-ff68-403f-86ef-78ce774166a8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>Do not use Saxenda<sup>&reg;</sup> if you are pregnant, think that you might be pregnant or are planning to have a baby. This is because it is not known if Saxenda<sup>&reg;</sup> may affect the baby.</p><p>Do not breast-feed if you are using Saxenda<sup>&reg;</sup>. This is because it is not known if Saxenda<sup>&reg;</sup> passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5e7a296c-f151-44fd-947e-9e8b8f8c6497 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Saxenda<sup>&reg;</sup> is unlikely to affect your ability to drive and use machines. If you need any further information, talk to your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Saxenda<sup>&reg;</sup> exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>Your doctor will start you on a diet and exercise programme. Stay on this programme while you are using Saxenda<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>How much to inject</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9d242e0b-eb12-4215-baea-c55d9b11d718 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Your treatment will start at a low dose which will be gradually increased over the first five weeks of treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you first start using Saxenda<sup>&reg;</sup>, the starting dose is 0.6 mg once a day, for at least one week.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should increase your dose by 0.6 mg each week until you reach the recommended dose of</p><p>3.0 mg once a day.</p><p>&nbsp;</p><p>Your doctor will tell you how much Saxenda<sup>&reg;</sup> to use each week. Usually, you will be told to follow the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Dose injected</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 1</strong></p></td><td style="vertical-align:top"><p>0.6 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 2</strong></p></td><td style="vertical-align:top"><p>1.2 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 3</strong></p></td><td style="vertical-align:top"><p>1.8 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 4</strong></p></td><td style="vertical-align:top"><p>2.4 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 5 onwards</strong></p></td><td style="vertical-align:top"><p>3.0 mg once a day</p></td></tr></tbody></table><p>&nbsp;</p><p>Once you reach the recommended dose of 3.0 mg in week 5 of treatment, keep using this dose until your treatment period ends. Do not increase your dose further.</p><p>&nbsp;</p><p>Your doctor will assess your treatment on a regular basis.</p><p>&nbsp;</p><p>Adolescents (&ge;&nbsp;12 years)</p><p>For adolescents from the age of 12 to below 18&nbsp;years old a similar dose escalation schedule as for adults should be applied (see above table for adults). The dose should be increased until 3.0&nbsp;mg (maintenance dose) or maximum tolerated dose has been reached. Daily doses higher than 3.0&nbsp;mg are not recommended.</p><p>&nbsp;</p><p><strong>How and when to use Saxenda<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f44e1d22-a47b-4242-86d3-cdf2755aab10 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you use the pen for the first time, your doctor or nurse will show you how to use the pen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can use Saxenda<sup>&reg;</sup> at any time of the day, with or without food and drink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Saxenda<sup>&reg;</sup> at about the same time each day &ndash; choose a time of the day that works best for you.</p><p>&nbsp;</p><p><strong>Where to inject</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_96b19bc0-630b-4ed6-b210-0e111bf7dcb5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Saxenda<sup>&reg;</sup> is given as an injection under the skin (subcutaneous injection).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The best places to inject are the front of your waist (abdomen), the front of your thighs or your upper arm.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change the place where you inject each day to reduce the risk of developing lumps.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not inject into a vein or muscle.</p><p>&nbsp;</p><p>Detailed instructions for use are provided on the other side of this leaflet.</p><p>&nbsp;</p><p><strong>People with diabetes</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_babc7148-f574-4c52-80be-b43feeadb1f7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_21" o:spid="_x0000_s1026"
 style='position:absolute;margin-left:35.4pt;margin-top:188.75pt;width:.7pt;
 height:25.3pt;z-index:251659264;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:page;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="black" stroked="f">
 <w:wrap anchorx="page" anchory="page"/>
</v:rect><![endif]--><img width="1" height="34" src="file:///C:/Users/ABBD/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Tell your doctor if you have diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not mix Saxenda<sup>&reg;</sup> up with other medicines that you inject (e.g. insulins).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Saxenda<sup>&reg;</sup> in combination with other medicines that contain GLP-1 receptor agonists (such as exenatide or lixisenatide).</p><p>&nbsp;</p><p><strong>If you use more Saxenda<sup>&reg;</sup> than you should</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_618e1dca-16fd-46b0-a34d-13aacc612eeb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>If you use more Saxenda<sup>&reg;</sup> than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you. You may need medical treatment. The following effects may happen:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia). Please refer to &lsquo;Common side effects&rsquo; for warning signs of low blood sugar.</p><p>&nbsp;</p><p><strong>If you forget to use Saxenda<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_af1af15c-2144-4a80-85f8-7b79b0659794 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget a dose and remember it within 12 hours from when you usually take the dose, inject it as soon as you remember.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, if more than 12 hours have passed since you should have used Saxenda<sup>&reg;</sup>, skip the missed dose and inject your next dose the following day at the usual time.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use a double dose or increase the dose on the following day to make up for the missed dose.</p><p>&nbsp;</p><p><strong>If you stop using Saxenda<sup>&reg;</sup></strong><!--[if supportFields]><b><sup><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b1fafdcc-b527-4a45-a5ef-1ee608af8456 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Do not stop using Saxenda<sup>&reg;</sup> without talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e0a98c55-b393-413f-800e-e50d0f0602ad \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_20" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:72.75pt;
  margin-top:11pt;width:429pt;height:171pt;z-index:-15728640;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAYw0b8bgFAAA6EwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWNtu2zgQfV9g/2GgpxaobfmWOkad
InWSokCaBnH6AQxFW0QoUktSvrTYf99DyorVpNhiu7svRRzEJjXUcOZw5sxIb95uC0VrYZ00epb0
u2lCQnOTSb2aJZ9vLzqThJxnOmPKaDFLdsIlb09+/+0Nm64sK3PJCRq0m7JZkntfTns9x3NRMNc1
pdCQLY0tmMfUrnqZZRtoLlRvkKZHvYJJnZwcVJ0xz6iy8idUKcPvRTZnes0cVCo+bV/Z26j4v9fM
pnr93paL8toGy/nV+tqSzGYJkNOsAERJby/YL8O09+iu1UHBdmmLsN4sl7SdJceD4fFgnNBuloyP
0+NhP63Via0nDvl4NJoMU+zFsWLQf91/jUm9Yf7p71Xw/PwHSmBmbQ4GLRNdGQzU66c+j/qN07fB
wHdmS4PGnKu4nvwWVxFZ8ZxdeYlzcqTNPGd6JU6tNZtcsMyFFTVQQLTeKILW7OmAN91tPpoMCLPK
m6jvPwLvwW82La3z74UpKAxmiRXcx53Y+tL52sBmSQTFXEilIv5K0wbnN8bpBYkzSmZBGCd2dTdX
ltZMIVDiZ+/tN8sK6YUlJYtZMnlYxKYBoHOdxV08k6oew2ilg3IgD9v2ozp9viJ0zifnk1FnNDg6
74zSs7PO6cV81Dm66L8enw3P5vOz/p/Bzv5omsssEzqY2qRyf/QkTwrJrXFm6bvcFD0Eq+SiSWck
cz89JPM3Lrm25xfx89Tz3rdmxHyBV81v9A7uhhgIbvrtIkZkCK1sF67c4RfxYQ2ODLkBPvOf8LVU
BkfClSwTyo398vhaWAdPIUloAzabJe6PilmRkPqgEZJQ5ZuBbQZ3zYBpjltniU+oHs49ZrinKq1c
5dBcB702p4jXpdyHT21rsFo5v/A7JeLBRo9CkBfMXiKO0kkKGsDkJuiMy/Wi5GHgSn7tXR1M/cFR
TLgYDQf5O7F8vHI4GjfIl/wgP13G0GnrbBTiWpRC9x75CL+FkQrZO0uE7nxeoD58gat98FDYUiyX
yJk6WeAi81KT35ViyTgy91YWwtGV2NCNKZhOqGTaOAjSAf6O0mE6Tkf4H2A0glR6nl+wQiqwXR+l
iOfMOhFPOaIm2P+mHF7D0+CSP7mR7p7Mkny+s0ZmNO9wgXTxVWGsC+xex2pcLXR2zSy7aaP0/t0v
jNLB4ZiwdSAH3NrRjDrVRHM/nYwne5JsR+JDTLfi7zlOf5gE7Ti9lJatVOVlJoizyiHXMqRXJxPo
xUDyHkyVkbeC+QKzTlZZJKjRrQXfDXFi6D6U1JIzpXZkhRJrBm1iWxpXWWyDLL8zPqdV2Me6kCxQ
7eJ+qB2iSx88SUeVvtdmg1KZC5+j2C3YFnewxtrv7v4K2rmqQk9KhcgqpZjdPeQiZ5ZLDTahFx9v
5y/DYsorkIt7RcxhmainjdVcBOPUAamO1FnFRYbyESH6rg2UQ5c2nu6E0I8y/gesSODRWdKpI/6X
pEf6Z4D8smUiE+jfCqlF1n2EyIEjD6XzuSi0i8LREM81sYNAuhxo/7ko/FRn1C4KDcWCfbnR3uKh
OwORezAeqLJEAUApcLSRoG9GJdjbaKbIWFrGzoty6bwB44I2wbCR0p/c+LFSXpZK0LnODLfIAXR5
plTMSUZupzNrChF7NRqAqM+vaPCyS3NTaSfUwQgrVsxGog+8XRoP0ySMsfsGLOwfDUVtC/Y0voWy
JnV41RAIvwgitytKb4pYihpKrxs2eiG6qy6qA9prF0tX2EwLfv+Ksp0rc7aSrB5qgUGABBCE8pmb
0H9q4RysvzGotHC0MFoCoFCewr7CVgXqmeK4qAEUgKxcEDZWACrLHFyHzdG8SnM8ieBcQk9fCYIf
JJhFpQ2MwkOFbsBvAx/rOE4xArJH4pl4HtrvphsN7fnDkyLiZlHeAFM8PkRBeJTEILzj6D16axQF
+7dc4dVUe37yFwAAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAABjbGlwYm9hcmQv
dGhlbWUvdGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thrz9rTjD3WzGzS
vaH2iISEKIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/LV+7FDB0QISlP
el79Ys1DJPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJxyIYRyQmCBglcg33vEip
dG1lRfpAxvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyGDP4lSmqCz8SeZkNQgmOQ
fnM6pT4x2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0wtjRuZP6ycdmA
YL9hZIpwUgitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ96DWrrVcfIl/
c0nnbr/fb3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZaLt6AIkaT/SW0
DuholHEvIFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4omSM1TMsU+5OQAxxNBsRaA
1wgufbEkXy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6/6Nl5IzawklYHvXi28/+
fPQx+uPJNy8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797WAHfEHhSho9pTCS6QQ7R
Lo/BMOMVV3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68LaB9VAGvzu46Cu9FYqZo
heRrUewAtzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFEHDV3GE4UDklC
FNLf+D4hFdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni7fhm+zbqc1Zl9SY5cJFQ
FZhVKD8mzHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwtBf0aho5VGfZt
No9dpFB0v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw36bECffp3eAW
DR2VFgmiv8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD5qSqStg61n5Pwh1vugMu
Avr299xNPEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR4xNXyFPK2J6aM3JdmkWy
hHkiGAFRjzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1KFHKJWzsDLmSt8bDIl3Z
bWFbbxhsP5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6VurM0upGNdPqHGmFyRDD
ZdOAWHgTFiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8V8xJAORORYz0
Ju8Ur5WkdTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjzuu1G20M+TnveFPa08Bin
EHWp13yYhXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKAJVqS1b/RBree
lwE2019Di+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJmYhdD+HWqgj0BlXA0YTqC
foFzNO1t88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiSPydTymn8PzNF
zydwUtAMdAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI5leQA/1ra87yMGUNGz61
S0MkKMxHKhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7bPRRBqptukrUBgzuef+57
VkGTUC9yyvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq5VUBwkpTQTcr
+9dU4RWnWtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZQdpAVl+wCw+k
G6QlTmDhZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xTi+fp7MzDjq8t7URXQ2SP
lyiQpvlGxgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQU+C7pRSYZk5p
5phWTmnllHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/BQAA//8DAFBLAwQUAAYA
CAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54
bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7Iz
eWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpE
fUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwG
MwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAA
AAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIB
AAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBjDRvxuAUAADoT
AAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0A
FAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAAAAAAAAAAAAAAAAFQgAAGNsaXBib2FyZC90aGVtZS90
aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAHA8AAGNs
aXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAAAf
EAAAAAA=
" filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.45pt;margin-right:0in;margin-bottom:
     0in;margin-left:7.15pt;margin-bottom:.0001pt;line-height:12.6pt;
     mso-line-height-rule:exactly'><span lang=EN-US>Risk of thyroid C-cell
     tumors<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:8.55pt;margin-bottom:
     0in;margin-left:7.1pt;margin-bottom:.0001pt'><span lang=EN-US>Liraglutide
     causes dose-dependent and treatment-duration-dependent thyroid C-cell
     tumors at clinically relevant exposures in both genders of rats and mice.
     It is unknown whether Saxenda causes thyroid C-cell tumors, including
     medullary thyroid carcinoma (MTC), in humans, as the human relevance of
     liraglutide-induced rodent thyroid C-cell tumors has not been<span
     style='letter-spacing:-.05pt'> </span>determined.<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:12.9pt;margin-bottom:
     0in;margin-left:7.1pt;margin-bottom:.0001pt'><span lang=EN-US>Saxenda is
     contraindicated in patients with a personal or family history of MTC and
     in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
     Counsel patients regarding the potential risk of MTC with use of Saxenda
     and inform them of symptoms of thyroid tumors (e.g., a mass in the neck,
     dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum
     calcitonin or using thyroid ultrasound is of uncertain value for early
     detection of MTC in patients treated with Saxenda.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:603px"><tbody><tr><td style="width:103px">&nbsp;</td></tr><tr><td style="width:103px">&nbsp;</td><td style="width:397px"><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Risk of thyroid C-cell tumors</p><p>Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda&reg; causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.</p><p>Saxenda&reg; is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda&reg; and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda&reg;.</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Some severe allergic reactions (anaphylaxis) have been reported rarely in patients using Saxenda<sup>&reg;</sup>. You should see your doctor straight away if you get symptoms such as breathing problems, swelling of face and throat and a fast heartbeat.</p><p>&nbsp;</p><p>Cases of inflammation of the pancreas (pancreatitis) have been reported uncommonly in patients using Saxenda<sup>&reg;</sup>. Pancreatitis is a serious, potentially life-threatening medical condition.</p><p>Stop taking Saxenda<sup>&reg;</sup> and contact a doctor immediately if you notice any of the following serious side effects:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).</p><p>&nbsp;</p><p><strong>Other side effects</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_814b033b-1516-414f-ae93-636b76338d9c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p><strong>Very common: </strong>may affect more than 1 in 10 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea), being sick (vomiting), diarrhea, constipation, headache &ndash; these usually go away after a few days or weeks.</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems affecting the stomach and intestines, such as indigestion (dyspepsia), inflammation in the lining of the stomach (gastritis), stomach discomfort, upper stomach pain, heartburn, feeling bloated, wind (flatulence), belching and dry mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak or tired</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changed sense of taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping (insomnia). This usually occurs the first 3 months of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reactions (such as bruising, pain, irritation, itching and rash)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar (hypoglycaemia). The warning signs of low blood sugar may come on suddenly and can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick, feeling very hungry, changes in vision, feeling sleepy, feeling weak, being nervous, being anxious, confusion, difficulty concentrating and shaking (tremor). Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of pancreatic enzymes, such as lipase and amylase.</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of fluids (dehydration). This is more likely to occur at the start of treatment and may be due to being sick (vomiting), feeling sick (nausea) and diarrhea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delay in the emptying of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflamed gall bladder</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including skin rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling generally unwell</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Faster pulse.</p><p>&nbsp;</p><p><strong>Rare: </strong>may affect up to 1 in 1,000 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced kidney function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney failure. Signs may include reduction in urine volume, metallic taste in mouth and easily bruising.</p><p>&nbsp;</p><p><strong>Not known</strong>:</p><ul><li>Bowel obstruction.</li><li>Lumps under the skin may be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known).</li></ul><p>&nbsp;</p><p><strong>Reporting of side effects</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c7898e3c-eeac-48bd-bac4-70b2058e0e66 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b9d6fe3e-9c60-4ded-9acc-7d1bcf60dfa0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><table border="1" cellspacing="1" cellpadding="1" style="width:326px"><tbody><tr><td style="width:323px"><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Do not use Saxenda<sup>&reg;</sup> after the expiry date which is stated on the pen label and carton after &lsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Before first use</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze. Keep away from the freezer compartment.</p><p>&nbsp;</p><p>Once you start using the pen</p><p>You can keep the pen for 1 month when stored at a temperature below 30&deg;C or in a refrigerator (2&deg;C to 8&deg;C). Do not freeze. Keep away from the freezer compartment. When you are not using the pen, keep the pen cap on in order to protect it from light. Do not use this medicine if the solution is not clear and colourless or almost colourless.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Saxenda<sup>&reg;</sup> contains</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is liraglutide. 1 ml solution for injection contains 6 mg liraglutide. One pre-filled pen contains 18 mg liraglutide.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Saxenda® looks like and contents of the pack
Saxenda® is supplied as a clear and colourless or almost colourless solution for injection in a pre-filled pen. Each pen contains 3 ml solution and is able to deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg. Saxenda® is available in pack sizes containing 1, 3 or 5 pens. Not all pack sizes may be marketed. Needles are not included.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p><p><em>Saxenda<sup>&reg;</sup>, NovoFine<sup>&reg;</sup> and NovoTwist<sup>&reg;</sup> are trademarks owned by Novo Nordisk A/S, Denmark.</em></p><p><em>&nbsp;</em></p><p>&copy; 2025</p><p>Novo Nordisk A/S</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>This is a Medicament</p><p>-&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.</p></td></tr></tbody></table><p><strong>Council of Arab Health Ministers</strong></p><p><strong>Union of Arab Pharmacists</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما المقصود بالدواء ساكسِندا<sup>&trade;</sup></strong></p><p dir="RTL">ساكسِندا<sup>&trade;</sup> عبارة عن دواء لإنقاص الوزن يحتوي على المادة الفعالة ليراجلوتايد. تُشبه هذه المادة هرموناً طبيعياً يسمى جي إل بي -1 يُفرز من الأمعاء بعد تناول الطعام. يعمل ساكسِندا<sup>&trade;</sup> على المستقبلات الموجودة في الدماغ والتي تتحكم في الشهية، مما يسبب لك الشعور بالشبع ويقلل الرغبة في تناول الطعام. وقد يساعدك هذا على تقليل الحاجة إلى تناول الطعام وبالتالي إنقاص وزن الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استعمال ساكسِندا<sup>&trade;</sup></strong></p><p dir="RTL">يُستعمل ساكسِندا<sup>&trade;</sup> لإنقاص الوزن بالإضافة إلى اتباع حمية غذائية وممارسة الرياضة البالغين من عمر 18 سنة فما فوق والذين لديهم:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مؤشر كتلة جسم 30 أو أكثر (سمنة) أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مؤشر كتلة الجسم 27 وأقل من 30 (وزن زائد) مع وجود مشاكل صحية مرتبطة بالوزن (مثل السكري وارتفاع ضغط الدم ومستويات الدهون غير الطبيعية في الدم أو مشاكل التنفس أثناء النوم تسمى &quot;انقطاع النفس الانسدادي النومي&quot;).</p><p dir="RTL">مؤشر كتلة الجسم هو مقياس لوزن جسمك بالنسبة إلى طولك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تستمر فقط في استعمال ساكسِندا<sup>&trade;</sup> إذا كنت قد فقدت 5% على الأقل من وزن الجسم الأوّلي بعد 12&nbsp; أسبوعاً من استخدام جرعة 3 ملجم/اليوم (انظر القسم 3 <em>كيفية استخدام ساكسِندا<sup>&trade;</sup></em>). استشر طبيبك قبل الاستمرار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام ساكسِندا<sup>&trade;</sup> لدى المراهقين من سن 12 إلى أقل من 18 عامًا ويعانون من السمنة على حسب تشخيص طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك لاستخدام ساكسِندا<sup>&trade;</sup> في المراهقين الذين تتراوح أعمارهم بين 12 إلى أقل من 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمية الغذائية وممارسة الرياضة</strong></p><p dir="RTL">سيطلب منك الطبيب اتباع حمية غذائية وبرنامج رياضي معين. يجب الاستمرار في هذا البرنامج أثناء استخدام ساكسِندا<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحظر استعمال ساكسِندا في الحالات التالية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:12.0pt;
mso-ansi-font-size:11.0pt'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span style='font-size:
12.0pt;mso-ansi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-weight:bold'>VAULT_ND_0d893d6d-b2d4-4f95-95fd-ca3a4ada34ca
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-size:12.0pt;mso-ansi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية تجاه مادة ليراجلوتايد أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6 <em>محتويات العبوة ومعلومات أخرى</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:12.0pt;
mso-ansi-font-size:11.0pt'><span style='mso-element:field-begin'></span> </span></b><span
dir=LTR style='mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span style='font-size:
12.0pt;mso-ansi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-weight:bold'>VAULT_ND_f25ef4ed-548c-42fb-a80c-8473ec805372
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-size:12.0pt;mso-ansi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">استشر الطبيب أو الصيدلي أو الممرضة قبل استخدام ساكسِندا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُوصى باستعمال ساكسِندا إذا كنت تعاني من قصور شديد في القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد تجارب قليلة متوفرة حول استعمال هذا الدواء مع المرضى في عُمر 75 سنة فما&nbsp; فوق. ولذلك لا يوصى باستعماله إذا كنت تبلغ من العمر 75 سنة أو أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد تجارب قليلة متوفرة حول استعمال هذا الدواء مع المرضى الذين يعانون من مشاكل في الكلى. فإذا كنت مصاباً بمرض في الكلى أو تخضع لغسيل للكلى، فيجب عليك استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد تجارب قليلة متوفرة حول استعمال هذا الدواء مع المرضى الذين يعانون من مشاكل في الكبد. فإذا كنت تعاني من مشاكل في الكبد، فيجب عليك استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُنصح باستعمال هذا الدواء إذا كنت تعاني من مشكلة شديدة في المعدة أو الأمعاء تؤدي إلى إفراغ المعدة المتأخر (خزل المعدة)، أو إذا كنت مصاباً بمرض التهاب الأمعاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعلم أنك ستخضع لعملية جراحية ستكون فيها تحت تأثير التخدير (نائم)، فيُرجى إخبار طبيبك بأنك تستخدم عقار ساكسِندا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>مرضى السكري</em></strong></p><p dir="RTL">إذا كنت مريضاً بمرض السكري، فلا تستعمل ساكسِندا<sup> </sup>كبديل للإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>التهاب البنكرياس</em></strong></p><p dir="RTL">تحدث إلى طبيبك إذا كنت مصاباً بمرض في البنكرياس حالياً أو سابقاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>مشاكل المرارة</em></strong></p><p dir="RTL">قد يسبب ساكسِندا مشاكل في المرارة بما في ذلك حصوات المرارة وقد تحتاج بعض مشاكل المرارة إلى الجراحة. اتصل بطبيبك إذا كان لديك أي من الأعراض التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; ألم في الجزء العلوي من معدتك (البطن)</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&bull; اصفرار بشرتك أو عينيك (اليرقان)</p><p dir="RTL">&bull; براز بلون الطين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>التهاب المرارة وحصوات المرارة</em></strong></p><p dir="RTL">إذا فقدت قدراً كبيراً من الوزن، فقد تكون معرضاً لخطر الإصابة بحصوات في المرارة، وبالتالي التهاب المرارة. يجب عليك التوقف عن استعمال ساكسِندا والاتصال بالطبيب فوراً إذا كنت تعاني من ألم شديد في الجزء العلوي من البطن، وعادة ما يكون بدرجة أسوأ عند الجانب الأيمن أسفل القفص الصدري. ويمكن الشعور بالألم في الظهر أو الكتف الأيمن. اطلع على قسم 4، <em>الآثار الجانبية المحتملة</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>مرض الغدة الدرقية</em></strong></p><p dir="RTL">إذا كنت مصاباً بمرض الغدة الدرقية، بما في ذلك العقيدات الدرقية وتضخم الغدة الدرقية، يجب عليك استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>معدل ضربات القلب</em></strong></p><p dir="RTL">تحدث إلى طبيبك إذا كنت تعاني من خفقان (تشعر بنبض قلبك بشكل واضح) أو إذا كنت تشعر بسرعة ضربات القلب أثناء الراحة خلال استعمال ساكسِندا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>مشاكل الكلى (الفشل الكلوي)</em></strong></p><p dir="RTL">قد يسبب ساكسِندا الإسهال والغثيان والقيء مما يؤدي إلى فقدان السوائل (الجفاف). قد يؤدي الجفاف إلى فشل كلوي يمكن أن يؤدي إلى الحاجة إلى غسيل الكلى. يمكن أن يحدث هذا في الأشخاص الذين لم يسبق لهم أن عانوا من مشاكل في الكلى من قبل. قد يؤدي شرب الكثير من السوائل إلى تقليل فرصتك في الإصابة بالجفاف. اتصل بطبيبك على الفور إذا كنت تعاني من غثيان أو قيء أو إسهال لا يختفي ، أو إذا كنت لا تستطيع شرب السوائل عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>فقدان سوائل الجسم والجفاف</em></strong></p><p dir="RTL">عند بدء العلاج بدواء ساكسِندا، قد تفقد سوائل الجسم أو تُصاب بالجفاف. وقد يكون ذلك بسبب الشعور بالمرض (الغثيان والقيء والإسهال). ولذلك يجب الحرص على عدم الإصابة بالجفاف عن طريق شرب الكثير من السوائل<strong>. </strong>كما يجب التحدث مع الطبيب أو الصيدلي أو الممرضة إذا كانت لديك أي أسئلة أو مخاوف. اطلع على قسم 4، <em>الآثار الجانبية المحتملة</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الاكتئاب أو أفكار الانتحار</em></strong></p><p dir="RTL">يجب أن تنتبه لأي تغيرات عقلية ، خاصة التغيرات المفاجئة في مزاجك أو سلوكك أو أفكارك أو مشاعرك.</p><p dir="RTL">اتصل بطبيبك على الفور إذا كان لديك أي تغييرات عقلية تقلقك أو تغييرات عقلية جديدة .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم يدرس أمان وفعالية ساكسِندا لدى الأطفال دون سن 12 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وساكسِندا</strong></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى في المستقبل.</p><p dir="RTL">كما يُرجى إخبار طبيبك أو الصيدلي أو الممرضة إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تستعمل أدوية للسكري تسمى &quot;سالفونيل يوريا&quot; (مثل جليمبيرايد أو جليبنكلاميد) أو إذا كنت تتناول الإنسولين - فقد تتعرض لانخفاض نسبة السكر في الدم عند استخدام هذه الأدوية مع ساكسِندا. وقد يقوم الطبيب بتعديل جرعة دواء السكري لمنعك من الإصابة بانخفاض نسبة السكر في الدم. راجع القسم 4 <em>الآثار الجانبية المحتملة</em> لمعرفة العلامات التحذيرية لانخفاض نسبة السكر في الدم. إذا قمت بتعديل جرعة الإنسولين، فقد يوصي طبيبك بمراقبة نسبة السكر في الدم لديك بمعدل أكبر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول الوارفارين أو أدوية أخرى تؤخذ عن طريق الفم وتقلل من تخثر الدم (مضادات التخثر). فقد تكون هناك حاجة لإجراء مزيد من الفحوصات الدموية لتحديد مستوى قدرة دمك على التخثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب عدم استخدام ساكسِندا إذا كنتِ حاملاً أو قد تكوني حاملاً أو تخططين للحمل. لأنه من غير المعروف ما إذا كان ساكسِندا له تأثير على الجنين أم لا.</p><p dir="RTL">ويجب عليكِ عدم الرضاعة الطبيعية إذا كنتِ تستخدمين ساكسِندا. لأنه من غير المعروف ما إذا كان ساكسِندا ينتقل إلى لبن الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b style='mso-ansi-font-weight:normal'><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span style='font-size:
12.0pt;mso-ansi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-bidi-font-weight:bold'>VAULT_ND_f0c40554-97f4-4e3b-ac39-c633def728bb
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-size:12.0pt;mso-ansi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">من غير المحتمل أن يؤثر ساكسِندا على القيادة واستخدام الآلات. إذا كانت لديك أي استفسارات أخرى استشر طبيبك أو الصيدلي أو الممرضة.<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> </span><span dir=LTR>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='font-size:12.0pt;mso-ansi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> </span><span dir=LTR>VAULT_ND_acf542c0-21be-420e-8e1c-18d0edcd523d
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام ساكسِندا دوماً وفق إرشادات طبيبك. ويجب استشارة طبيبك أو الصيدلي أو الممرضة في حالة عدم التأكد من طريقة الاستخدام.</p><p dir="RTL">سيطلب منك الطبيب اتباع حمية غذائية وبرنامج رياضي معين. يجب الاستمرار في هذا البرنامج أثناء استخدام ساكسِندا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مقدار الجرعة</strong></p><p dir="RTL">للبالغين</p><p dir="RTL">يبدأ العلاج بأخذ جرعة منخفضة، ثم تزداد الجرعة تدريجياً خلال الأسابيع الخمس الأولى من العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند البدء في استخدام ساكسِندا لأول مرة، تكون الجرعة المبدئية 0.6 ملجم مرة واحدة في اليوم لمدة أسبوع واحد على الأقل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب زيادة الجرعة بمقدار 0.6 ملجم كل أسبوع حتى تصل إلى الجرعة الموصى بها والتي قدرها 3.0 ملجم، مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك بمقدار الجرعة التي تأخذها من ساكسِندا كل أسبوع. عادةً سيطلب منك طبيبك إتباع الجدول التالي.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>الأسبوع</strong></p></td><td><p dir="RTL"><strong>الجرعة المحقونة</strong></p></td></tr><tr><td><p dir="RTL"><strong>الأسبوع الأول</strong></p></td><td><p dir="RTL">0.6 ملجم مرة واحدة في اليوم</p></td></tr><tr><td><p dir="RTL"><strong>الأسبوع الثاني</strong></p></td><td><p dir="RTL">1.2 ملجم مرة واحدة في اليوم</p></td></tr><tr><td><p dir="RTL"><strong>الأسبوع الثالث</strong></p></td><td><p dir="RTL">1.8 ملجم مرة واحدة في اليوم</p></td></tr><tr><td><p dir="RTL"><strong>الأسبوع الرابع</strong></p></td><td><p dir="RTL">2.4 ملجم مرة واحدة في اليوم</p></td></tr><tr><td><p dir="RTL"><strong>الأسبوع الخامس وما بعده</strong></p></td><td><p dir="RTL">3.0 ملجم مرة واحدة في اليوم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">عند الوصول إلى الجرعة الموصى بها 3.0 ملجم في الأسبوع الخامس، يجب الاستمرار في هذه الجرعة حتى نهاية مدة العلاج. فلا تأخذ جرعة زائدة عن هذه الجرعة.</p><p dir="RTL">سيقوم طبيبك بتقييم مدى فعالية علاجك بصفة منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المراهقين (من عمر 12 عامًا أو أكبر)</p><p dir="RTL">بالنسبة للمراهقين الذين تتراوح أعمارهم بين 12 إلى أقل من 18 عامًا، يجب تطبيق جدول زمني مماثل لتصعيد الجرعة كما هو الحال بالنسبة للبالغين (اطّلِع على الجدول أعلاه للبالغين). يجب زيادة الجرعة حتى 3.0 ملجم (جرعة مداومة) أو الوصول إلى أقصى جرعة يمكن تحملها. ولا يُوصى باستخدام جرعات يومية أعلى من 3.0 ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام ساكسِندا ومواعيد أخذ الجرعة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل استخدام قلم الحقن المعبأ مسبقاَ لأول مرة، سوف يوضح لك الطبيب أو الممرضة كيفية استخدامه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام ساكسِندا في أي وقت من اليوم مع الطعام أو الشراب أو بدونهما.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي الحرص على استخدام ساكسِندا في وقت واحد محدد كل يوم - ينبغي اختيار الوقت الأنسب لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موضع</strong><strong> الحقن</strong></p><p dir="RTL">تؤخذ جرعة ساكسِندا كحقنة تحت الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أفضل أماكن للحقن هي الجزء الأمامي من الخصر (البطن) ومقدمة الفخذ والجزء العلوي من الذراعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; احرص على تغيير مكان الحقن كل يوم لتقليل خطر ظهور الكتل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لا يُحقن في الوريد أو العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التعليمات المفصلة للاستخدام موضحة في الجانب الآخر من هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرضى السكري</strong></p><p dir="RTL">يرجى إبلاغ طبيبك إذا كنت تعاني من داء السكري. فقد يقوم طبيبك بتعديل الجرعة التي تأخذها من أدوية السكري لوقايتك من انخفاض مستوى السكر في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تمزج ساكسِندا مع أدوية أخرى (مثل الإنسولين) في حقنة واحدة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ساكسِندا مع أدوية أخرى محتوية على ناهضات مستقبلات جي إل بي- 1 (مثل إكسيناتيد أو ليكيسيناتيد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة أخذ جرعة زائدة من ساكسِنداعن الجرعة الموصوفة</strong></p><p dir="RTL">في حالة أخذ جرعة زائدة من ساكسِندا عن الجرعة الموصوفة، استشر طبيبك أو اذهب إلى المستشفى على الفور. ينبغي أخذ عبوة الدواء معك. فقد تحتاج إلى علاج طبي. وقد تحدث الآثار التالية:<!--[if supportFields]><span lang=AR-SA
style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> </span><span dir=LTR>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR>VAULT_ND_8c7f7885-68b0-4389-a9f4-b3a22c889756
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوعك (غثيان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوعك (القيء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السكر في الدم (هبوط سكر الدم). &rlm;‫يُرجى الرجوع إلى &quot;الآثار الجانبية الشائعة&quot; للاطلاع على العلامات التحذيرية لانخفاض نسبة السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة ساكسِندا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة نسيان الجرعة وتذكرها خلال 12 ساعة من موعدها المعتاد، يجب حقن الجرعة بمجرد تذكرها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انقضى أكثر من 12 ساعة من موعد جرعة ساكسِندا، اترك الجرعة المنسية وخذ الجرعة التالية في اليوم التالي في موعدها المحدد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ جرعة مضاعَفة ولا تزد مقدار الجرعة الموصوفة لك في اليوم التالي لتعويض الجرعة الفائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام ساكسِندا</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:12.0pt;
mso-ansi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR>VAULT_ND_bafa0c31-61fb-4e22-bd10-e20d54df05ba \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:12.0pt;
mso-ansi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">لا تتوقف عن استعمال ساكسِندا دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، استشر طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو حال جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، ولكن لا يُصاب بها الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:2.6pt;margin-top:1.3pt;width:450.75pt;height:109.5pt;z-index:251657728;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">خطورة الإصابة بسرطان الغدة الدرقية</p><p dir="RTL">- ليراجلوتايد يحدث سرطان الغدة الدرقية بالقوارض من خلال الدراسات الإكلينيكية التي أجريت عليهم، ومن غير المعروف أذا كان ساكسندا يسبب سرطان الغدة الدرقية، بما في ذلك سرطان الغدة الدرقية النخاعي، في البشر، حيث انه لا يمكن تحديد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- يمنع استخدام ساكسندا للمرضى الذين يشمل تاريخهم الشخصي أو العائلي على سرطان الغدة الدرقية النخاعي أو المرضى الذين يعانون من متلازمة تكون الورم الصماوي المتعدد.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير عن حدوث ردور فعل تحسسية حادة (تأقٍ) في حالات نادرة من المرضى الذين استخدموا ساكسِندا. ولذلك يجب الذهاب إلى الطبيب على الفور عند حدوث أعراض مثل اضطرابات التنفس وتورم الوجه والحلق وتسرع في نبضات القلب.</p><p dir="RTL">وردت تقارير عن حالات التهاب البنكرياس بشكل غير شائع في المرضى الذين استخدموا ساكسِندا. يُعد التهاب البنكرياس حالة مرضية خطيرة ومهددة للحياة.</p><p dir="RTL">يجب التوقف عن استخدام ساكسِندا وإخبار طبيبك فوراً عند ملاحظة أي من الآثار الجانبية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد متواصل في البطن (منطقة المعدة) قد تشعر به في الظهر، وغثيان وقيء، لأن هذه الأعراض قد تكون أعراضاً لالتهاب البنكرياس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL"><strong>شائعة جداً:</strong><strong> </strong>يمكن أن تصيب أكثر من مريض واحد من بين 10 مرضى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوعك (غثيان)، توعك (قيء)، إسهال، إمساك، صداع - عادةً ما تزول هذه الأعراض بعد عدة أيام أو أسابيع قليلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong>: يمكن أن تصيب مريضاً واحداً من بين 10 مرضى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في المعدة والأمعاء، مثل عسر الهضم والتهاب بطانة المعدة (التهاب المعدة)، واضطراب المعدة، وألم في أعلى المعدة، وحرقة المعدة، وشعور بالانتفاخ، وريح وتجشؤ وجفاف الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف أو التعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (أرق). عادةً ما تحدث هذه الأعراض في الأشهر الثلاث الأولى من العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصوات في المرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل في موضع الحقن (تشمل كدمات، أو شعور بألم، أو تهيج، أو طفح جلدي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السكر في الدم (نقص جلوكوز الدم وقد تحدث العلامات التحذيرية لانخفاض مستوى السكر في الدم فجأة ويمكن أن تشمل: عرق بارد، شحوب وبرودة الجلد، صداع، تسرع في نبضات القلب، شعور بالتعب، شعور بالجوع الشديد، تغيرات في الرؤية، شعور بالنعاس، شعور بالضعف، شعور بالتوتر، قلق، ارتباك، صعوبة في التركيز، رعشة. &rlm;‫سيخبرك طبيبك بكيفية علاج انخفاض مستوى السكر في الدم وماذا تفعل عند ملاحظة هذه العلامات التحذيرية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات البنكرياس، مثل الليباز والأميليز.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong>: يمكن أن تصيب مريضاً واحداً من بين 100 مريض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان سوائل الجسم (جفاف). يزيد احتمال حدوث هذا العارض في بداية العلاج، وقد يحدث بسبب التوعك (القيء) والشعور بالتوعك (الغثيان) والإسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخر في إفراغ المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية تشمل الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الارتياح بشكل عام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة سرعة نبض القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong>: يمكن أن تصيب مريضاً واحداً من بين 1000 مريض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور وظائف الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي حاد. يمكن أن تشمل الأعراض نقص كمية البول وطعم معدني في الفم وحدوث كدمات بسهولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل انتشارها من البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انسداد معوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; قد يكون سبب ظهور الكتل تحت الجلد تراكم بروتين ما يُسمى أميلويد (الداء النشواني الجلدي؛ ولا يُعرف مدى تكرار حدوثه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">في حال تفاقم أي من الآثار الجانبية أو إذا لاحظت ظهور آثار جانبية غير مذكورة في هذه النشرة، يُرجى إخبار طبيبك أو الممرضة أو الصيدلي.</p><table border="1" cellspacing="1" cellpadding="1" style="width:379px"><tbody><tr><td style="width:376px"><table cellspacing="0" cellpadding="0" align="left" style="width:350px"><tbody><tr><td style="vertical-align:top; width:350px"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية<strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; بريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الموقع&nbsp; الالكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال. لا تستخدم ساكسِندا<sup>&trade;</sup> بعد تاريخ انتهاء الصلاحية الذي يظهر على ملصق قلم الحقن والعبوة الخارجية بعد كلمة &quot;Expiry&quot;. يشير تاريخ الانتهاء إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل الاستخدام لأول مرة</strong></p><p dir="RTL">يُخزن الدواء في الثلاجة (عند درجة حرارة 2 إلى 8 درجات مئوية) يُراعى عدم التجميد. ويُحفظ بعيداً عن وحدة التجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعد البدء في استخدام قلم الحقن</strong></p><p dir="RTL">يمكنك الاحتفاظ بالقلم لمدة شهر واحد في حالة حفظه في درجة حرارة أقل من 30 درجة مئوية أو في الثلاجة (عند درجة حرارة 2 إلى 8 درجات مئوية). يُراعى عدم التجميد. ويُحفظ بعيداً عن وحدة التجميد. وعند عدم استخدام القلم يرجى تغطيته بالغطاء لحمايته من الضوء. كما يرجى عدم استخدام هذا الدواء إذا كان المحلول غير صافٍ وغير عديم اللون أو غير عديم اللون تقريباً.</p><p dir="RTL">لا تلقِ أي أدوية في الفضلات السائلة أو الفضلات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات ساكسِندا<sup>&trade;</sup></strong></p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي ليراجلوتايد. يحتوي كل 1 مل من محلول الحقن على 6 ملجم من مادة ليراجلوتايد. ويحتوي كل قلم حقن معبأ مسبقاً على 18 ملجم من مادة ليراجلوتايد.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ثنائي هيدرات فوسفات ثنائي الصوديوم، وبروبيلين جلايكول، فينول، وحمض هيدروكلوريك وهيدروكسيد صوديوم (لتعديل درجة الحموضة)، وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل ساكسِندا</strong><strong><sup>&trade;</sup></strong><strong> ومحتويات العبوة</strong></p><p dir="RTL">يأتي ساكسِندا<sup>&trade;</sup> في شكل محلول صافٍ عديم اللون أو عديم اللون تقريباً للحقن في قلم معبأ مسبقاً. يحتوي كل قلم على 3 مل المحلول ويعطي جرعات 0.6 ملجم و1.2 ملجم و1.8 ملجم و2.4 ملجم و3.0 ملجم. ويأتي ساكسِندا<sup>&trade;</sup> في عبوات بها قلم واحد أو 3 أقلام أو 5 أقلام. لا تتوفر جميع أحجام العبوات في بعض الأسواق. الإبر غير مرفقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p><p dir="RTL"><em>ساكسِندا<sup>&trade;</sup> ونوفوفاين<sup>&trade;</sup> ونوفوتويست<sup>&trade;</sup> هي علامات تجارية مملوكة لشركة</em> <em>Novo Nordisk A/S</em>، <em>الدنمارك</em></p><p dir="RTL">&copy; 2025</p><p dir="RTL">Novo Nordisk A/S</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">إن هذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافاً للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول أيدي الأطفال.</p></td></tr></tbody></table><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">واتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saxenda 6 mg/ml solution for injection in pre-filled pen

Warning: Risk of thyroid C-cell tumors
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.

Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of solution contains 6 mg of liraglutide*. One pre-filled pen contains 18 mg liraglutide in 3 ml.

*human glucagon-like peptide-1 (GLP-1) analogue produced by recombinant DNA technology in
Saccharomyces cerevisiae.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Clear and colourless or almost colourless, isotonic solution; pH=8.15.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>&nbsp;</p><p>Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&ge;</em>30 kg/m&sup2; (obesity), or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&ge;</em>27 kg/m&sup2; to &lt;30 kg/m&sup2; (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.</p><p>&nbsp;</p><p>Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.</p><p>&nbsp;</p><p><u>Adolescents</u></p><p>&nbsp;</p><p>Saxenda can be used as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescent patients from the age of 12 years and above with:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; body weight above 60 kg and</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; obesity (BMI corresponding to &ge;30 kg/m<sup>2</sup> for adults by international cut-off points)*.</p><p>&nbsp;</p><p>*IOTF BMI cut-off points for obesity by sex between 12&ndash;18 years (see table 1):</p><p>&nbsp;</p><p><strong>Table 1 </strong><strong>IOTF BMI cut-off points for obesity by sex between 12&ndash;18 years</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Age (years)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Body mass index 30 kg/m<sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Males</strong></p></td><td style="vertical-align:top"><p><strong>Females</strong></p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>26.02</p></td><td style="vertical-align:top"><p>26.67</p></td></tr><tr><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>26.43</p></td><td style="vertical-align:top"><p>27.24</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26.84</p></td><td style="vertical-align:top"><p>27.76</p></td></tr><tr><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>27.25</p></td><td style="vertical-align:top"><p>28.20</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>27.63</p></td><td style="vertical-align:top"><p>28.57</p></td></tr><tr><td style="vertical-align:top"><p>14.5</p></td><td style="vertical-align:top"><p>27.98</p></td><td style="vertical-align:top"><p>28.87</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>28.30</p></td><td style="vertical-align:top"><p>29.11</p></td></tr><tr><td style="vertical-align:top"><p>15.5</p></td><td style="vertical-align:top"><p>28.60</p></td><td style="vertical-align:top"><p>29.29</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>28.88</p></td><td style="vertical-align:top"><p>29.43</p></td></tr><tr><td style="vertical-align:top"><p>16.5</p></td><td style="vertical-align:top"><p>29.14</p></td><td style="vertical-align:top"><p>29.56</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>29.41</p></td><td style="vertical-align:top"><p>29.69</p></td></tr><tr><td style="vertical-align:top"><p>17.5</p></td><td style="vertical-align:top"><p>29.70</p></td><td style="vertical-align:top"><p>29.84</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>30.00</p></td><td style="vertical-align:top"><p>30.00</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>The starting dose is 0.6 mg once daily. The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerability (see table 2). If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended.</p><p>&nbsp;</p><p><strong>Table 2 Dose escalation schedule</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Weeks</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Dose escalation 4 weeks</strong></p></td><td style="vertical-align:top"><p><strong>0.6 mg</strong></p></td><td style="vertical-align:top"><p><strong>1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1.2 mg</strong></p></td><td style="vertical-align:top"><p><strong>1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1.8 mg</strong></p></td><td style="vertical-align:top"><p><strong>1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>2.4 mg</strong></p></td><td style="vertical-align:top"><p><strong>1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>3.0 mg</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Adolescents (&ge;&nbsp;12 years)</u></em></p><p><em><u>&nbsp;</u></em></p><p>For adolescents from the age of 12 to below 18&nbsp;years old a similar dose escalation schedule as for adults should be applied (see table 2). The dose should be increased until 3.0&nbsp;mg (maintenance dose) or maximum tolerated dose has been reached. Daily doses higher than 3.0&nbsp;mg are not recommended.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Missed doses</u></em></p><p><em>&nbsp;</em></p><p>If a dose is missed within 12 hours from when it is usually taken, the patient should take the dose as soon as possible. If there is less than 12 hours to the next dose, the patient should not take the missed dose and resume the once-daily regimen with the next scheduled dose. An extra dose or increase in dose should not be taken to make up for the missed dose.</p><p>&nbsp;</p><p><em><u>Patients with type 2 diabetes mellitus</u></em></p><p><em>&nbsp;</em></p><p>Saxenda should not be used in combination with another GLP-1 receptor agonist.</p><p>&nbsp;</p><p>When initiating Saxenda, it should be considered to reduce the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia. Blood glucose self-monitoring is necessary to adjust the dose of insulin or insulin-secretagogues (see section 4.4).</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em><u>Elderly (&ge;65 years old)</u></em></p><p>No dose adjustment is required based on age. Therapeutic experience in patients &ge;75 years of age is limited and use in these patients is not recommended (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>No dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance &ge;30 ml/min). Saxenda is not recommended for use in patients with severe renal impairment (creatinine clearance &lt;30 ml/min) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2).</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Saxenda is not recommended for use in patients with severe hepatic impairment and should be used cautiously in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em>No dose adjustment is required for adolescents from the age of 12&nbsp;years and above.</em></p><p><em>The safety and efficacy of Saxenda in children below 12&nbsp;years of age has not been established (see section 5.1).</em></p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Saxenda is for subcutaneous use only. It must not be administered intravenously or intramuscularly.</p><p>&nbsp;</p><p>Saxenda is administered once daily at any time, independent of meals. It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment. However, it is preferable that Saxenda is injected around the same time of the day, when the most convenient time of the day has been chosen. Injection sites should always be rotated to reduce the risk of injection site amyloid deposits (see section and 4.8).</p><p>&nbsp;</p><p>For further instructions on administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to liraglutide or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Aspiration in association with general anaesthesia or deep sedation</u></p><p>&nbsp;</p><p>Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric content due to delayed gastric emptying (see section 4.8) should be considered prior to performing procedures with general anaesthesia or deep sedation.<!--[if supportFields]><span lang=EN-GB style='mso-ansi-language:
EN-GB;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_50bb624b-634b-49bd-afeb-0f83fad086a5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB;font-weight:normal'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Patients with heart failure</u></p><p>&nbsp;</p><p>There is no clinical experience in patients with congestive heart failure New York Heart Association (NYHA) class IV, and liraglutide is therefore not recommended for use in these patients.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>The safety and efficacy of liraglutide for weight management have not been established in patients:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aged 75 years or more,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treated with other products for weight management,</p><p>&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with severe renal impairment,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with severe hepatic impairment.</p><p>Use in these patients is not recommended (see section 4.2).</p><p>As liraglutide for weight management was not investigated in subjects with mild or moderate hepatic impairment, it should be used with caution in these patients (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>There is limited experience in patients with inflammatory bowel disease and diabetic gastroparesis. Use of liraglutide is not recommended in these patients since it is associated with transient gastrointestinal adverse reactions, including nausea, vomiting and diarrhoea.</p><p>&nbsp;</p><p><u>Pancreatitis</u></p><p>&nbsp;</p><p>Acute pancreatitis has been observed with the use of GLP-1 receptor agonists. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, liraglutide should be discontinued; if acute pancreatitis is confirmed, liraglutide should not be restarted.</p><p>&nbsp;</p><p><u>Acute Gallbladder Disease</u><!--[if supportFields]><u><span style='font-weight:
normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e0d32090-49bf-41b3-b82c-979c4c71066d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p><u>&nbsp;</u></p><p>In Saxenda clinical trials, 2.2% of Saxenda-treated patients reported adverse events of cholelithiasis versus 0.8% of placebo-treated patients. The incidence of cholecystitis was 0.8% in Saxenda-treated patients versus 0.4% in placebo-treated patients. The majority of Saxenda-treated patients with adverse events of cholelithiasis and cholecystitis required cholecystectomy. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Saxenda-treated patients than in placebo-treated patients even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy. Patients should be informed of the characteristic symptoms of cholelithiasis and cholecystitis.<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_eff89ae4-e626-486e-9a14-c91c4966ca56 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Thyroid disease</u></p><p>&nbsp;</p><p>In clinical trials in type 2 diabetes, thyroid adverse events, such as goitre, have been reported in particular in patients with pre-existing thyroid disease. Liraglutide should therefore be used with caution in patients with thyroid disease.</p><p>&nbsp;</p><p><u>Heart rate</u></p><p>&nbsp;</p><p>An increase in heart rate was observed with liraglutide in clinical trials (see section 5.1). Heart rate should be monitored at regular intervals consistent with usual clinical practice. Patients should be informed of the symptoms of increased heart rate (palpitations or feelings of a racing heartbeat while at rest). For patients who experience a clinically relevant sustained increase in resting heart rate, treatment with liraglutide should be discontinued.</p><p>&nbsp;</p><p><u>Renal Impairment</u><!--[if supportFields]><u><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ef68bbde-ac94-4618-afb7-782cee071096 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p><u>&nbsp;</u></p><p>In patients treated with GLP-1 receptor agonists, including Saxenda, there have been reports of acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis. Some of these events were reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, and/or diarrhea leading to volume depletion. Some of the reported events occurred in patients receiving one or more medications known to affect renal function or volume status. Altered renal function has been reversed in many of the reported cases with supportive treatment and discontinuation of potentially causative agents, including liraglutide. Use caution when initiating or escalating doses of Saxenda in patients with renal impairment.<!--[if supportFields]><span style='font-weight:normal'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_137f8b01-44ca-418d-90dc-82437d42f900 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><u>Dehydration</u></p><p>&nbsp;</p><p>Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with GLP-1 receptor agonists. Patients treated with liraglutide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.</p><p>&nbsp;</p><p><u>Hypoglycaemia in patients with type 2 diabetes mellitus</u></p><p>&nbsp;</p><p>Patients with type 2 diabetes mellitus receiving liraglutide in combination with insulin and/or sulfonylurea may have an increased risk of hypoglycaemia. The risk of hypoglycaemia may be lowered by a reduction in the dose of insulin and/or sulfonylurea.</p><p>&nbsp;</p><p><u>Hyperglycaemia in insulin treated patients with diabetes mellitus</u></p><p>&nbsp;</p><p>In patients with diabetes mellitus Saxenda must not be used as a substitute for insulin. Diabetic ketoacidosis has been reported in insulin-dependent patients after rapid discontinuation or dose reduction of insulin (see section 4.2).</p><p>&nbsp;</p><p><u>Suicidal Behavior and Ideation&nbsp; </u></p><p>&nbsp;</p><p>In Saxenda clinical trials, 9 (0.3%) of 3384 Saxenda-treated patients and 2 (0.1%) of the 1941 placebo-treated patients reported suicidal ideation; one of these Saxenda-treated patients attempted suicide. Patients treated with Saxenda should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Saxenda in patients who experience suicidal thoughts or behaviors. Avoid Saxenda in patients with a history of suicidal attempts or active suicidal ideation.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Excipients</u></p><p>&nbsp;</p><p>Saxenda contains less than 1 mmol sodium (23 mg) per dose, therefore the medicinal product is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro, </em>liraglutide has shown very low potential to be involved in pharmacokinetic interactions with other active substances related to cytochrome P450 (CYP) and plasma protein binding.</p><p>&nbsp;</p><p>The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products. Interaction studies did not show any clinically relevant delay of absorption and therefore no dose adjustment is required.</p><p>&nbsp;</p><p>Interaction studies have been performed with 1.8 mg liraglutide. The effect on rate of gastric emptying was equivalent between liraglutide 1.8 mg and 3.0 mg, (paracetamol AUC0-300 min). Few patients treated with liraglutide reported at least one episode of severe diarrhoea. Diarrhoea may affect the absorption of concomitant oral medicinal products.</p><p>&nbsp;</p><p><u>Warfarin and other coumarin derivatives</u></p><p>&nbsp;</p><p>No interaction study has been performed. A clinically relevant interaction with active substances with poor solubility or narrow therapeutic index such as warfarin cannot be excluded. Upon initiation of liraglutide treatment in patients on warfarin or other coumarin derivatives, more frequent monitoring of International Normalised Ratio (INR) is recommended.</p><p>&nbsp;</p><p><u>Paracetamol (Acetaminophen)</u></p><p>&nbsp;</p><p>Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000 mg. Paracetamol Cmax was decreased by 31% and median tmax was delayed up to 15 min. No dose adjustment for concomitant use of paracetamol is required.</p><p>&nbsp;</p><p><u>Atorvastatin</u></p><p>&nbsp;</p><p>Liraglutide did not change the overall exposure of atorvastatin following single dose administration of atorvastatin 40 mg. Therefore, no dose adjustment of atorvastatin is required when given with liraglutide. Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.</p><p>&nbsp;</p><p><u>Griseofulvin</u></p><p>&nbsp;</p><p>Liraglutide did not change the overall exposure of griseofulvin following administration of a single dose of griseofulvin 500 mg. Griseofulvin Cmax increased by 37% while median tmax did not change. Dose adjustments of griseofulvin and other compounds with low solubility and high permeability are not required.</p><p>&nbsp;</p><p><u>Digoxin</u></p><p>&nbsp;</p><p>A single dose administration of digoxin 1 mg with liraglutide resulted in a reduction of digoxin AUC by 16%; Cmax decreased by 31%. Digoxin median tmax was delayed from 1 h to 1.5 h. No dose adjustment of digoxin is required based on these results.</p><p>&nbsp;</p><p><u>Lisinopril</u></p><p>&nbsp;</p><p>A single dose administration of lisinopril 20 mg with liraglutide resulted in a reduction of lisinopril AUC by 15%; Cmax decreased by 27%. Lisinopril median tmax was delayed from 6 h to 8 h with liraglutide. No dose adjustment of lisinopril is required based on these results.</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>Liraglutide lowered ethinylestradiol and levonorgestrel Cmax by 12% and 13%, respectively, following administration of a single dose of an oral contraceptive product. tmax was delayed by 1.5 h with liraglutide for both compounds. There was no clinically relevant effect on the overall exposure of either ethinylestradiol or levonorgestrel. The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong><u>Pregnancy</u></p><p>&nbsp;</p><p>There are limited data from the use of liraglutide in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Liraglutide should not be used during pregnancy. If a patient wishes to become pregnant or pregnancy occurs, treatment with liraglutide should be discontinued.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether liraglutide is excreted in human milk. Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk is low. Non-clinical studies have shown a treatment-related reduction of neonatal growth in suckling rat pups (see section 5.3). Because of lack of experience, Saxenda should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Apart from a slight decrease in the number of live implants, animal studies did not indicate harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Saxenda has no or negligible influence on the ability to drive and use machines. However, dizziness can be experienced mainly during the first 3 months of treatment with Saxenda. Driving or use of machines should be exercised with caution if dizziness occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile:</u></p><p>&nbsp;</p><p>Saxenda was evaluated for safety in 5 double-blind, placebo controlled trials that enrolled 5,813 adult patients with overweight or obesity with at least one weight-related comorbidity. Overall, gastrointestinal reactions were the most frequently reported adverse reactions during treatment (67.9%) (see section &lsquo;Description of selected adverse reactions&rsquo;).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Table 3 lists adverse reactions reported in adults. Adverse reactions are listed by system organ class and frequency. Frequency categories are defined as: very common (&ge;1/10); common (&ge;1/100 to</p><p>&lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 3 Adverse reactions reported in adults<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_888325a6-d756-40c6-b559-2cfd773b3bba \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoglycaemia*</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness Dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea Vomiting Diarrhoea Constipation</p></td><td style="vertical-align:top"><p>Dry mouth Dyspepsia Gastritis</p><p>Gastro-oesophageal reflux disease Abdominal pain upper</p><p>Flatulence Eructation Abdominal</p><p>distension</p></td><td style="vertical-align:top"><p>Pancreatitis*** Delayed gastric emptying****</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cholelithiasis***</p></td><td style="vertical-align:top"><p>Cholecystitis***</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Cutaneous amyloidosis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute renal failure Renal</p><p>impairment</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site reactions Asthenia</p><p>Fatigue</p></td><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased lipase Increased amylase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*Hypoglycaemia (based on self-reported symptoms by patients and not confirmed by blood glucose measurements) reported in patients without type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise. Please see section &lsquo;Description of selected adverse reactions&rsquo; for further information.</p><p>**Insomnia was mainly seen during the first 3 months of treatment.</p><p>***See section 4.4.</p><p>****From controlled phase 2, 3a and 3b clinical trials. <u>Description of selected adverse reactions:</u></p><p><em><u>Hypoglycaemia in patients without type 2 diabetes mellitus</u></em></p><p><em>&nbsp;</em></p><p>In clinical trials in overweight or obese patients without type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise, no severe hypoglycaemic events (requiring third party assistance) were reported. Symptoms of hypoglycaemic events were reported by 1.6 % of patients treated with Saxenda and 1.1% of patients treated with placebo; however, these events were not confirmed by blood glucose measurements. The majority of events were mild.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia in patients with type 2 diabetes mellitus</u></em></p><p>&nbsp;</p><p>In a clinical trial in overweight or obese patients with type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise, severe hypoglycaemia (requiring third party assistance) was reported by 0.7% of patients treated with Saxenda and only in patients concomitantly treated with sulfonylurea. Also, in these patients documented symptomatic hypoglycaemia was reported by 43.6% of patients treated with Saxenda and in 27.3% of patients treated with placebo. Among patients not concomitantly treated with sulfonylurea, 15.7% of patients treated with Saxenda and 7.6% of patients treated with placebo reported documented symptomatic hypoglycaemic events (defined as plasma glucose &le;3.9 mmol/L accompanied by symptoms).</p><p>&nbsp;</p><p><em><u>Hypoglycaemia in patients with type 2 diabetes mellitus treated with insulin</u></em></p><p><em>&nbsp;</em></p><p>In a clinical trial in overweight or obese patients with type 2 diabetes mellitus treated with insulin and liraglutide 3.0 mg/day in combination with diet and exercise and up to 2 OADs, severe hypoglycaemia (requiring third party assistance) was reported by 1.5% of patients treated with liraglutide 3.0 mg/day. In this trial, documented symptomatic hypoglycaemia (defined as plasma glucose &le;3.9 mmol/L accompanied by symptoms) was reported by 47.2% of patients treated with liraglutide 3.0 mg/day and by 51.8% of patients treated with placebo. Among patients concomitantly treated with sulfonylurea, 60.9% of patients treated with liraglutide 3.0 mg/day and 60.0% of patients treated with placebo reported documented symptomatic hypoglycaemic events.</p><p>&nbsp;</p><p><em><u>Gastrointestinal adverse reactions</u></em></p><p><em>&nbsp;</em></p><p>Most episodes of gastrointestinal events were mild to moderate, transient and the majority did not lead to discontinuation of therapy. The reactions usually occurred during the first weeks of treatment and diminished within a few days or weeks on continued treatment.</p><p>&nbsp;</p><p>Patients &ge;65 years of age may experience more gastrointestinal effects when treated with Saxenda.</p><p>&nbsp;</p><p>Patients with mild or moderate renal impairment (creatinine clearance &ge;30 ml/min) may experience more gastrointestinal effects when treated with Saxenda.</p><p>&nbsp;</p><p><em><u>Acute renal failure</u></em></p><p><em>&nbsp;</em></p><p>In patients treated with GLP-1 receptor agonists, there have been reports of acute renal failure. A majority of the reported events occurred in patients who had experienced nausea, vomiting or diarrhoea leading to volume depletion (see section 4.4).</p><p>&nbsp;</p><p><em><u>Allergic reactions</u></em></p><p><em>&nbsp;</em></p><p>Few cases of anaphylactic reactions with symptoms such as hypotension, palpitations, dyspnoea and oedema have been reported with marketed use of liraglutide. Anaphylactic reactions may potentially be life threatening. If an anaphylactic reaction is suspected, liraglutide should be discontinued and treatment should not be restarted (see section 4.3).</p><p>&nbsp;</p><p><em><u>Injection site reactions</u></em></p><p><em>&nbsp;</em></p><p>Injection site reactions have been reported in patients treated with Saxenda. These reactions were usually mild and transitory and the majority disappeared during continued treatment.</p><p>&nbsp;</p><p><em><u>Tachycardia</u></em></p><p><em>&nbsp;</em></p><p>In clinical trials, tachycardia was reported in 0.6% of patients treated with Saxenda and in 0.1% of patients treated with placebo. The majority of events were mild or moderate. Events were isolated and the majority resolved during continued treatment with Saxenda.</p><p><em><u>Cutaneous amyloidosis </u></em></p><p>Cutaneous amyloidosis may occur at the injection site (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Post-marketing experience:</u></p><p>The following adverse reactions have been reported during post-approval use of liraglutide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Gastrointestinal Disorders:</u></p><p>Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, sometimes resulting in death, ileus.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>General Disorders and Administration Site Conditions:</u></p><p>Allergic reactions: rash and pruritus.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Hepatobiliary Disorders:</u></p><p>Hyperbilirubinemia, cholestasis and hepatitis.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In a clinical trial conducted in adolescents of 12 years to less than 18 years with obesity, 125 patients were exposed to Saxenda for 56 weeks.</p><p>Overall, the frequency, type and severity of adverse reactions in the adolescents with obesity were comparable to that observed in the adult population. Vomiting occurred with a 2-fold higher frequency in adolescents compared to adults.</p><p>&nbsp;</p><p>No effects on growth or pubertal development were found.</p><p><u>Reporting of suspected adverse reactions</u></p><p>To report any side effect(s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>From clinical trials and post-marketing use of liraglutide overdoses have been reported up to 72 mg (24 times the recommended dose for weight management). Events reported included severe nausea severe vomiting and severe hypoglycaemia .</p><p>In the event of overdose, appropriate supportive treatment should be initiated according to the patient&rsquo;s clinical signs and symptoms. The patient should be observed for clinical signs of dehydration and blood glucose should be monitored.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues. ATC code: A10BJ02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid sequence homology to endogenous human GLP-1. Liraglutide binds to and activates the GLP-1 receptor (GLP-1R).</p><p>&nbsp;</p><p>GLP-1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear. In animal studies, peripheral administration of liraglutide led to uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP- 1R, increased key satiety and decreased key hunger signals, thereby leading to lower body weight.</p><p>&nbsp;</p><p>GLP-1 receptors are also expressed in specific locations in the heart, vasculature, immune system and kidneys. In mouse models of atherosclerosis, liraglutide prevented aortic plaque progression and reduced inflammation in the plaque. In addition, liraglutide had a beneficial effect on plasma lipids. Liraglutide did not reduce the plaque size of already established plaques.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Liraglutide lowers body weight in humans mainly through loss of fat mass with relative reductions in visceral fat being greater than for subcutaneous fat loss. Liraglutide regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. Liraglutide does not increase energy expenditure compared to placebo.</p><p>&nbsp;</p><p>Liraglutide stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner which results in a lowering of fasting and post-prandial glucose. The glucose-lowering effect is more pronounced in patients with prediabetes and diabetes compared to patients with normoglycaemia.</p><p>Clinical trials suggest that liraglutide improves and sustains beta-cell function, according to HOMA-B and the proinsulin-to-insulin ratio.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of liraglutide for weight management in conjunction with reduced calorie intake and increased physical activity were studied in four phase 3 randomised, double-blind, placebo- controlled trials which included a total of 5,358 adult patients.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Trial 1 (SCALE Obesity &amp; Pre-Diabetes - 1839): </strong>A total of 3,731 patients with obesity (BMI</p><p>&ge;30 kg/m&sup2;) or with overweight (BMI &ge;27 kg/m&sup2;) with dyslipidaemia and/or hypertension were</p><p>stratified according to prediabetes status at screening and BMI at baseline (&ge;30 kg/m&sup2; or</p><p>&lt;30 kg/m&sup2;). All 3,731 patients were randomised to 56 weeks of treatment and the 2,254 patients with prediabetes at screening were randomised to 160 weeks of treatment. Both treatment periods were followed by a 12-week off drug/placebo observational follow-up period. Lifestyle intervention in the form of an energy-restricted diet and exercise counselling was background therapy for all patients.</p><p>The 56-week part of trial 1 assessed body weight loss in all the 3,731 randomised patients (2,590 completers).</p><p>The 160-week part of trial 1 assessed time to onset of type 2 diabetes in the 2,254 randomised patients with prediabetes (1,128 completers).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Trial 2 (SCALE Diabetes - 1922): </strong>A 56-week trial assessing body weight loss in 846 randomised (628 completers) obese and overweight patients with insufficiently controlled type 2 diabetes mellitus (HbA1c range 7&ndash;10%). The background treatment at trial start was either diet&nbsp;and exercise alone, metformin, a sulfonylurea, a glitazone as single agents or any combination hereof.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Trial 3 (SCALE Sleep Apnoea - 3970): </strong>A 32-week trial assessing sleep apnoea severity and body weight loss in 359 randomised (276 completers) obese patients with moderate or severe obstructive sleep apnoea.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Trial 4 (SCALE Maintenance - 1923): </strong>A 56-week trial assessing body weight maintenance and weight loss in 422 randomised (305 completers) obese and overweight patients with hypertension or dyslipidaemia after a preceding weight loss of &ge;5% induced by a low-calorie diet.</p><p>&nbsp;</p><p><em><u>Body weight</u></em></p><p><em>&nbsp;</em></p><p>Superior weight loss was achieved with liraglutide compared to placebo in obese/overweight patients in all groups studied. Across the trial populations, greater proportions of the patients achieved &ge;5% and &gt;10% weight loss with liraglutide than with placebo (tables 4&ndash;5). In the 160-weeks part of trial 1, the weight loss occurred mainly in the first year and was sustained throughout 160 weeks. In trial 4, more patients maintained the weight loss achieved prior to treatment initiation with liraglutide than with placebo (81.4% and 48.9%, respectively). Specific data on weight loss, responders, time course and cumulative distribution of weight change (%) for trials 1&ndash;4 are presented in tables 4&ndash;7 and figures 1, 2 and 3.</p><p>&nbsp;</p><p><em><u>Weight loss response after 12 weeks with liraglutide (3.0 mg) treatment</u></em></p><p>&nbsp;</p><p>Early responders were defined as patients who achieved &ge;5% weight loss after 12 weeks on treatment dose of liraglutide (4 weeks of dose escalation and 12 weeks on treatment dose). In the 56-week part of trial 1, 67.5% achieved &ge;5% weight loss after 12 weeks. In trial 2, 50.4% achieved &ge;5% weight loss after 12 weeks. With continued treatment with liraglutide, 86.2% of these early responders are predicted to achieve a weight loss of &ge;5% and 51% are predicted to achieve a weight loss of &ge;10% after 1 year of treatment. The predicted mean weight loss in early responders who complete 1 year of treatment is 11.2% of their baseline body weight (9.7% for males and 11.6% for females). For patients who have achieved a weight loss of &lt;5% after 12 weeks on treatment dose of liraglutide, the proportion of patients not reaching a weight loss of &ge;10% after 1 year is 93.4%.</p><p>&nbsp;</p><p><em><u>Glycaemic control</u></em></p><p><em>&nbsp;</em></p><p>Treatment with liraglutide significantly improved glycaemic parameters across sub-populations with normoglycaemia, prediabetes and type 2 diabetes mellitus. In the 56-week part of trial 1, fewer patients treated with liraglutide had developed type 2 diabetes mellitus compared to patients treated with placebo (0.2% vs. 1.1%). More patients with prediabetes at baseline had reversed their prediabetes compared to patients treated with placebo (69.2% vs. 32.7%). In the 160-week part of trial 1, the primary efficacy endpoint was the proportion of patients with onset of type 2 diabetes mellitus evaluated as time to onset. At week 160, while on treatment, 3% treated with Saxenda and 11% treated with placebo were diagnosed with type 2 diabetes mellitus. The estimated time to onset of type 2 diabetes mellitus for patients treated with liraglutide 3.0 mg was 2.7 times longer (with a 95% confidence interval of [1.9, 3.9]), and the hazard ratio for risk of developing type 2 diabetes mellitus was 0.2 for liraglutide versus placebo.</p><p>&nbsp;</p><p><em><u>Cardiometabolic risk factors</u></em></p><p><em>&nbsp;</em></p><p>Treatment with liraglutide significantly improved systolic blood pressure and waist circumference compared with placebo (tables 4, 5 and 6).</p><p>&nbsp;</p><p><em><u>Apnoea-Hypopnoea Index (AHI)</u></em></p><p><em>&nbsp;</em></p><p>Treatment with liraglutide significantly reduced the severity of obstructive sleep apnoea as assessed by change from baseline in the AHI compared with placebo (table 7).</p><p>&nbsp;</p><p>Table 4 Trial 1: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 56</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_22" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:70.55pt;margin-top:-102.85pt;width:453.55pt;height:250.8pt;
 z-index:15729664;visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Saxenda (N=2437)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo (N=1225)</strong></p></td><td style="vertical-align:top"><p><strong>Saxenda vs. placebo</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Body weight</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Baseline, kg (SD)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 106.3 (21.2)</p></td><td colspan="2" style="vertical-align:top"><p>106.3 (21.7)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Mean change at week 56, % (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -8.0</p></td><td colspan="2" style="vertical-align:top"><p>-2.6</p></td><td style="vertical-align:top"><p>-5.4** (-5.8; -5.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Mean change at week 56, kg (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -8.4</p></td><td colspan="2" style="vertical-align:top"><p>-2.8</p></td><td style="vertical-align:top"><p>-5.6** (-6.0; -5.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Proportion of patients losing &ge;5% body&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;63.5</p><p>weight at week 56, % (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>26.6</p></td><td style="vertical-align:top"><p>4.8** (4.1; 5.6)</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Proportion of patients losing &gt;10% body&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; 32.8</p><p>&nbsp;&nbsp;weight at week 56, % (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10.1</p></td><td style="vertical-align:top"><p>4.3** (3.5; 5.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Glycaemia and cardiometabolic factors</strong></p></td><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>Change</p></td><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>Change</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HbA1c, %</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>-0.3</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>-0.23** (-0.25; -0.21)</p></td></tr><tr><td style="vertical-align:top"><p>FPG, mmol/L</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>-0.01</p></td><td style="vertical-align:top"><p>-0.38** (-0.42; -0.35)</p></td></tr><tr><td style="vertical-align:top"><p>Systolic blood pressure, mmHg</p></td><td style="vertical-align:top"><p>123.0</p></td><td style="vertical-align:top"><p>-4.3</p></td><td style="vertical-align:top"><p>123.3</p></td><td style="vertical-align:top"><p>-1.5</p></td><td style="vertical-align:top"><p>-2.8** (-3.6; -2.1)</p></td></tr><tr><td style="vertical-align:top"><p>Diastolic blood pressure, mmHg</p></td><td style="vertical-align:top"><p>78.7</p></td><td style="vertical-align:top"><p>-2.7</p></td><td style="vertical-align:top"><p>78.9</p></td><td style="vertical-align:top"><p>-1.8</p></td><td style="vertical-align:top"><p>-0.9* (-1.4; -0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Waist circumference, cm</p></td><td style="vertical-align:top"><p>115.0</p></td><td style="vertical-align:top"><p>-8.2</p></td><td style="vertical-align:top"><p>114.5</p></td><td style="vertical-align:top"><p>-4.0</p></td><td style="vertical-align:top"><p>-4.2** (-4.7; -3.7)</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>Full Analysis Set. For body weight, HbA1c, FPG, blood pressure and waist circumference, baseline values are means, changes from baseline at week 56 are estimated means (least-squares) and treatment contrasts at week 56 are estimated treatment differences. For the proportions of patients losing &ge;5/&gt;10% body weight, estimated odds ratios are presented. Missing post-baseline values were imputed using the last observation carried forward.</p><p>* p&lt;0.05. ** p&lt;0.0001. CI=confidence interval. FPG=fasting plasma glucose. SD=standard deviation.</p><p>&nbsp;</p><p>Table 5 Trial 1: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 160</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Saxenda (N=1472)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo (N=738)</strong></p></td><td style="vertical-align:top"><p><strong>Saxenda vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline, kg (SD)</p></td><td colspan="2" style="vertical-align:top"><p>107.6 (21.6)</p></td><td colspan="2" style="vertical-align:top"><p>108.0 (21.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 160, % (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>-6.2</p></td><td colspan="2" style="vertical-align:top"><p>-1.8</p></td><td style="vertical-align:top"><p>-4.3** (-4.9; -3.7)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 160, kg (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>-6.5</p></td><td colspan="2" style="vertical-align:top"><p>-2.0</p></td><td style="vertical-align:top"><p>-4.6** (-5.3; -3.9)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients losing &ge;5% body</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>49.6</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>23.4</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.2** (2.6; 3.9)</p></td></tr><tr><td style="vertical-align:top"><p>weight at week 160, % (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients losing &gt;10% body</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>weight at week 160, % (95% CI)</p></td><td style="vertical-align:top"><p>24.4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.1** (2.3; 4.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Glycaemia and cardiometabolic factors</strong></p></td><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>Change</p></td><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>Change</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HbA1c, %</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>-0.21** (-0.24; -0.18)</p></td></tr><tr><td style="vertical-align:top"><p>FPG, mmol/L</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>0.04</p></td><td style="vertical-align:top"><p>-0.4** (-0.5; -0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Systolic blood pressure, mmHg</p></td><td style="vertical-align:top"><p>124.8</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>125.0</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-2.8** (-3.8; -1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Diastolic blood pressure, mmHg</p></td><td style="vertical-align:top"><p>79.4</p></td><td style="vertical-align:top"><p>-2.4</p></td><td style="vertical-align:top"><p>79.8</p></td><td style="vertical-align:top"><p>-1.7</p></td><td style="vertical-align:top"><p>-0.6 (-1.3; 0.1)</p></td></tr><tr><td style="vertical-align:top"><p>Waist circumference, cm</p></td><td style="vertical-align:top"><p>116.6</p></td><td style="vertical-align:top"><p>-6.9</p></td><td style="vertical-align:top"><p>116.7</p></td><td style="vertical-align:top"><p>-3.4</p></td><td style="vertical-align:top"><p>-3.5** (-4.2; -2.8)</p></td></tr></tbody></table><p>Full Analysis Set. For body weight, HbA1c, FPG, blood pressure and waist circumference, baseline values are means, changes from baseline at week 160 are estimated means (least-squares) and treatment contrasts at week 160 are estimated treatment differences. For the proportions of patients losing &ge;5/&gt;10% body weight, estimated odds ratios are presented. Missing post-baseline values were imputed using the last observation carried forward.</p><p>** p&lt;0.0001. CI=confidence interval. FPG=fasting plasma glucose. SD=standard deviation.</p><p>&nbsp;</p><p>&nbsp;</p><p><img alt="" width="580" height="581" src="data:image/png;base64,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" /></p><p>Figure 2 Cumulative distribution of weight change (%) after 56 weeks of treatment in trial 1</p><p><strong>&nbsp;Table 6 Trial 2: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 56</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_13" o:spid="_x0000_s1028"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:70.2pt;margin-top:25.65pt;width:454.35pt;height:145.45pt;
 z-index:15732224;visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Saxenda (N=412)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=211)</strong></p></td><td style="vertical-align:top"><p><strong>Saxenda vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline, kg (SD)</p></td><td style="vertical-align:top"><p>105.6 (21.9)</p></td><td style="vertical-align:top"><p>106.7 (21.2)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, % (95% CI)</p></td><td style="vertical-align:top"><p>-5.9</p></td><td style="vertical-align:top"><p>-2.0</p></td><td style="vertical-align:top"><p>-4.0** (-4.8; -3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, kg (95% CI)</p></td><td style="vertical-align:top"><p>-6.2</p></td><td style="vertical-align:top"><p>-2.2</p></td><td style="vertical-align:top"><p>-4.1** (-5.0; -3.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Proportion of patients losing &ge;5% body&nbsp;&nbsp;&nbsp;&nbsp;49.8</p><p>weight at week 56, % (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>6.4** (4.1; 10.0)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Proportion of patients losing &gt;10% body&nbsp;&nbsp;22.9</p><p>&nbsp;&nbsp;&nbsp;&nbsp;weight at week 56, % (95% CI)&nbsp;</p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>6.8** (3.4; 13.8)</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Glycaemia and cardiometabolic factors</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Change</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Change</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HbA1c, %</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>-1.3</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.9** (-1.1; -0.8)</p></td></tr><tr><td style="vertical-align:top"><p>FPG, mmol/L</p></td><td style="vertical-align:top"><p>8.8</p></td><td style="vertical-align:top"><p>-1.9</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>-1.8** (-2.1; -1.4)</p></td></tr><tr><td style="vertical-align:top"><p>Systolic blood pressure, mmHg</p></td><td style="vertical-align:top"><p>128.9</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>129.2</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-2.6* (-4.6; -0.6)</p></td></tr><tr><td style="vertical-align:top"><p>Diastolic blood pressure, mmHg</p></td><td style="vertical-align:top"><p>79.0</p></td><td style="vertical-align:top"><p>-1.0</p></td><td style="vertical-align:top"><p>79.3</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>-0.4 (-1.7; 1.0)</p></td></tr><tr><td style="vertical-align:top"><p>Waist circumference, cm</p></td><td style="vertical-align:top"><p>118.1</p></td><td style="vertical-align:top"><p>-6.0</p></td><td style="vertical-align:top"><p>117.3</p></td><td style="vertical-align:top"><p>-2.8</p></td><td style="vertical-align:top"><p>-3.2** (-4.2; -2.2)</p></td></tr></tbody></table><p>&nbsp;</p><p>Full Analysis Set. For body weight, HbA1c, FPG, blood pressure and waist circumference, baseline values are means, changes from baseline at week 56 are estimated means (least-squares) and treatment contrasts at week 56 are estimated treatment differences. For the proportions of patients losing &ge;5/&gt;10% body weight, estimated odds ratios are presented. Missing post-baseline values were imputed using the last observation carried forward.</p><p>* p&lt;0.05. ** p&lt;0.0001. CI=confidence interval. FPG=fasting plasma glucose. SD=standard deviation.</p><p>Table 7 Trial 3: Changes from baseline in body weight and Apnoea-Hypopnoea Index at week 32</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_12"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:70.9pt;margin-top:25.65pt;width:453.15pt;height:163.1pt;
 z-index:15733248;visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Saxenda (N=180)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=179)</strong></p></td><td style="vertical-align:top"><p><strong>Saxenda vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline, kg (SD)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 116.5 (23.0)</p></td><td style="vertical-align:top"><p>118.7 (25.4)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 32, % (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -5.7</p></td><td style="vertical-align:top"><p>-1.6</p></td><td style="vertical-align:top"><p>-4.2** (-5.2; -3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 32, kg (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -6.8</p></td><td style="vertical-align:top"><p>-1.8</p></td><td style="vertical-align:top"><p>-4.9** (-6.2; -3.7)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients losing &ge;5% body&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 46.4</p><p>weight at week 32, % (95% CI) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>18.1</p></td><td style="vertical-align:top"><p>3.9** (2.4; 6.4)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients losing &gt;10% body&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.4</p><p>weight at week 32 % (95% CI)</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>19.0** (5.7; 63.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Baseline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change</p></td><td style="vertical-align:top"><p>Baseline&nbsp;&nbsp;&nbsp;&nbsp; Change</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p><strong>Apnoea-Hypopnoea Index, events/hour&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>49.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -6.1* (-11.0; -1.2)</p><p>&nbsp;</p><p>Full Analysis Set. Baseline values are means, changes from baseline at week 32 are estimated means (least- squares) and treatment contrasts at week 32 are estimated treatment differences (95% CI). For the proportions of patients losing &ge;5/&gt;10% body weight, estimated odds ratios are presented. Missing post-baseline values were imputed using the last observation carried forward. * p&lt;0.05. ** p&lt;0.0001. CI=confidence interval. SD=standard deviation.</p><p>&nbsp;</p><p><strong>T<u>able 8 Trial 4: Changes from baseline in body weight at week 56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Saxenda (N=207)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=206)</strong></p></td><td style="vertical-align:top"><p><strong>Saxenda vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline, kg (SD)</p></td><td style="vertical-align:top"><p>100.7 (20.8)</p></td><td style="vertical-align:top"><p>98.9 (21.2)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, % (95% CI)</p></td><td style="vertical-align:top"><p>-6.3</p></td><td style="vertical-align:top"><p>-0.2</p></td><td style="vertical-align:top"><p>-6.1** (-7.5; -4.6)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, kg (95% CI)</p></td><td style="vertical-align:top"><p>-6.0</p></td><td style="vertical-align:top"><p>-0.2</p></td><td style="vertical-align:top"><p>-5.9** (-7.3; -4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients losing &ge;5% body</p><p>weight at week 56, % (95% CI)</p></td><td style="vertical-align:top"><p>50.7</p></td><td style="vertical-align:top"><p>21.3</p></td><td style="vertical-align:top"><p>3.8** (2.4; 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients losing &gt;10% body</p><p>weight at week 56, % (95% CI)</p></td><td style="vertical-align:top"><p>27.4</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>5.1** (2.7; 9.7)</p></td></tr></tbody></table><p>Full Analysis Set. Baseline values are means, changes from baseline at week 56 are estimated means (least- squares) and treatment contrasts at week 56 are estimated treatment differences. For the proportions of patients losing &ge;5/&gt;10% body weight, estimated odds ratios are presented. Missing post-baseline values were imputed using the last observation carried forward. ** p&lt;0.0001. CI=confidence interval. SD=standard deviation.</p><p><img alt="" width="589" height="361" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAk0AAAFpCAYAAACBLxzlAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAKagSURBVHhe7d1nlDVHee59fzrrtY9zwJgD2EY2YDgEYxNMMiBEzhJJCCMyRiCiBBhENAhEOIAJBiSCyCAyRogkMgITTDoiGxAZE40xOPW7fm1dc241e8/smdmzZ57nuf9r1epUXVVdXV119V3V1T83NE3TNE3TNBvSoqlpmqZpmmYBWjQ1TdM0TdMsQIumpmmapmmaBWjR1DRN0zRNswAtmpqmaZqmaRagRVPTNE3TNM0CtGhqmqZpmqZZgBZNTdM0TdM0C9CiqWmapmmaZgFaNDVN0zRN0yxAi6amaZqmaZoFaNHUNE3TNE2zAPu0aPqv//qv0TVN0zTNgcZ//ud/rrWD//Ef/3H23mYn2edE0yyh1MKpaZqmOdAglLh/+7d/63ZwRewXoilqu2mapmn2J9LmzXLavvhpVkN3zzVN0zTNHiXt3CxXu+e4Zudp0dQ0TdM0+zixOjU7yz7fPWddYfnxj388/OAHP2jXrl27du32G/f9739/rvvhD384uu985zvDv//7v5/dKjY7ya6KpoifqQgK1mcdq/stf/SjHw1PfepThyc96UnDU57ylDX3N3/zN+fYbteuXbt27fYlpx2b55785CePfh772McOp5566tgmNjvLroomo/6JnpgV0z+b9WxXgRT/9fPKL3zhC8PDH/7w4VOf+tTwj//4j8OXvvSl4Ytf/OK437Jdu3bt2rXb35z27qyzzhre8pa3DCeccMLZLWKzk+yaaJoKpYikEKEE60yPVTTlPBBJT3/604d//ud/Hrebpmma5kDh05/+9Gh5anaeXRNNVQBl21wTZ5xxxnDyyScPL37xi8flS1/60uEb3/jGz0zcVQXW5z73udFMGdGUsOt6u3bt2rVrt6+5RSCatIHNzrPrY5qq+PnJT34yvOlNbxoe97jHjX20D3rQg4aLX/ziY7cbaiGK5QnMlAqMAXEgsGq4TdM0TbO/cuaZZw7/5//8n7O3mp1k10RTLEcRQhnfxEXwPO1pTxuuc53rrAmkapWqEE1MkxFNiJ8WT03TNM2+StrFqdO2pR1lWPAhVLPz7Gr3nJueJSKcQChd97rXHV7wgheM29kf/z63/NCHPjR84hOfGL8aYJ2ajmniN+c1TdM0zf5C2kJoB3tM02rY9e65ukTWX/Oa1wzXvOY1h69//evjdv6tk4LCuvTc5z53HPfkq4FHPOIR49QDcJyr4ddzs69pmqZp9lXSjn3yk59sS9OK2FXRNA8WpyOPPHJ45CMfOYql7KuC56c//elobfqXf/mX4WMf+9jwxCc+cbQ0pRBFNGU7S1jvicCapmma/YH/+3//b49pWhF7UjR94AMfGP78z/98/JIOBFMd1zQVPOaqoLKNacoxyyqyiC/hpAuwiqimaZqm2Vdp0bQ69qRoYmFiaWJJQkROhM5U8BBNZgSvA8ER61Q9L6IJ1pumaZpmX6ZF0+rYc6LJP+Re+MIXDu973/vO3nPO6QUifGJFwuc///lxEJzuOceIqG9/+9vjMdsRStXyVJdN0zRNs6/Soml17ElLEwia2g0X4ROqCDIo3P93/vVf/3UcOH7jG9947au7wH/CiGuapmmafZ0WTatjz4mmiKHarZb1HKtLGAh+7LHHjrOHP/rRjx6uf/3rD7e5zW2Gl73sZcPrXve68XisVXFN0zRNsz/Qoml17KpomideCKKpyInfWecYMH6Pe9xjuPnNbz5c5CIXGQ477LDhkpe85HClK11peMxjHjO87W1vG/1tFE7TNE3T7Gu0aFoduyaaqmghkqrTjQZ+arec5fQ8vOc97xkntzSuiaXpXve61/gblmOOOWZ461vfOpx++umj35yb9ZzfNE3TNPsqLZpWx66JpgiWKmYw3Ub82p9jdf3d7373cNxxx43WJULpile84jgx5lWucpXhYQ972PDOd75z9EeARZDNiqdpmqZp9jVaNK2OXe+eq1al8IMf/GA45ZRTRuvRs5/97DVrU4ROljnX71T+9E//dLjJTW4yjm262c1uNtziFrcY/uqv/mq43OUuN5x22mlr4VtydZB50zRN0+yrtGhaHbvaPcfFihQRY9oA8zT95V/+5fhF3JOf/OQ1CxG/1UKUpekJiKR3vetdw2c/+9nhVa961XDUUUeNSxYo4SATXIa63jRN0zT7Ii2aVseui6bq8Ja3vGW0GH3zm98ct5HjEVioliLiyM9973rXu47jmQwKZ3m6/OUvP4qpI444YvQX4SWsDDRvmqZpmn2ZFk2rY9e756ZC6MQTTxytQ5/73OeG97///eNkl4jAyZLf7373u6NlymDvW9/61sPxxx8/PP7xjx8HhN/73vceDj744OEhD3nI8OY3v3k8B87n2srUNE3T7A+0aFoduzoQPAImzuSUrER/8id/MnbPHXroocOtbnWr8fcojuc8fOYznxnuec97Dve9732H29/+9sMDH/jA8ee9EUNnnXXW+CXd29/+9vFcXXM1jKw3TdM0zb5Mi6bVsauWJlTx8qMf/WjsXuPAyuQLuFe+8pXjNoifap3Cl7/85eHpT3/6aHlCuu6MjfLj33/6p38a47HfudPzm6ZpmmZfpUXT6tgToiki5qc//enwrGc9a3jUox41bsN4pGc84xnjegQPa5LzIrj8RiX/nnOcsMIHPvCBcYLLiKmcn/OsN03TNM2+TIum1bGrA8GraImQ8SXcTW9603HupZe//OXj3EtEUfUbUZRz/KDXF3Lf+973xu34Zal6wAMeMDzxiU8ct+PfMsKraZqmafZlWjStjl21NE0tPREzp5566nCnO91pHNf0xje+cTzGr2OWETs5//Of//zwhCc8YRz7BN1wEVYvfvGLxzFSH//4x8dt59YwmqZpmmZfpkXT6thVS1OWdR3Eka46SxBBGaeEiJ6IJpYm8znpngs59q1vfWu4+tWvPk5wiYSZ403TNE2zL9OiaXUsTTSx9phcMs72ekS8oAqYWSIK/FR/df0LX/jCOKYplqZ6Pn8nnXTScPLJJ69ZnyD+Gn7TNE3T7Iu0aFod2xZNBJL/vP3cz/3cOKGkdctsO75ZImYibAifWQIn+1iaMhC8kuMGhF/hClcYpx9AwpsVZtM0TdPsS7RoWh3bEk3+7UYk/d3f/d3Ze86J/Y7ztyiETKxIETfZnoqcbG8kmlig7njHO679TsV+rlq7mqZpmmZfpEXT6tiyaPrbv/3bcaD2IvD3mMc85uytxYjgIWzmWYayvZFoglnBFaqf/OQn43bCbJqmaZp9mRZNq2NbosmkkYvAH/+LYFZwv1AxJsrSeKUIpqnIyfYiokk4fqtiEkxMw2qapmmafZEWTatjaQPBg0/8WZU2I6oqZ5xxxnDuc597uPa1rz06czbNswptRjQJw69W/JOOMMu+pmmaptmXadG0OpYqmm5+85ufYzC45WZ5xzveMdz4xjdeEzYgfkw5MM869KUvfWkcr7SeaIIf+z7iEY8YvvnNb569p2mapmn2bVo0rY5tdc9N8cVctS7Z3oipsHnnO985Cq4XvehF4095c9yyWpzSjfeVr3xlFFqPf/zjx3/XVaZhGxB+1FFHDU960pN+ZlbxII4eIN40TdPsK7RoWh1bFk3/8A//MA7wrvMx+UruoIMOGi1Mlot+NUe4RLyceeaZw+1ud7vx/3PGIBFDSFda/BFUfo/CPfShDx0e9rCHjb9NqcRv7YYzc7guv1ilEneEkvXutmuapmn2FVo0rY5td8+xOFWrU8Y0WS5KFSrEC4uRr9zMq3Txi198tCZF2HDWddexHLE4KTCsR/O65yyzrivv2GOPHb7zne+M26EKpeq/aZqmafYyLZpWx1LGNLE6sSptNAv4ZiFk/Dfuwx/+8LhNyETcVJHjy7jpb1QQ4VPPw/3ud781K9hUINX1pmmaptnrtGhaHUsRTWFqdVqEqUgxJuo973nP8IlPfGLservGNa4xWpMifOI/Fids9PVczk0XnDmbLn3pS69Zm2pYWTZN0zTNvkCLptWxZdFE3BjTZPxSHdsUq9Mi0w1UgZJ1ViNTAzzgAQ8YnV+gROxENGWZc8S9iKUp4sgg8KOPPnoMOzgeathN0zRNs5dp0bQ6tiyafOFmigHjlzLVQCCY7J/3exXMEyUEzVe/+tXRehQRNBVLWxFNOS/i6JRTThlufetbD//yL/+ydiz+UdebpmmaZq/Soml1bFk01ekFLGdNL7CVn/VOqYJmKmSyvejklgaPhy9+8YtjF91rXvOacZvfzAUV1zRN0zR7nRZNq2PLookliVCKs70sIlh0p0UwVcET4m+RMU3VCcs4qcc97nHDS1/60tHPlJzbNE3TNHuZFk2rY8uiCbrFWJN24qu5Ov4oYmdK9m0kmhJWti1Zx17xilcMd7jDHYbnP//5Y6E766yzxq7B73//+6O/pmmaptnrtGhaHdsa07Ro9xt/m/mlClFTxxhFRE3J8UUtTSxMwsJLXvKS8bcq17ve9YY//MM/HMc3mVncl3VvetObRj9N0zRNs9dp0bQ6tiyafCVn1m/L9VjU3xQWJr9UMcElInwq2d5INEUopbsP/L/xjW8cjjzyyHFagz/7sz8bC91znvOc0QLVNE3TNPsCLZpWx7a65wihfEVnfiYWpTjb+apus4IJr33ta4crXvGKwy1ucYtR6ETsVBYVTbCecAgyXXLOufKVrzym8drXvva4fNrTnrY2OLxpmqZp9jotmlbHtkRT8MsUAolFyaBwS9uL/EqlCpvw9a9/fbjlLW85dpnd5ja3GUVOmOV/UdEUrJ900kljd5wB7Pe85z2HBz3oQePcTaYieN3rXrfmrzIr7qZpmqbZTVo0rY6liKatwOJDhHDVimTdV23HHXfc8LznPW844ogjhp/+9KdnHx3WxiVZGrDtJ70f+9jHzvHvuYQbkVO3E5cf9xJJr3rVq8Yf/hJoJ5988nDIIYesWZoygBw5l8u+pmmaptltWjStjl0TTYRHphGwHiHiFyqHHXbY8LnPfW4UL7e61a1GfwRMxiRxX/7yl4dnP/vZo7Aish75yEeOE1Ui4SXMCB3hJM673vWuww1ucINx1vG73e1uwzHHHDN2B17wghccHv7wh49+wqxB6E3TNE2zF2jRtDp2TTRhKm7MneSXLDe60Y2G008/fbQ2Xe1qVxvXEdFk+d3vfnf4yEc+MlqZzDxOOM2zNEU0ZUlcHXzwweNXcmecccb4O5X3ve99w9WvfvXh937v94bb3e52Y1qC87LMetM0TdPsBVo0rY5dFU0ESKw4xMyPfvSj4a//+q+HBz/4wcMJJ5wwHH744cNlL3vZcbzSVABVjGl6ylOeMvzwhz8ctx2PQ86JI5r83+4Zz3jG8NSnPnU89+lPf/rwiEc8YrQ2HXvsscP3vve98dxQz2+apmmavUKLptWxFNE0bzbw9f49V8USl0ksjV9i5XH8BS94wdhVV7vd7M85IQPB54kmyyqcdNH95Cc/GcMl1Koz3YA5pepUB3U5S7Q1TdM0zW7Roml1LEU0zfrvnBm3f+3Xfu3srZ+F8CBA4hAhFT70oQ+NY5bit46Byjn4whe+sKFoyjnZN51pPF/oEWy+prvzne+81kVX44r/pmmaptkLtGhaHdsSTcYf1f/PTZ15j+YREQPLrM+yJFW/2V+FzFQ0hWkYcF7WLWft//SnPz1OQXDqqaeeIz3TNDRN0zTNbtOiaXVs29Jk4koWpTqxZdxGVDGS9biIFceqqziOReZpmkXiynrFIHEzhetiTLzxP/Ub5u1vmqZpmp2iRdPqWEr33Lwf9s4b64QIjCpEqotIqpYerpLtrYqmIJ5Zfu93v/uNY6qMf0p65vnFovE1TdM0zbJo0bQ6liKajF/y2xQiKe6v/uqvxi66eRAfiNCwjCCZLmE954Qc265oqv6ItMTzta99bZzHyT/q7A9J16LhN03TNM1O0aJpdSxFNPltCuerszjjmdYTTSA6IlDmCZCIk6lgQs7ZjmhaL14YjH6hC11oeOYznzluLxJm0zRN06yKFk2rYymiyZgm1qYpxNM8Ij4sOaKI+9KXvjS8/OUvH57znOcMb37zm8dpAKq/SraXIZpiPQp1+2EPe9hw3eted/xlyzwWiatpmqZplk2LptWxFNHkx7yzBn6vJ5pAaMTp/uLe+c53Dve5z33GySdvcYtbDI961KPWBNWUCJXtds+hpiUO4vVVnt+0uM7pF3oh/pumaZpmlbRoWh1bFk03v/nNz9Edt9nuuQiTCKJssyxlfqR3vOMdYzgGYlemAsWUA09+8pO3JZpmUccxve1tbxvTYsbyt771reNPft///vePv2AxRUH9qXDTNE3TrIoWTatjy6LJYG+iqA7+rm6jgeCIUCJOLCOgTDRpqZuOtSnHuRzjzOhtwkuiZdmiKfHFffzjHx//SXfooYeOXXVE47Oe9axROPmx8Le+9a1txdc0TdM0W6FF0+rYsmgyhmmjuZiIp3lEjCCiCEQQsXTDG95wuOpVrzqKkvjl+OX8qPeud73rcNRRRw1HHHHEOBnldMxRwtwqhFni9EPf+9///uPPhC94wQsOF7vYxYbLXe5y4+zhZi3/xje+cfZZTdM0TbM6WjStji2Lpso8i5IxQCxOs8QTMUIgVWFjWzfXN7/5zeEjH/nI+ONcY5r4IWBQ50wKO9E9lzg4aSLSTORJnJ3//OcfrnOd64zTLHBnnHFGi6amaZpmV2jRtDqWJpp8QWdpbBNxkf0wq/Y84ZQla84UYujiF7/42n/i4ifWppy/jIHgs6jxuaYnPvGJw7Of/ezxR8I3uMENxm65O9zhDsPpp58+fPvb3x79Nk3TNM0qadG0OpYmmliUdNexvBBO2R+yr0LUxGJk3QBw4uSjH/3oKIQIrStf+cprg6z5zTmWEUU7IZpiZYpzbde61rXGr+he+tKXDocccsj4U1+Dw41z+sxnPnP2mU3TNE2zOlo0rY6liaZKtuv+qZ9YcaoIYlF62cteNtz+9rcfjjzyyOHe97732E2H6scyDvlh77IHglde+MIXDle60pVGcajb0M+KrRuoThASUk3TNE2zalo0rY6liCZTDMTS5KsyznqEUn7qWyFKMqapChRjln7wgx8M3/ve99amHsjxqd+s71T3XDANgnmjbn3rWw9PeMIThuOPP3549KMfPTz+8Y8fjjnmmOGiF73oKJpe+cpXDn/xF38xfmmXuF2jr/xe9KIXDV/5ylfGfY4RgU3TNE2zXVo0rY6liCZf0mXeJl1q2SakdNfpwmKZqRAOERYREbPERMYuVf8h2zslmhKnNPz93//9ODaLO+2004bXve51o/NfOvse+9jHjmOdzB6u204eSA/LmC8AL3GJS4xzPNnOvFOutcVT0zRNsx1aNK2OpYimjWB1mv5mpQqaqbixXQVF1mf5w06IJucSSzUd6+GLP4PEdS9+9atfHc9nlTr66KOHW93qVmPX3tWudrXhSU960vD5z39+PC7c6ReETdM0TbMZWjStjh0TTUTSdBzTLCIYIlKqgCAq7ONmEb87JZpyfkRTFVDSlPFVET62X/KSlwxPe9rThu985zvjVARXucpVxskwr3/96w+HH3748PCHP/wc80lFmDVN0zTNVmjRtDq2LJrq13DWCaRZbh5VlFgSDtkXkZRtxwiTKY5hJ7vnImiSFiSt9VjSRzj55YoxT89//vNHwWTdoPaLXOQiw41vfONx6gJpTjhN0zRNs1VaNK2OpViaTGJJIOmGizPOZz3RFCI4Ih4M/v7sZz87zn30uc99bk0wzRIX2bdTlqZpvNYJurrM8SqALF2/Wc39o85vXozvuuMd7zic73znG+5yl7uMXwXm/IivpmmaptksLZpWx1JEEzKhZYV4mkcEQ9ZBpBhkfdhhh42/SLniFa84nHTSSXNFRfbvpKUJsSKJj4uYqumK3+wzcNwEmPe6173GrjnddKxM3GUuc5lxrJM0f+lLX1o7RxgJxxd7vrrDrHimzNvfNE3T7N+0aFodSxFNxi/5as7Xc8HXcrOEVCAEIhLS4LPe5Msy+OqMwKhTD1QXMUE0PeUpTxl++MMfjtvVz6pJmnxJ5we/z3jGM8YvCVmXWOQ++clPDje5yU3G7jpjnO5xj3uM458quvg8AKeccsrZe/6baZ7Vbsyp5atpmqY5MGjRtDqWIpqIJdMKTLvj7FuP2tDXxj7rb33rW4drXOMao5DKvuovnHXWWcNTn/rUPSWaCB7TD/iajkXJ/E3mebrlLW85Ttz55je/ebwuXXfmpCI6n/WsZ40WKuLq8pe//PjV3Rve8Ibxv3dwPfIslq6pUIqoShqapmma/Z8WTatjKaKJWJr1tdxGY5rS4KfRJwbS8BMEuumIIUQMZKlb67jjjhse8YhHjNaahzzkIWvdWQmTWzWJ833ve984yaXr+PrXvz5OP2Bep1e96lXDCSecMAokggn8mO/JGKib3vSmw41udKPhcpe73Ojudre7jeOjvv/9749+XXvyIfnFoe5rmqZpDgxaNK2OpYgmX8+Ze6iKJN1zs/43F9KwRwCAeIDuqfvd737DEUcccY6uK/7ijF8SJ/f2t799FCUZ01T97RbGc73zne8cl6eeeupocXr9618/CqCXv/zlozWJIDQ9wac+9anxHF/ZmXn8Cle4wnDZy152nCTT13dmGye2kOuSRzUPs548bJqmaQ4MWjStjqWIJmOX0j2nq45Y8tsUAmEjImzS2BM+LEisTPW3I45bVktKlqxOe617TpfaiSeeODz3uc8dB7NbnnzyyaMzweWZZ545jtVibTIeS/rNnk4oGQf1gAc8YPijP/qjsXtS956wgh8YJ0+SL7lW8bdwapqmOXBo0bQ6liKaoHuO9cTYHI0/C9B6pNEPGntO19Uf/MEfjOLiQx/60DgYnF/Hck6ESZamJiAs9oJoAisQl3TPI6IHrE23ve1thz/8wz8cJ8D002KDxz0Iv//7vz8ccsghw6Me9ahx/Fao4ZuF3ID43bzupmmaZvW0aFodWxZNxNF2SINfG36WF1aZu9/97sODH/zg4dhjjx3HKmXgc/xlGXHwxS9+8RyWprAb4iFxWma9isOaprofhx566PDkJz95HPx9z3vec7jFLW4xdjsat+U3LL64e8tb3jJ84xvfGIViDcv9uN71rjdOVRDmpaFpmqbZOurV1KmpY2t9jNpO8Ws5y0/8bYcWTatjy6JJV5yGevpPuUWpBSrrxJEvyn7wgx+MA58tCSHHp4UN2bdT8zStEpama13rWqNo8vNfX9kZFH7f+953nBSTgGK9wnve857hZje72ThhpgHl97///cdxUOc617lG65TuPsIKyVsPbcRn0zRNsz3UqVzq2LRTljlWt4N92W8Zf9uhRdPq2JZoMmZJw80t0iU3jxSeeWjsIxgqOWd/EE3+R6fQ65aUl6xKuukMFCeKfEVnYLkHjLD0ZR7/BpqzyF30ohcd7nCHO4ziyRgzVjvXnwc2gmlfypOmaZq9iDo1QzC4rNuf+jaog2FffXG1P21f9m2VFk2rY8uiaTrbN8GksffV3GYFVC1stfBUMTWrYGV7fxBNIJhMfukXK8ZzffSjHx0+/OEPrz0Qz3zmM4fHPe5xo1VKXpnW4Pjjjx9nHPdfu6tf/erj3E5mIdfF993vfvccD/Y0f5umaZqtoX0igma1U/areyOM8vEObKuLEf/bpUXT6ljaQPAKC5Sv5zaa3HJeYan7FTak8FXib38RTX4h88IXvnCcnsC0BH74m+kJTHoJX+URpc973vPGL/Ie+chHjsede5/73Gc444wzxq480xwY64WIpX0tP5qmafYi6lL1ahVAIcdm1bnZdrxao7ZLi6bVsbSB4IRS5mbSdUcw6bbbCIWuFqwUtOyr29kXsr0/iKaN0up4Hk4PG0vfMcccM07xYOZxFiZjoDj7jjrqqPGLOkzFZtM0TbN10m6lbvUBjl6BvKjWYyZd/uAHPzh861vfGrfTRZf6fNoGboUWTatjW2OaiCJCiVUpQmnRrrmqzmuBSUFTsAwyt0yhmhasbO8PoinXPb3WWdcg7zhf1RkoTiD5IfCd7nSn8Su7P/mTPxl/2aKrDwm7aZqm2T6pp6GNIlh86WwcKvHkGD8mZ37Qgx40fuBjaIU5BUPq+WXUzy2aVse2RBPnZ7SEUgaELzKhJWaJgeCruYc+9KFjw++/bEgBw7SQEWlEU51yYL3w9zLTdM+6Dvs8qAaAm0Xcw+jnwH6/Yp+JMY1rMuYJyS/LKlabpmmazVPr0S9/+cvjC6wvll/72teO40xT5xpWoS0zvokfv9JSfztuGbddWjStjm2JJl9pTckXdSxQiwqoii/DTHDph7U+wa9dTHEpdCGWpv1BNC2K6/dbFpN/GhhujNPRRx895sOzn/3s0eoUix+B5SFf1gPaNE1zIKMejXDy39AXvOAF4z4f72i/1M/q3fe+973j2FP4q8Ob3vSmtXq4uu3Soml1bFk0Tb+eCxnblC67zaIgfvvb3x5e+cpXjnMRffOb31zbDwVRIbPtM33bCgzzZ+2eW0ZB3Mt4KD2ABoD7Uo6A8n86A8N12R188MHD6aeffrbv//ZvGoKmaZpme2hftD0w/QuhxJrkQxwTM+el3kut32ZBj4x6up5rfRltVYum1bFl0WSwMfL7lCqUdNnZt9WJL+EnvAY1M3kqVAphLWAG3PnSzM9sWVeYRKezYe/PuD5vMUQqcfTWt751nPRSfpjXyYNr9vCaDzX/mqZpmq2hHo0wMtDbkAhfPRNIXmSNJ/3ABz4w/rnB5MRebI13IqpybnXbrZdbNK2ObXXP5Se9xBLRtF2hVCEEiK+vf/3rawWLOo9CFw+RwCmslP6BJJrA0mYuJuO+LM2irouSgPLTX184stglL+Rh0zRNs30y5AGmgvELMJYk+4klw1dYn0xK7M8NEUxTV8PZKi2aVse2RBNRs5VxS4ugoN3kJjcZRROIpVrAqgAwEG/677ntFsJ9keSJbrgXvehF469YrnGNa6z9UkWeHIj50jRNs0ymbVCl1rHT+jbb2jFUQ8B2aNG0OrbdPbdT6Fo67LDD1ua2SCG1rA4Ggvvf2oEqmjyAyZvg01bmYObijPWqedY0TdNsDfVo6lyix3r+vmA9znatny1z/jJp0bQ6tiyadhqfy9/97ncfu+HmFbRs7y8zgi+LXLeuS1/SmbrBYMXgeCx2XB7opmmavUxtC1JnRbRgWp/ForMTiCP1KJKGWfCTdMb/MmnRtDr2nGhKQQy1QE4LZY61aJqPX7Fc+tKXHgWo/Eg+yuP6EGfZNE2zl1F31XorznbajuzDTtdrwudYmr7whS+MHzEZ2+SjHF84+2DHEIlYoqpFKudvlxZNq2NPWpoUplkPxpQUthZN58R1p/JgqTNv1mMf+9hxf1zyGMRT1pumafYqtR2o9buPYiqp32a1G8ug1qV5+TTHoC/mDPr2kmoIi4mHzdNETGH6oop6HVulRdPq2JOiqRaoqPK6L6SwtWg6J9O8MvmlT2JNRZCvGx33AGd9mrdN0zR7jdoWECj+u/nABz5wHIJg5m2/MlHf8VNfvHeCmhauvniaEsfXcvnhfPzNSssy0tiiaXUsRTT5km6R/80tgoKnoNUCiSwrKWgtmn4W+RUHX9Nd+MIXXpudNg943nyapmn2OmkXYBLkT3ziE2MX2B/+4R+Ovyz5zGc+s/ZBUPW7bPLCWetPcWXdr8D8zcJx+9W3nDbKfm2c7Zyz3XS2aFodSxNN5gTSDbSMuZpSgFKYUrimBSvbLZrOSfIs6/LRHE4PechDxun+K45X1zRNs5eZtgcEiImO9UrA8fjZSWoc6tgqft72trcNj3rUo9b+nWpqHr+2MmHzxS52sXHCS+2l+Z2Wkc4WTatj6d1zJvRSGBadFXxWgTHPkBlV9QOnIEaxV7Ldoulnce2c/AserEMPPXR4/OMfP07l4G/cJsX0qxqiqj70mLWecLPeNE2zFaZ1yax6ZbrPMvVUHMuSMZuzfhNV/YXpdpi1r9afmBXOVDzBlDnHHXfcWK8ix9/85jePP1PPGKyEsV1aNK2OpYim/IeOQPJ/nYMOOmht4stYoKbiKQXfMg6Ej//I3fWudx3ufOc7j3+NRvzWQpal/uM6T1P85PiBSvIrmLvJA2smd+ObfFVH2JpI9NWvfvVo7kbuRc3v7EO2676mafZfTCDs7wL+vmAaE9391tW9W6HWIVlPXTPdrpYlLl1j1mH27Yte9KJj21H9o9ZR1lmjLBN+xb6cGz/pfqsux5Hj9iVd8EeGy13ucmv5k7jUsf52YdC4feJLWNuhRdPqWFr3XP49RyBNxzcRTNPJMBWYFKQUOvgFyHWuc51xMB9VfvnLX340caaAzbI4iY+lqUXT/8O152HMkvWOCH3EIx4xXOlKVxq/8iCe8JrXvOYcD3jyTp5DhfSSl7xk+OxnPztuT8Nummb/hWh6xSteMQqn3/7t3x4tO9ZZ+bdC6qdaR9c6pdbz2a4CJeIHBoRf4hKXGMczIX6yzDqX8yJWpv5S36H6z7H4y7Zj9Tjkye1vf/vhPOc5zzi5cI7jda973ThpszFP9ieM7dKiaXUsdUzTevAzJQUpUN/C8Zf+cMghh4ziCfx7cFJ4rUM3Xoumc1KvPw8z0WSwJOvShS50oeGNb3zj8MhHPnKcQ0Qe1wpw+jAbcHnZy152FFqVAzmPm+ZAQ52QOgPbrWcjKKrLPkQ8pT7KcS7c7W53G1/KvbDXYwkj2I6bQhzV48JIvZl90zox+7MeiMvb3e52Y/fc1a52tdG65DxdcocffvjwC7/wC+PYUuck3u3Soml1LEU0zRJM6bILxjpVakFRGG3rk773ve89PPGJTzz7yDDc9ra3HU2dUPByHqFk/9Oe9rTRcsL52zT4iTvQyYOPM888c3xYb3WrWw3Xv/71h6te9apjvumy80bkjY1wVVF5mK2zErqXukrdizvc4Q6jVco/AeVvrUSaptk/Sd1r+cEPfnCtsa918mYxgDsvvmkDhGs99ZZ964VvEsm73OUu49dz6jUWMWH4ebv2xLmWxm6qy9Rp4jXWyLhO+2w7x+BtzlQBznGcZZ5VLcNEHCdOiKLTTjttDPfBD37wcJvb3GZsu9Shhqac73znG575zGeO3ZiPfvSjx3SwzBm6okdG1520YL3rW5QWTatjy6JJQ7qeY1li0ZhHLShZJ3ruec97jg148JVBRFP8KeDf+c53xoHMH/3oR8cHxyRiHhTwF3cg4rojZlIZwZgmDzQB5GsTgsn6jW9849HyxJL09Kc/fcxfwsib24Me9KDhfve733Czm91sFFlXv/rVxwrjQx/60AGdx01zIOE5j5i51KUuNVqts387OD/WpCniYp3RlQUWG+JA3ePjFefd4x73GK597WuPaWI5V5/5au2v//qvh+c973mjIDKGiKghqvgRrhfFS17ykqOFiggU3vWud72xntP+GBKifdHrQZSZ3RvveMc7hhNPPHGcuoUhQJtjPCgBJRz1qp/HezllTCDKjjnmmPErOWn7pV/6peG3fuu3hvOe97zjONxlvXS2aFodWxZNChthtJ6jqtejNuigvE844YRxsrIgHgPKQ/zX83og+Dlx3XkDrPngoVbBvP/97x+3VUjGKRnXZOA9k7tKQGVEjOqK85ZldltWKmLpWte61vjZrDe6pmkODNTVUA9c5jKXGV+qpvXLZnCO+oez/pWvfGUcOuCF2/hJQwXUPX46bsJKfvwSivjRxUUIvfvd7x7rJuLE5/ys30cfffQoWrQZ6jmiycu4weJeGr1sC4sQ01tBLKkrc31hakGzPm2vpriGY489dnzplDaTbWqT5JkX0wte8ILDuc51ruHXf/3XR2uTF1Ciahm0aFod27I0ZXA3i8TUqqTQrmdpwqwC+IY3vGFU/AqbcTR/9md/Nqr+KPKcUwt1Tzkwm+mD7y3oyCOPHD796U+PQlNF4g1J37uKKG+PFRXPjW50o9ECxczsQf9f/+t/jaZogot5eiOkYVop4UC/P82+geco9Q+U25TdPGPLKMs1jMQ3jStsN87p+bOuY1b4RImPfrxATT/xn+Xfi7Afh/vAR33uhcw6C9ERRxwxWm5AbAiXVYb48XGPoRcnn3zyOHml9JkU0n5da6xOLOV+7K6t8CJHHPF70kknreVVrms96nVbOifn1XCm61wN+/jjjx/Fm+496Wbxkh49Ib5U/uVf/uXh3Oc+9ziQ/jd+4zdGi5NelBrGVmnRtDqWMqaJVWkKBT1r/0Z4IEyNf4Mb3GCcUyjCS6M7bXhT2Fo0zcb1Jw+8/cij6173umPlpNvTGCXrN7nJTUZTtR9NIpWD/Gb1I2RVTt6emKS9ORFPV7ziFUdztu34T2UCP6qMEMv+HAs1jQf6/Wr2Fsqj8poymvJdl1yOc1ulnl+fk7pfXGE7cakLEgc3jXte2F6giJorX/nKo3jS/UXIeMZZbFh1jNtRt/gCmuWauFGPe8lSl7Nk614zbQExwfoDXWFe4mL52Qh1ksl6+ZUGooRA8zJoP4HmOjJmatkIO/dDHNKhm043nqVxufLIi6rhDb/zO78ziiRiiSOcdNXJp+TBdmjRtDqWIpo0vFxMjd4GjJ3ZqHtuHky2phwQjoKZQjklD3eLpvmk4pCPBjZ6i5NfutfOOuus4Wtf+9q47iH3OWytmFmh9P2zKjKd67JT4emf95bnqxWVl/ukQjUIMuZ2cTGl++ddJs4M4uCHW6SCbJrdQllVRuMwr17ZTnmuYWfdUvx5XpDn07F56dgI56oTnF/DJqYSfvZZJj2edxadP/7jPx7FgC/D1POs1wZIE0TqA+N9fI1LxAiPqCGeWITEMYXYWvRapFu4RBjBwWKl7WENP+qoo0ZH1BEuwlw03K2QfEkcrk36kMktiUAWJ70nuui8aP7+7//+mHZDJbzEmidvu+ls0bQ6liKaiCUFdzqeafrF3FZQMFNBTAtWtls0zSb5lgd5imOpJFVsut+87QUWpOc85znjwEdvhpx1E5haGlQZCCvWJ+WAedwbqa5V4x+8+enKS3yJs3Kg36tm76GceoY8P5YaRQ08C4rxMB/5yEfGFwgvDawFs8r1oqT8b/QcSMd2iXBZL04vP67rVa961fiipGH3xa3n2nPvHGOOWFasJ8zk1TzkEf/xx9nOclHcB46Akk5CSTtkm0udJ0z+dgJh53qm18z6ZtyXfHQsZYO4NLg8Y0dTxrZLi6bVsRTRFBRajed2xVIKY8ibyLRw2YcWTT+La1eRpTLKg2uZfalYkq+601SE3ggdT4UQrM/azsPvPnnD1KdvArff+73fG03UrE0sh4H/aThJU9PsFfJcpIxbapDNw+PrLNYCFg4WBYOVDS7eahnOs+l8Da1JZD0zXmKspwssz2TStgxcmzg1vMQRy7CPRm5xi1uMX3zpmjc3E8szWJn5Nx7JQG1WpHrd0livJ9tJuyWsc8nbab0wi4SZJVjKr3CFK6zV/45N41o2wk784kh6XAMMOHfv1MH2G/+lfLiHBLe2Uj2rPDl3u7RoWh1LE03UPguELxn0Xaerbiuk0KcAKnSzClYKbYumc1LzKw+z/KwVSB7mHIelMQmsS9O30cA/597k/ky3CWemaE55IJyMh1KRQJg13HnrTbObpJwq33U76IZiacnx7eDZTNi6zFlmfXyhG4pIMWDYgOo8l9X/ZnGecHwQQnBIv0/kjXE0xQirs/rb12DwPOv2IuKk7QIXuMA4/lEXPMuyOYxSt9R6JuviSx6lrqjr/FjnL24eCSvhgRhRv9R4+bNMPbdsko7EOU2Tr/t8PUeAgkXS18jENWsdS712Mnm8XVo0rY6liCaWJZ9Q6pLzRR1ne6sWJ4UvhT4FvhbIkGMtmn4W184lL+s2Vysu+Zz8lYfy0hsnsj/nZz1h5Nw4b6DeTlWu/k2lUfGmrOvuhje84dgAzKoohCm8WLmaZrdRnlMWraOWTRYDLs/Ddsptwvc8sT54DoiX+9znPuMEiZ4rLs+buLYan5cXVqSDDz54OOWUU8YwP/7xj4/djWnka9i+hCbeCDdCzrxFfvqt4ffVm/FNqU+cR6gkjcJOWDUP4+yrLvvnUf2oq9QtxloSKK5BN2nNp5yzbJKO6fX5MlAdZyyo8V4mviSUDHQ3OJ1jNZTXROiy6rsWTatjKaKJWDLtQIVg8mPY9VBYFLQUwFq4bWdfLVR5c4iDistPfls0bUzNN8xal58edEvUe5D1OJVlvW8GgrrvygPxfMtb3nLswzf5nEnjvJ37wsXAcl2BBpDnfALLvCvzTNY1HVBhIWmZRSq1ugzzzmmWR83jer9yfy1zb+K2gzrAW73uJXWQpQ8UYvlOGarxxHpjXy1jlknzrDSaN8gLhvIK+6dl1HrORcRFqOnJel2y5mhYkTCm/rIPtrMvS8JC/WjgsU/ghWe8jcY78xZV6rZ1n/LLPy9CPiTxRa3xjtZ1zRmfMz1nGiam++b5W4/4d73urTqFWCDq1Flm4c64zOTPZuNYhFlh2ic/5I089y881jyOkNuI1KVJ82bS3aJpdSxFNG1lyoEUiFpIUrkoYCa59DaTB5LjN/6R/W1pWj6+/vAmmTyVl2lAPNzJ+9wTxyyN8zDYUYWh8vAwq0CY8H19k/NUwGZxJ6wyduLCF77wOPEboeVtLZ/i1vvOIRWMeFNu4uI3ZNsS1nNes/PUvM+y3rfcn6kA3wqsDRpOk936KbWPG0x2qIEVdsouahnIsqbVek1XzoO545RTXVV1old+6otdzsu50311O8eDMYKstawU8Zt0YlZ+2TZUwsuJ58s5rB+er5e//OVrlo0IvVDTsB7iNz2JOLDIOcukptM4Idcjn+SFbQIvfuzbK0jPNK+kM+Vxmv/xb/8itGhaHUsRTRq+Oms3waSve6MpBxSKaYWk0Bt0aBCxz0kJqAwE98BaqpRq5dGiaTkkf90PFZCv4PKlzCz45zcPtvvAdM/KxGxvfITZxg0E9ybI4jRvMkxf6fjaTpnRGAnTW3DespFyUpfZn/VKTXc9J+vNziKPk8+5P9N92V+f561SwyYKjKczrUaYpiF+LVMmUqZr2Y4lKudDeTXOR7eQSQ1zLOeEhB0Sb/zV49bFlcbeWB2f+BOB8WdZUV+yGBFExhmpKw1MNz7JOKV6Tn2+s12PZ/968OPlh2jcDZJWy1pmbOcYqr9FrmuZSFfSVteTDm0aC7sXy+R/0ssv62K+rqvXtB4tmlbHUkQTM7jGTrcMAcXCtNGYphSUFKQULOZNDz9Lk35hQoi/iKsUpFqYVIzeLFs0bY88wLknHmpfCene0KWmu84bJmc994Zz/zbK7xp2zgOrk646b8SsVESXCp9oI8IsZ70Z17CyzHrItsYo5yyS1mY5yO96X7KdJSzdk+3cl4SZcN1v845p3BOmYxBPhEnOQcKw5KeSMIj4jKHxbOge8s9G5dYzAmP2lOlYdRJ+sC/xo8YLabfua9ZDDjlknOw3Y41gygODwi11/eguMyea8UkJI9jOtSR/k57EOT1nFqy+wifOWI1ZwHRPxuK0KmqaXY/tXA9yffEzPb7TJF0haUlaCSYznSs7xjspNzlueeqpp44DxVlGk/5FaNG0OpYimoKvARb9ei6FhJuFAYd+3qthTsHjVDbO1eXD/MyxZqhYpv3G88Ju5pP7AmKUYPHmmqkEfGbsLYll0afI/Lo/EbWoD3rCq/c7/oPK2BxQulYIZmLb7wh0S5h1mKByb32RIi2+lPGGDWF5u0bCjwuJO2m0XdPY7BzyXV4n/3Nvss+Sy7Ht3pecb1zLJS5xibEuEm4t19aRNNSyG+z30pDfQRFELJ/K5TWucY1RqKh7TFpowK+JHvNLEOOHjM0z7Yaxe6yrBIZyHKuRQd7G/3E+Q4cyHnEkjX/xF38xDgI3z5mXCHgezcJvgLjBxOpHaRNmvZbpdsX+7Kt+10NdYBwUC5uJI31lawwi6/KqqfeyLuOm15TlqhD/NM+Ddkt7RRgTTKZsqOn1AY6eFoK5XsNGtGhaHUsVTZtFwdEQ+8Rd41i/qvKlBjNwumcUHoUrlYDKRYWkgTUdvwqJSbOyaIFr/pvkcTCgVh77/Fllr4ImUDgVtXFP/NeHHqnU0jhlYHe9H1n3tuzesVypjI1lEo/xbN5mkXBUOKxQuizyHytfoCSumva6zl/is6zpaHYO+Zz74FnPPZrmf8oLtnNvhJOyomHyny9dvcpTpZYNYsA2EeMlzTQZ/humzBhYzNJpRmciTJe1hs5vh9Q7XhpYRwkHIonoT5iZENLLI2uXsq1Os4Ryq34TFkEkbPFc7nKXGwWY8q+L2+Dt85///GO6iCvneWkxjiovC0i+cvI626kvrVtmPfmUvLd/XyDpD/V66jXU9ep/VRDABLdxob4uNMaMQCZ0jbFzj1gJGRkimlO3suaZ5kG6F017i6bVsS3R5Ma66ZbwRqZbTvecMU3rWZsUBgVbwysMFVQqMJjzyfw+EUKpIHJeRQPeY5qWg7xV0cJAbveHoDUeiUnZfbFtP+sTnJPKN9uzhErCrX4JXt26Bqrq2jV4189ArXurz9iJVPIEmDd+YWmsCKirXOUq4xuwMqIMJJ6gDGloWKo0XKxa3uTylU2zc6Qxy/1nQSYWzC5NELjvhHDKyHZIvUBY3PrWtx7LB6uPuoWIIU4IG2WE9cb/ynSteQHzJZjGTJm2Di9sjhE0KVMsobpVpFVYGiuwfhL/02uwneuXFwlHoylsVqiMX1Gu1YHqM2JP+BpCk2n6f5nuxhq+dU5YWeeSD4mr7rPM82c9aeM2ImHEb87fDcTrukNNU0j6Frm2ZSGupIFAUucoM8S2cqlOZaGUdnWSYSjWM/yA2FJOI5rq9axHi6bVsWXRREUTRxnDpDG1ZKrOL1VUhltFBaZynQqhSh4GlWOLpuUgz5JvmU/EtoZEFyjLE1iGVAaLPtSz0MWmm8OAcfdPA8dZJ6T9+DPxTSvAiChLaSSANEK6LVQe9oF/52lwfEn1m7/5m2vTHxgXUsOM3+yL0/jkWOK1Xddznn01jBzfKs6t4VQXrE/jXI8aBpfr0Gjnnssv1jzrxhmixjG9vro/+4SbfdWBRdG4IHmb+HO8hhus121km+iQRg2PsAzQ9hWnssAS5AMD//iynQki80l4tdasR+K61a1uNVqLlH/WLOKLRVajaCzKVrurXHfygWWCpYlY89xZeg40tpl1PIKo2bcgilg0WZN8QKDL0zNmW1l0r4lkPTDT8r4eLZpWx5ZFE+sAoYQIJg1dsI/VaasoRPp2Y2lKZVtJoWrRtFySbxoDb9AeapW2N3bCw7rBsOZ82WoeO8891SXr/mnANETEjwbNujdulQi/3PTNMg7C0pAknX5ADGNCmMiJAeu+KtIlUifvTANkPeHVcK1nqWGLGAiOxUGakXO4rTZyOT9xcsLNdhrarNd0zCN+qoM80li7x+c5z3lGEUDQ+hAAiZ/DNA2Jf7oO2/EHFidxaSgSnjxyTrYrNc6UGbBU5ktNVhoNjpctdYcJVZUr5UHXiDCS3pq2efCT9OQc9Zr8YSEg+OURC5OuNccMAN8KyRviT5isEso7YSntMP7Fvch1LHINzd4h9039RnizdkOZcb8zjEFXsRcY8L8ILZpWx5ZFE5FUu99s1y8pHLNvqyg4Gs5acU3JvhZNyyH5lcqYpcHgVhW18RvMySw0GoyM59hqHjtvkXP50aBUv9aTxoTDz1SY2Ed83+EOdxgOPfTQcUkIesNjBWWZCgknJI6UvSzTeMa/9aQvx6VDg5dty62KpqRh3vmJ1/GkjVuP+KvU81gzdFvFWlfD5cSHLLOPv7pd/VfnRYgV8fKXv/yayMixkG2WFkJYmghq99C8XrpZHfcRgcHRuos1NISYrjgou9Kk/BJVxo7UtNX4ZuF4rt369B4QZOq8jcJZBHGAmNc97Rkj/I888shRFBJkLGWEU73Xzb5DylAtL+5jnhvk2HS5ES2aVse2RFNllkDaqmhSGaRCsExlNS1A2W7RtDzqA5wxTXnz4TRE3rR13+iS2Cq1UkhF4l6L33qW2Z99IX6D7epyLpjETV/BKqEh8kd0kxL6oolVyDiWWC6QcGvc0mg98JPtxDkL+6cV5Wao18GSy7rhWpj4rfuIwhsqP9IUsTYPx2q6bU+fL1YaXVoZu4N6DZa5/uyr65bxg3oMunXlP2uWjwzi3/g194JYc65n2qBo83yxOjpuWIAyyKqU8AOrqK8rCXri2NgQgsnLlzFOrFDiyfXKq+TFLJLuqQvEmjIUC+h6YW1EwjXGiejTjeh6uLpu8DC/yf9m38J9SzliZU0Zzv2f1hXTMj6PFk2rY1uiyWC1uOl2xjxtBZUBpwClYqgFKWRfi6blIK/lGWedtZAwMneIxsxEl0SUeUZYarxp5/5sFufVc9MIJP5UFrVhm56TdPLL2Ub8ZJ8G1kcFBJL5vAgNVgtjX3SHGGRrUPDtb3/7cZtVQ6NLbKWBDYkjacy2PGIF8RWVwc3CZiHIF1XbQR6Ii9WFADCuhrCRVhPhSQPnurNcj/gPwg6eJZYOX575VyBrI5LPxqHJE+v2EWz2aQBsS6t9rEkRc5aeTf6kWVeWDwtYf651rWuN55iX5o//+I/HeYnMAyTvfVmpK8M5tRsvSENtZIgNY6XUBe6zDwR0b7HS2K/8Jp25nvUQLn8pA7al1Zekd73rXccpATjrxvulK3mrJL4g34zt9AxOw7W9nbia3SP3OPe7lsV6bDO0aFod2xJNi7itkAJTK4ZZhSj7WjQtD3nmwbX0IOdtKA+2/Ro/FhvWpu2Q+5O4xJEGuaYDtXG0n6vkmPTym4YOZiPXlShcDXC65Yx10SDZz4pBSGn4DM5kaTGYOGOfjPfRgPM3jRvCgIrrvOc97zjmK9eioU36NkvNAxCqvjxzTa4l8LNoHPwRNUSx65Vnrs0EhsbTsMhc8YpXHD/qYKFxDMZhsDL6itJAVRCGxBUBpJH3KT6BarJFQgXGkhFHwiQwdDkRmBe60IXG/Zm7SFrkFRdcf/IW8rTe/3qsIi2+kmQlDeLI+daneTslxzlpSpzWk2/WxaVMrRfWIqTcCpNV17QC7oepN9wrX/O53qSp2bfIfeNSbpWplCvU48qC9UVo0bQ6tiWa6pimKRuNaUphmC6nTCuJup7C1qJpOUzzOPnr4YXt+CEwdIWkQUU9fyMSR9aRe12Z+qnL6reuI9sGWPp8W4WijLAEsSwZE2ObKOA315bKTINoDBchocuERcG4KFYLDaYyR1DpwmSZAkFFDBx++OGjJWVemtZjlp/sszTfC0uQtPicuaKxZVUjrHRnQcNLMBJCKlYNPKHoyy/Cy5gc1ipfvF70ohcdpwEgxliKCSGWH3kFlhxjiHSpuW74GMBEh9IizzjWMHFJC2Ixsk/+uCe6/jh5ZtqIzJ5dr7+u13og96j6z9K1ELgci7d0svapj/jJfU7Z3oiEi5xjX5x9df9WybmWhB5rqPGDyqtuWBYn1+MeI3nQ7DukzIRZ25Xp9nq0aFodWxZNHuCNWM9PKpsUnBQQZvl8wlv/UzbLbyorlbQGMBNhIn6a5ZD8rPmvu4PFKaJBhV6PZ7kKElfKScoG0ZDBwiwP5pjirNvHqgSNUM6p6a7rhIhuJBAiBjPrihOGa9dFQ5AZU+O/iZbyxmBnS+Er3xpFwiSWFSKHX2GzACnHnp2MYZE2woOQ0eV0kYtcZJzDyrgmwsPXW9LGGe8kTfl6UDjSoutRF6s4TzvttOFZz3rWuEy6pIcI9rm7a9ZYS6u8Yymq+bAozqmNu7RIH8yrxSGf2G8ljinEmbFMro8VzJeTupMJNeQeYxnxLRtpYsnVFavsui/Kj3X1YV5gmqbSoml1bFk0LYNUWioyzluwSk5D4C3Y7wKY+6s/6/EfNBbexFo07RzJT5V2GkKVu7dhY1CQe2O56jfhpC/lwnKRBsZ5U7FXw3Ad9ics6/Y7hyVF+fQJPGuG32b4zN2cQATCVa961dGCo0uK4HEeoWkfF5Fk/JMuLtYflhLWLfP/GABNtEgDK49w+SNobPu03jYrki/DdBHpNmMhy1ddninWHBag9dCdKM7Myq/rjABhodElF4uitCRPkhfzyPGkg0VJWREWEcNJp0+vWQPTlcb/VhEfceGa1QfWXYPrT5oT/nbi2Qlq3s7D9SmLey3tze7Soml17Jpo8tCnAkDWvVWpPFV2Pq81PqJW+BqrVMSpOFS8bWnaWZKfuW9Z103H0sFakn27UamnTEDDg5SpWl6mTnmCc/jjcj74gf0ph/bZrujCIiCJGd1aGmqWG1YaIkgj7jz7iQXdRrqTxSUPCQnlXnoJDBYG1gZ+7OPHGCvCyNdnrLHCNe4o1zeLut+6sEK9BvMmmQLAZ+0sU8QYa5auIeO7CDPpQsJc5D4nXy1Z4jynxjDpYiSUWIFU9iZudD3bJfGhps2+er17Eemd5ud03yw/TdOiaXXsuqVJRabyTUNVKwUmdmMgUhFyjtWKEd7429K089Q8rY2vT/k1uqwmgd9VN1LKxWbve9IZa1PCcH1Jf6wUqH5y3PgmX2mlC4jgge6wDHJGlsH5XMJE/CSObJtuQD7bZoX1bIBgrb/XEF61qiSNwuNsT8PmX7cdKxfxqwI2WNv8SLaJtxpm7n3OX4+cI07niUOXoG5Mg5x1OxGSSdt2cH7CmC6T1iyXEd8ySfnDvHTZX9PPNQ1aNK2OHRVNdYbwWaxXcalY/aJF90StTKw7z5u7+Ut0RxiIqvGYNtrNckmeWnK5H6wfHljjfOrxVVPLk2Vc0jPLVXHkfPvquXH1nLrtHOVPF5txR8YJmXGc1eTDH/7wOCA8k0TWsCyROKHhzDUkfBAt/qxvziHdgWY192Ua6xMLkC/VapiWwknYOWYZwWPpuGXiYSUzlQExkz/pG4MkXtRw6vZ6VD/i8wWeFxwTjPoKj+XJ2DL+kuatMg1jVtpy/fxye4l5aar74meWv+bApUXT6liKaPKm6KsiIinOPD4bTTng7VUjowEgeryxg2DSRWDcR4SQijAVhcbF2AuDR8VrLAbTvzE2oSuV5ZM8TcNZGzhjesy/Qyxk/yrvQeKqS+lMWudR/eecCKmcO10ix5VFP6rOf8gIDWObdNERBsYzEU+YhosabvZNG32iyWBpwsnEnAcffPDw53/+52N3GnFDOOXL0ZyTcIVVXfbDdvWT+KfU8+LHcp7/Svw41/V72fHhhm54S1ZiLmmpcWyGpKeeH4GEhJ3jdX2vME1f0la3q5+mCS2aVsdSRNNBBx00OpahOP+m20g0qdR8quwnrcY2EEK62AgmjUEGpaogUnHPqiz48/baUw7sLPPyM/tZBd2HVOyhrmMnKv1peLan8c4i502XNY3KXpjlX9eWht9gapNBqsCISNsET03HrPPnUY9ZN7jc5KK+LLXU/cfyVFkv/FxH9tVnKmnMdqjrW7lv8b/RveCv5vNmcf40bXV7us5t5XpWxTRdezWdzd6gRdPqWIpo8mNe1qYpxNM8ZlUC3tp9MWQOmgwKrf7mVSQ9T9PuowHyiboJIzXmldwHfurbf9M0TbN9WjStjqWIJt0T3oKnrCeaoDHVkOYt1NgYXwhd7GIXG+ejudSlLjVanTS0sxrbFk27T+5h8trki7pmfWLPImICSGOddMMaWIy+L03TNMujRdPqWIpo8tnzVrrn0nha1i+UaiNcRdWU+GnRtLuwEHIwxsyXXf7SbgC0wcW6qswddPLJJ49+5t3PpmmaZvO0aFodSxFNBn4TSJsZCE7QsB5ZZmyF7algsp5l9odst2jaPXJ/sm42Zl80+jJKGfBlGWsTZ8wTWjQ1TdMsjxZNq2Mposl4plndc75+m0cGfVpqRC3TBRexEzEVK9S0sY2/Fk27S0StpX9mGRjNumTGal1zJkU0H8/LX/7y0X/ufdM0TbN9WjStji2LJrNwB4Jp6oxpWc/SVEVSLEywTCOcbV0/sxraFk17A/co9+f5z3/+2r30Y1cD+33daBqJiKa+L03TNMujRdPq2LJoqoO8rRNIs9w8NJwRTUSR7bhKtuvxNMpZRjT1jOC7Q703fobLquQTfL8QMbmjrjoWJyIq/lF/y8G5nznWNE3TLEaLptWxlO45liXTDlR02a0nmlAbyHTBsRb5Aa9/cZkIL7BkxJphWc8lmp7ylKe0aNol3I/cP/9gM+j7TW960zj1gPmE/ObDV5AmI43/Knzrvco9bpqmaRajRdPqWIpo2goayjSQGk6OxclAYr9uuOMd7zjc5S53GScLDLWBretmFm7RtDvI53SvcqxLBoL79Ya/+JtmwLb9Zsx+wxveMAqsnGs9IoprmqZpNkeLptWxa6KpCqasa3z9vd14KX9817VDOKUx1cjGVYsE/909t3vUe6hbzgPM5W/+1t2jT37yk+NUBH77kS5ZOJ94ssy9bpqmaRajRdPq2HXRVBvOjHEJJ5544nD7299+PFbF0rRhNXt4W5p2B/kcsZMxamHWPfDPsSc+8YnDs5/97PF+u5+5r5je26ZpmmZ9WjStjj3RPVcbVz/dNXu0rpyb3vSmw7vf/e61Rhnx6w/vJlF85jOfOc4LZbBx/7B39cjnem+sW0YM1eNZmvmdZdD9y6SYyLlN0zTN4rRoWh1LE03TuZrq+jw0rH44+prXvGYcLPyNb3xjtD6YrsDEiERTxjSlwXWOdYPE3/Oe94zjZkygqNvnRz/60egH3fiujoijrFdyLOLIvePcZ7OHP/rRjx5/aotZ54bpsaZpmua/adG0OpYimvx7ztdz9Ws5+wif9dCdQ/Acc8wxw3HHHTd+MVc56aSTxgkyZ1mkKj1P074J8WTupsc+9rHjWCjknllmgDmmXX9N0zTNf9OiaXUsRTQRTETSdIqB6TQElQihin3f/e53z94axk/UDz/88HG/RnQqgrLdomnfI2KIBYplkcXJwHG4b45HNOU+5pymaZrm/9GiaXUsRTRFLFXRpNttvXmaNIBVONk2JunhD3/4cMQRRwxHHnnkcOihh44NKtKQVlo07btUMWRp7JqxaX7yW6n3fHr/m6ZpmhZNq2Qpokk3nAaPSDKWKd116/17DhrBak0goj796U8P73jHO8ZG1GfqaSgdnzaaaXRbNO2buN9ve9vbxlnElRnddA996ENHC6P5ul796lcP3/72t8/23TRN08yiRdPqWIpoAtF00EEHjcKJYCKkDA6fR0SSJZcZpafY5wews6wM8d+iad/EPX/jG984WiVNgmlgP/Fk9nCiyVeUdaxTj2tqmqb5WVo0rY6liabNkskN44gijpDKOur2VARlu0XTvokv6E499dRRML33ve8dTj755PE3LG9/+9tHEc7y5Ge/yCziTdM0zTlp0bQ6liKa5o1dyhd0GsApBA1BlHXUOXvsi0uDGX/IMbRo2jdxX/2bzlQT+NCHPjROPYFvfvObwyMe8YjhhS984Tnm3wq5t5YpR03TNAciLZpWx9JEU6Yc0EWnuyX7YTD3LOGE2vhlPZalWKOyHWJ1in//nnvyk5/comkfg2jSBRfRxNrk33Tum3v/1re+dfyqznxOube591VwV7HdNE1zoNGiaXUsTTSxKBkEroEjnLI/ZF/Q2FVRk21Og8jluGXGs6TRzDoMGG/RtG/h/v74xz8eRVOmmdBNF9FkHBsR5cOA5z//+aMl0f8I4b5zwohg6nvdNM2BSoum1bE00VTJdt0/9TNFo1cbPtYqX98ZEIwcS4NZ/bZo2jcxpoloOuWUU8axTE996lPH/9L5vcpznvOc0UJpTJP77Uu6448/fm0C1JQXYjpWp6ZpmgORFk2rYymi6ZrXvOaapenmN7/56KxHKBFA6010ORU3frx7t7vdbbjwhS88duulgUTWuVifvvzlL48NboumfQv3j2WJQDII3NQDRLKlfwqaLfxb3/rW6JcwSjfvmWeeuVYGUNebpmkONFo0rY6liCZTCxBKxJNGLduElO66P/3TP507Z9Osxs4f8I866qhROD3ykY9csyxxumNsV3TbtGja98g9rUzvre1Ykizf+c53jj9nPuOMM9bOtZye1zRNc6DQoml1LEU0bQSr03pzNlU+97nPDYcddth4jsbRZIdpXNOAWv/a1742CjL/pzNYmN/pV1ZpVJu9ifvpHuWeVuGTY5ge85PmRz3qUeNAcUyPN03THEi0aFodOyaaiKSNxjFpLP024yUvecnwmte8Zuxm85k5CxUsNY4hjSi+973vjbNJmz3cZ+ksXC2a9k0ieKb3K9uzlsaxGeOk3CAiq4ot1PWmaZr9kRZNq2MpoonFJ1MOTN16+OTcvDz+N0ccGfv0u7/7u8MNb3jD4T73uc9w5StfebjKVa4yjnHBvBmhzRr9lKc8pbvnDgDc09xXg8Qf9rCHDS996UvHsqTrdpbVqmmaZn+mRdPqWIpoIo4IJ11qcQbtriea0vBp5DR4BJHPzP1Kw3iVD3zgA+NPe+94xzuOA38xFUHZ7sktDwzcz4ii8P3vf3/8ctJg8h/96Efjvmp1apqm2d9p0bQ6liKaDACfNWZp3oSWIQ0b0WQ5beSc/6QnPWluA5jGs0XTgYN7SjjF2Vb2TFlw4oknrv3gN/eeGG/x1DTN/kyLptWxFNHEqpQpBxa1NGnM0rBlqXGrjZxxK1/84hd/xroQsq9F04GDe8qlrGSdlcnYtsc97nHnmASzaZpmf6dF0+pYmqUpY5imbh4atDR4lplKII1inVogoomrZLtF04GB+5mykLJSxbfJMl/72tcOj3/848dKBClDTdM0+ystmlbHUkQTyxLhVNno6zmNX5ZpAGHJpXGs4il+QrZbNB04uKfVpexwOW4up4c85CHDJz/5ybV9TdM0+ystmlbHUkTTPDJ1wCwimlAbNetVRE0tUJVst2hqQsrK+9///nH6Ch8WVNEdMT7LIX6zbJqm2QypT9Qhte4J0/Xq3zJ11GZo0bQ6liKaDNiedstxG/06Ja5uV8tTHbNisPiUnNuiqUmZSXnBJz7xiXFG+Te+8Y2jO/3004e3vOUto3vTm940WqT4QcpKwkkYTdM0i5I6KPVJ1mfVJ/bXMbxI+2fJLUqLptWxFNFEHGXKgYMOOmgcBG7bch4pVLDOopQCNot5hQ4tmhrlw/1OhZN7/9GPfnS4xz3uMdzpTncaf89jQkzOP+5e9apXDc997nNHf/X8WWWtaZpmI2odkvXURd/5zneGj33sY+MfDb75zW+O+4im9KaYWid1T+1hWYQWTatjKaKJVSnoknvxi188rvvn3HooEFP3vve9b/znHOf/c6YcULBqQxiy3aKpgfutnKQigrF1Zpw3OJxIMlDcHGDgx/xOoZaXLjtN02yXWo+86EUvGush7eNnP/vZ8RhhpL7yQmc4ga9/v/71r599xmxjwSxaNK2OpYgmg8AzENw0AflBbxVT81BwUrAsn/CEJwyHHHLI8O53v3vsUnnve9+7VnBqAUS2WzQ1IJhSVlRE7r95m/yjzi96WJXud7/7jeOd8OMf/3icbd45U1G+aGXVNE1TUY9UBxM3+z/qscceO7z+9a8ftwNDgfZL22m+OaIq56mXFqFF0+pYimjyNq87LuiWI6JicdqINFpgWbrzne88rgfHZ41pCl/60pf6NyrNeL+Jpcq3vvWtcQyT8uN/hcqpX6+wNvlXobc/TMtKi6amaTaLeuMLX/jC+AGKF35LXXLmkXvZy142umc961nDE5/4xLU65kMf+tDw4Ac/ePwtlF+KnXDCCeMxddKibViLptWxFNE0j0VmBJ9CaV/1qlcdB/DqVtHQQSGqDdkPf/jDsQ+YmZMlgdkzv9EIixa4Zv8g1iIuItzYAYO+iSb73vzmN48Vl9nDTzrppOGZz3zmz7zN1XIWalnqctU0zSy8tBnbq15Rv6hn/BuTYSEv9fwcfvjha/WOpaEDxxxzzHDTm950ePrTn74mmqZ10zxaNK2OpVqaiKQ4Y5s26p5TIAifU089dbQG6Epx81/5yleOsztf/epXH4477rjRbxrDNGjOe+hDHzqaPO973/uO67pbKt24HXikfGRJNLF8mlneTOEqMNvGDVh/wAMeMLz61a8eLVJImXF+Ki6uVnAJu2maZsqsdkc99LSnPW2sc7SVxi/Z9/a3v3342te+Nu7z83rtGCt46p1F65oWTatjKaLJF3NcxjZxxjWtJ5oUBm//BBKBZTJCQqjCvHmJS1ziHP2/+aqgFiZmzac+9andPdeslYvc+x/84AdjZcS65G3OwG9vgK95zWuG0047bbRmEk3Kz9ve9raxfKWymvWWZ3+Xq6ZpZqFuSL2RugSsS8bp6klR1/jRuBc3xgL+faDCKvWGN7xhPCfhLFrXtGhaHUsRTaYcYG2aksHhs0jjRhAZW6JrLYN3g24VXXV+j5ECmOO18WJF6IHgBzYpGylXQblRNlVQ3/jGN8Yli6YlxzrpHIJdpeVtUJdvylfKUCqwWXE0TdOE1BHqDIaBWXWGfRFXqVeC/dP2biNaNK2OpYgmA771405ZTzQpDBFJKRgKyjve8Y5xMDgRdPDBB49fPClEcfFX+dznPjc8+clPbtF0AJN7XSunzd5/Akr5U/mwPnkbDAmry1TTNPNQP0QwWee0c7NetKpfbZr17LNE2ryNaNG0OrYsmm5+85ufoztus91zSKFKAYMvD3xdwIzpqwLHaiHKEilQzmnR1MA9z31PuYmrlVKOZz3nWH73u98du/OMzfP1C0socn7TNM0sUr/Udoto0lti3KRxTJas3j5yIpZq+5c2rdZNi9CiaXVsWTRpUIiiOvi7uo0GgiskKVgpXCk4qOuO18JUj6EtTQ3m3e9q0YyfLFP+UsZqGLrpTGVhHNSnP/3ptbJn2TRNMwv1SNqrLM0Td8opp4yTWGob/ZHAPISs2+oUdRSm9cuidU2LptWxZdFknMisLrkK8bQI08ZKQakOjsdPXUdPbtlgo/utLKUSS7myrOWp+oEypZwTT7qhfemC+J8uQ90/PdY0zf5LnvfULRFE+MhHPjLWJfm4qdYP0/W63IgWTatjy6JJQxI3ZTOTWlaXQqPRSj9w3Z4WoGy3aGp2gpRLGDTuCxcz1vtAoU5voZytV9amLwVN0+y/5Fmvz3zW/SDcHE6665ZJi6bVsWXRxMToq7lZAomQMuZp1hd1QSGKEKqNimXWUcVU3Y9st2hqlo2yE8GUcmRbl50xdyo+3cKxSjG/m7LAvCs+LX7nO985/P3f//34k04krKZp9l/UFdN25zOf+czw2Mc+dnjUox413Ote9xpucYtbjPMxmQVcd10mcN4OLZpWx5ZFkwkC17MoOUZYzaM2ShFGWYdPNU1DMH2jr2S7RVOzEyg/BmoypVfRY9scYiaoMwcUsaT8mf9JxaUy9CGDCes45bNpmgMH9UXqDC9Sf/AHfzD8xm/8xvDbv/3bw7nPfe7hXOc61/CLv/iLw3Wve92l1A8tmlbHlkWTr+U2giVqHnlDj7CxzPqnPvWp8bcoD3zgA8dJCBU+/mvDhfhv0dTsBMpcxiOk/NUy6Fc+Zq43q7iuO358GePtMdNinH766WN5bprmwCBtWdofPS+///u/P/zWb/3WKJoIpt/8zd8cfuVXfmW49rWvPVqst0uLptWxZdG00XQCuuY28oMUrDROH//4x8f/7ygAfq/iC4PaeFVyboumZtkoOxFJnG3lsC5h3Rgnv/M5+eSTx3/bmSAzx/0X0Zd3TdMcGHj246Cr/vznP/9oaSKcIpp+6Zd+aTjkkEPGKXO2S4um1bFl0WQepo2659azRuWNPQULuuRMbOmXKpUIpuq30jOCNztFKr9aXuu2svkP//APwwc/+MGxy075fdCDHjR2X3/pS18ahX+LpqY5cEj9kDqCaLrABS4wCiZiibXJ8ld/9VfHOQ27e27fYsuiSaMwbyC4fY4ZzzEPb+hQwIL/hPnT8wknnDBOV/DEJz5xbSBt/KVAEkg+3zTIjjXqcY973DlEUw23abZLLU/Ws60bTjkknKDyIpyMY3jRi140PPrRjx7HOn30ox8dJ8ms4qs+AwmvVrbI/up/lp+6rx5rmv2JWWU85b+S5wY78TwIv8ZRt6fHdNFnTFNE03nOc57hl3/5l8fuOS/926VF0+rYsmgCYaMLjmN5opqzvd4g8KAwE0r+BRZ3pStdabj+9a8/vP71rx/ucpe7DIcddtjaFPO1i45Yyu9WHvawh42DcjNzM2qhbZplkrKVMvnhD394rLRgagJf1jnGGZPnR8GveMUrhuOPP34UUAQVfxlgHjGEaYULx+0Tl0+VdX1nNmHn55h11lrLptlfyfNhmWcDeRaqWwXTeBJ3nkNf0xJKv/7rvz6KJt1zv/ALvzD8/M///HCNa1yjxzTtY2xLNOHzn//8KJ7y+xRiadbcTbPwZZyZvC9zmcsMV7/61cexIbe85S2HV77yleNxIugSl7jE8LGPfWzcRgqjZUSUNBBPBuaGaUFummWh/KVCVGn71Qoh5AXAmDx/Mf/qV786lkeCyc+AQSTpqjMzMCsqS+xpp502fPKTnxx/q6C813JrPdsGmBt07tNl1lgfSVj3V3Tx8JfnIoPQm2Z/o9b9eQbzjEy3UV9IdoI8d7D0jHuhURd4Li2Nc9Q2Xvaylx0ueclLDn/0R380XP7ylx8NDbe//e3H6Uq2S4um1bFt0bRVasEO3qLNZfG85z1v3Fb4FCwFIg8LakEFpd6iqVkVylYtX8YkEEoGgxuP52s6ViXdzLroCB7Uc1T6Kktdy6xPftXiJ8FeOJT36dwtz3/+80cBZoyUsA02J7ic85a3vGX045kQbpf9Zn9GOU97wGU7zDq+bKbWYdjHgkwk+Zr2pS996fiM+hjkrLPOGgXU+9///vGFiT/PuJ+C5+V/O7RoWh27JppSkC1roVHADj300LGL42Y3u9nYRZeGIKbYPAgprBotU9O3aGpWQcpgyiP8iPN973vfOKHlBz7wgXHdOCZvnuCvVuQV24TVGWecMVa2L3nJS8Yv8V7+8pePIsqvW7xIpOvNMeMk4EXDQFPMC79p9idSzusLgqX9syxLs/ZtF3Eh8WZd7wmLsTrA2F7PrnYpaTAjeP2NCpyX69gqLZpWx66JJqSgpNAofBoGjYDJAZ/73OeO3Rzxk4KXxirn+2SzRVOzKuZV2rOwP/4rtuNS6cK2cqzLWbefrjwvELq9vbXq6jMjeUSTyjfd4Ymnhtc0+xNpA+aVc/vh2DIsOIuQOCtEjHG5rEsgprwYsUL5aMnzbWzitC3bKi2aVseuds8pMAp3XC082YZl9ZOClgeIaOruuWaVpAyiLmu5TJnNeo5nO8dgf/xUvESoeHXHmX3cOKj73Oc+o4nfF3tM/LE0QUNRw22a/QnPR8bsqfdPPPHE4QUveME4GbJ142Hzop3nYBXPw/TZNU7RRyD5OIlg0rVuDKIudeLJc+v5XgYtmlbHnrA0wXq2636kgZruz3ZPbtns7xjTxKqkktVVp7ybedxgcB9TGGBOXEWwQflPZZ71WrlnX0WDVP2jntPsv9R7nnJkHyFu22+tOC+nWa/lbRXU8pp0EUkssdKl/NrHH1fTl3Id6vZ6x2r5T7h1H7Lt+bT0QsNK7Jl0TDqSLsezb1m0aFodu2ppUnCyrgBZ5k2Zs25f9VuxHy2amv2VlGFfzhm/5DkgmvzvDsZMsD6xROnS9harwvY1nucHzkk4dRmHPHNNUxv3YMCycXrGnLLqsHq+4x3vWPvIYZXUcovvfve748cXusDqMdeRZ6Dut0x7k+1gPc/BVNRMn6Mcz37tkAluTXRrihHd6qYbML7JAPDpxx3LpEXT6thV0ZQCWgtp1pG3BsR/Jdstmpr9HaLIeCaVo7LuyxyT4vmvnak6PDe+IjXprG4KX+R50zWHVB10ilTy9aXEc+b5MZCdINMgagA4jVJzYJDyUMsH1MUafSKJQDGgmZCalq1VUNsImAD5uOOO+5nB1SHrKffTdcuEOV2H7XnH4+ArVlOPsPoaf+gZ9ALjgxAvM57f+F02LZpWx66PaaoFrxbOimPpx67YjxZNzf4O8WLKAc7UBsY0EUgq6ukPgT0HJn8lfIz3MB2CpXEWeQlBXlKy1Oh89rOfHSv6e9/73uMAc+HUsYLNgYMyMa17bftNkE/mZ9XVO03i1A0mDQS9udHuf//7j+0ACythxyqLWJog7XEQVq6Ryzo8E/VZqefEf7Y5eHnJeKqMafJM8fuhD31oFDY5b9m0aFodu25pqoXPg0CRe1M2XkM3hC/o7K8FOmS7RVOzv6LSV/ZV4KYkMJCUBcmAV+ve+BE/tcxb90wYMMt6pBvPPGimNGCVqo2Ct2Njo172speNx+973/uOz6BuBs/WMibga/Y+yhEXlKFsR0gQTeYdyr5V1rPi4lhvTL3hpUGbceyxx47WHc8EK6wXiaTdMmU9+0LCW5Rcb3WeUfu9pLD+aq983eoFR5eh47ro2tK0f7BroimFuD6k3g7MbWH6gKc//enDbW972+EKV7jCOQp5JQWwRVOzP5OKWuXrzTXd1p4XS5W0dX5S5tNYZMk519u5cSk+e/acqdyNizIOI5NkqugNrGV1cp43Zs9Ys/+TsoKUHZZGlhN/ZiBGWHV0Q7FCEu0GhK+KpI011DghfOUrXxmFXL5UY5UlquI35No4z5DnwXPjPF2N2g8Dt00FwPmtl2dAF7f4jOkiykwlwLHeGrdkLCFr7tFHHz08+MEPHn/pJT0mrM0zKq1eTKZpWhYtmlbHrnfPcbWCr9zjHvcYH1D7YyKeVej8TV4D0KKp2V+ZPhsp254fOJ7nCPPKvv055rlhWXrCE54wOpZdb8oaSZW/CTuhG5C1asq8OFDTUeMMdXt6bKvMigfTuDYT33p+c2x6b7bCrHjm3XNs5how71zr2bZMnNUPoUQgGO9m7jBdtz6ft63ejaCehrWTEHCsN9Al57dCusaMbzJBLKuT8k1MEHaEj8/87Wd19SJgtn4WW0sv6Xo4WGPN5K8L3IuFdWKEVcuzYsJZwomAkhesv+LhxGv+JYiTBYwg84zy191z+we73j03Jfs8qFe96lXHP8hDwXMsjYO+bA+tvmKFVQGvbzw7VTibZl9n+mx4IfE7l4c//OFjw6FL/H73u98oljRIni+NQnB+nseKbS7P6HQ9ZDv74gfV32ZZ71zHarxx61H9zFpn+bOMcM3xrZDrTxqzXkmeJ25ke7oeZh3LuvCFWeOu64FAYVnKeawoygWUm838pZ9V1MttpiwgcpQtYVgS56xa6nVOHc+Z00hcxBpHwLDkKKN6J/yPkaDRpfzoRz96FHOO+6k7QUT0KNcEEtFDQLGyElOsUuLU5ci6ZMB7xiItCr/CZLUFqxJrlHDkJYHXomn/YNdEk4KkABE/HhZvKzGvgtK/3e1uNz5YKWg5h/MW7CHwKba35Ec+8pHnOH+nCmfT7Mt4LtLgep7SOBpv4c3ZM6Sx0gixLnhb9q87DZJxUBq9oMGtgiEigsuzWuOI31lU/9vBIGCWBA2sMSU+jdfI6pasiCsiZB41/Ukf6r6Ijlz7dkh4HDGhjlMvsqBYd2/EEVfTn+2Q9NXjU5fjidN6/DoWNMjG69ivPtZ1S0QpM8QIsWBbPrPkGBBNmBAtRAwhTuRkvJE5x5QnYty57pFt90s44rLPcfeRVcen+8K2bWmsHUfwOIfI113oPkuHc5TVWHo2S/JiHsLM/Upesya5Pt3c2iYv8imHrj+DxHeCFk2rY9dEE6hwXQJHHnnkcMc73nF8CKGP+uCDDx4r7JACWgup/md9xkyh3ihq99xGhb5pDkRqg1ifEV8gZe4nx3V3ePP2TGkINFBElOfMiwr/1drhubSswinOMfstWQ0MNPc5tsZUY0msJRxuOxiP5SVMA/qYxzxmHKvFipEXqqQn6+tR/cI1sMql/qn5GJd9WyFhSqtxORp/U02wjhAXrkMcdajCrDizP27KdP8sP1A/y0v3yNxMLDY+JDBsQppYeXRfETFEDeeLS+JB/mvI1c2cbennCEHhsspk7BCR6AVanS5e10j05FqnsAylF2I65YA0EP65Lkt5lO2scym3dT9yfB785lzONkHp+rRfniVlXB7osnOttSwtmxZNq2PXRBOxo6B5SLwdepPKA+KBvPa1rz0+WOAPtSDXAs4fc2z9NDrHmqY5J54dz1oqe5W5RkjDTBgQSkST54ofb8qxMnlWDYplYfAmTUhpJHVpOF6fO2HXZ9d6Btx6xr0wee41nBFb8b8VXJOGSzrUBf7RR/jZJqYsayNZ1+fheHXSp+5yDSwHGnxxCX87aU/YSRPhJFxildAUZ+rHKiT4rY2xMGpasz0L58kTYbsHBj0bsKy7y701oJlQMr0Fy4mX2szTlDFuLEIZx5N4w1bzYxoO6j5L3WqEpbxwH1i/iCfbLFW6FPmreRrmrQf7Zu2vOJ5wZ/mVV7rnlAtsFN52adG0OnZ9TFMerCy9bRx++OFjl1tQOGsB5bc+kB7gFk1NszF5hvJ8eK5gDKEvgHQjcAb7+irIQFkNpzfokOePQNE9wr9GVreLt3zPIzFECFUc03WjUfP7F5U8awqxpktjKmo2i4bSV7QafWKO8NM9xLKl4Sc+hC1dtf6YR/KJ36RJHSMccei2ZGlheWMV32q6Q+KSPvlAOMl/AgF50UTSFIe6PoV/Qs9YJPfSfdN1xIrkCzAWJPfEvTTWh2XICy1YinxxKWzhPOQhD1kbu0MY1IHgSV9lVrrqvlyLZc7PsVrvx4EYJrrdB4O3TZFhWxl0L9IdK8+ck3BqHGG6L3EsQsJELe/yV94STSlvedZ2ghZNq2PXRFMKkMKUQmrpjUd3gIc2++rx6j+FVSXQoqlpFsOz4fnz/HCxXKjgWRuID10wGbeisQ15/uKyTxiEl6+SCBVzSem+ITA0cPyyVmhsiQFCg7VK42afho4VYzvokmEpEZf0SEcaT105XG2Ecy3rEb+zhBahRwhO92+FpIXFjgVFlyVHyKoPDSTW/UXA8MvlWqZIq3Dku2smeFgLWfd0GRGWukYJDnGwKNa6c4pBzdKQLjFzIhFWumjdw4gmJD2Ws9JpWV3FdvJheixh2T+9bhYmAjndc8hx5yBh1m3hzKKGPY+El3UkbHiOqqVpp2nRtDp21dLk4bac9fArgNlfl3lwKt5sTcxXK3dM/TVNc84Kv1b0LAvGAGmcCQIWIV1vutQqzsl5CauG4zn1TBIULCWsFxpsH3fo5oNGnHMuawCBxsq8HQg0A4CFSTTpnjO+BN78CY6kF7OW9Xi9TthPYGigvNS5JmKCyBS2a3bts6jhhuwTR44RIBrbjAMi/FjjvBgSU4RotWiAxY+wkd/Ep3MMwiZSOWlk4SN4dKXxvx7TdBK5ziWwfMVmGhiDupUT+2q9m2vK+jzqsep/ek72VTfdz6pZxzTZl/uWvI2b3s8ps/atR8JM+MobkapssL66l+6bPKr3GUnLZuOcRYum1bGroimFqBaeWeuW04oCKWwqmp7csmn2Hp5bXUIsVrqAWJg06Bo5VhSiTMOrcdfgs1BZEluZ+dy4Hl0dlo5ZsnAYJG1gepyB3w996EPHdQ2ILwAJNd1PuvvFKy5iRJqqZaKSuocjvmpdRIAQZ7rMpFk6bBOYBA2rR8h5qYdqfWR91ksgC4U80VUp73xBRpTB+CnbBBWRKX7djvJBFxVxqsFmbXONxvoQPMtEemv33G4wFaZ6J0yD4H7Ky1n5vRMkHYmTI/yVdSImjphON2HSlPbMclbbtllaNK2OXRNNIQUpBcdDWQtUClmWlexr0dQ0ew/PX23giBZWK42/7iHjgVhRWJw8vxp9IokjkhzTLWXgOQsYoWKpG85+b/AsS9btI2CICuFrqIzFci4riTCJDGmwn8DSpWNcElElPtY14ftlDGuMRlhjl3rItbDipH5ivXGO/eK0Pqubq9ZDzlXHOYcjjggzS/sJItYc8RM88iRdaUQnISi9xCPhxHKnW3MrcwttBeFLQ0STNK8S8cexjLp+otWUA8SK+x5L2k6nLemo7dQ80q7xZz3OvV8GLZpWx653z2U9leu08NmfAjYlfls0Nc3ex0DdPOeEEkHgudbYs5AYf5RnPaIi5PmfVQ+E6ZgmYkPXTY4RUOqciBSNru4qYowAYkVisTE5YgQVkWVQufQKm2VHFwyRQqCxLhEQhBYhQ6AZS8QPpzGLqNNFSAjqsnGepfCl01gjjpgzZkjcLGbmn3Pc+USiz/uNk3GN8iJ13Ly6zv6p2wryTF6yXvl6znWxqhGVq6ReA2shoUpkEpCxsrk3iN9ajpZFFTtJj2X2R3QnDcF+ArsKqKmfrdCiaXXsqqUpBSUFR+FOQVLgUkFmX7ZDzm/R1DR7l7wcEU0sMZ5LgsmXThoRjS8BEYEzFUvTesCyrgeihBgxvscgZXUCoaGryqfxxFF9UZvWJxWNH4Fg8HPGCrFUETQsZMTTwx72sHHciv2EDcFjv3g5li9iy7muV8NOQLFm6YIjtHQtEVmuXZqklZ+IOwPrXQuIyli26vXHYbrP9ix/m0U6zT3kOljqfJFINGZm8FXhWiI4Zl1L9smjeq93ioRd02P8GcGrbLhn2c9yqGtZ2TDmiWiv522HFk2rY1ctTXXpYQBzq0rJv6+Me1AYUrCmhSvbLZqaZm/iGcyzTTwY+0PIeF59vJHfYxA7BBS/9S3eds6f9zznuK4/4bE4cMYziVNjz6WB16A6J40vssyxeXGxOrH0SCvhkHFMhM+87rnNQDQRVdLGCT+iiUVLHHVqBs56tuv+KfYlr5bFvLh2iloW6jXbX6+tpmnZ14x510wY+QCBsCSMtGcRb8q9do018k53utNoPVxW3rVoWh27bmmKg8roqKOOGu5+97uPX2aYe+PQQw8dC331F7Ldoqlp9h6evzy7GjbigvWGuNGgsDwRAvbpsqiNW33mZz3/0/V6LggL44/qF3lTYYGclzhgGVfj5nShWYIQI9JsE1E+w2eRCTknJKwaF+o26xNrTgbAm4lbI0w8yTOiiX/XkOuwXcOG9RpHXd8KOT/xTLdXRa4114n10rRTaROusWQG7nOsm+49kXTjG994HPdlcLpjSat7e8QRRwy3ve1tx8mb89HAMtLYoml17PpAcA9+CpW+6Jvc5CZjZQdvXFe5ylXGN08FK/6yDC2ammZv4hmsThcZUWDckBmnDXD2gjTL71bQHcK6RNwI3xgl3YAGCEO46o/UO9O6BNO4I1AgXPWN8Uq+7uNsa7TEu8i0CfOuTVqIPY0vMWl6A5YtYkz3nWsjzpyf9EzZar4tyk6Hvwh7IQ1e8IlYQkXbo1vWNqsgYcSKpDyYIDb3SnemsWr8ZLyca5lVBjdLi6bVsavdc7MKizEAl770pcdPhG90oxuNlRRismfqdJ4BiJS7ysT4AAVGhVLZCw9X0xzoeF7z4mPpOdWNoeExdnEZn8WLI3WDcBM2Jz7xOq4BW7Shij/nZGmME2sPoadBZAUyVskAbYJwqwOj07CKM/WWNBuLle45xB/ir1k9yoN7XcsZx2JqCgjj0nTfGutGABPWBLAXBl24PjwwA7twuO3eyxZNq2NXLU0qMYWJ6PHZqMqNQr/pTW86Wpgue9nLjr9YQApWKjCVl89MTbSmf9j4JwW40pVK0+wenr88g7VhqOvxk5eibG+XCKiEp95IuFU8rUc93zlcRfdcnRF8o/DWo6ZHXrC6eynU0BJlGuNYmSDOxNusnpSviNh6L4zbu+td7zp+Zajr2XQWLKrEk3bqXve613is/ppou7RoWh27KppUDj7z9csGAog6v+ENb7h285m+L3OZy6x9WYLMZ1IrqPywt7vnmmZvoVGpDUsaF88mF7GQ/VU8bJYa/jQe21lOj60HvzVN6h/1kTpHdwzLgbmVdNdth5oWX1V5iWTRYq3wBZ2G2AtmhNtG6W52ntyDlK1sz7o39XiwnXO3S4um1bFroimVF1OlcQAGh6oULn7xi49zbYRLXepSa+bpFDCVmPXgvB7T1DR7jzQMyDNf96EKp+08szm3hm09VgHH46qfeUhXsB5nsK+ZxXXJETYm2CRytpt26UwcrEqcOs1S/ZiuP8cXSX+zc8h/9yFlabqMsx0r6ix/sL5dWjStjj01pkmf8N3udrfhute97vhlzdFHHz1c//rXHysOflNZ1ILHtWhqmr1NnlfkuUUVAPZVf5sl59Z6YiqYso2N4uEvYdUGUiNIwMTZng4N2CxJX9K6HvG7kb9m50j+u1/TMmU99zHblsqQsmI75Sluu7RoWh272j2HFBiFCEzTuuzM1eSrF6bwigLqnBRM+DKmf9jbNHuPaaNQty1rg5J9W6XWCdPwUm/U8BP3PBxLeMh6wsm5iavGvxUS3zTcSo0j/prdIfk/637lPk79WNb7V/1shxZNq2PXRNO8SjLbtfLArIKVfW1papqmaQ5UWjStjl23NIG4iSOWqrkT9Xgl2y2amqZpmgOVFk2rY1dF0zwhxArFWZ9anCrZ36KpaZqmOVBp0bQ6dnUgeIg4ikDKera5fIFQSRgtmpqmaZoDlRZNq2NPiCbiKFjXPZefUtqO1WlKi6amaZrmQKdF0+rYNdEUoUTYVHFD+PhRpT+U+3ouQmjqD9lu0dQ0TdMcqLRoWh27ammKi4BiXfIvp2td61rj1PN3vOMdxx97VvGTdedkvUVT0zRNc6DSoml17OpA8HS/RTT535Kf9JqnCWbCvdKVrjT+0LMODkfOQX6jYnZx8BPXNE3TNPszLZpWx66KJsInk86BaDr88MOHF77wheO2n1Re4hKXGD71qU+N20QTnGMSTPs///nPjz/OfPzjH/8zXXktmpqmaZr9nRZNq2PXRBMBRPxY6pbzOwLrT3rSk8af9Oqmu93tbjdc4AIXGP/zhAgszv+fnvrUp44zgT/0oQ8dHv7wh48WKbRoapqmaQ4UWjStjl21NPnX3PHHHz9aky572csOH/rQh0bh8653vWt42tOeNnz4wx8e/vRP/3T41re+dfYZ/22d4ggsliXLM8888xy/UWnR1DRN0xwotGhaHbsmmliNIoCyPRU5f/d3fzfc+MY3HoURf47P8qeLzkDwHtPUNE3THGi0aFoduyaaCJqIpogbgujjH//48IIXvGB49rOfPdz85jcfhRMIp3nk67kWTU3TNM2BRoum1bGroinLKm4+9rGPjdMMcG9961tHsTTLbyxUIJp8PVe75yLIsl3PrdRjm3VTZu2bUkViDSfrUxesT8/NMi7UfbNc/GQ5K59mOdQ0IPdnnkNdTtdnuTCNa+pvURdynQl3J1xIXGGW30VdTS+8XHCo/rbrpvlSqfs343JuyHqsx5j6s9yKm5J9U3/LdqjXsh1Xy03+gjDL3yIuWF9G+uaRY9M46voyXSXb4p7620lXr7XeM9g3i3r+Ztx65LiPoh73uMeN683OsqtjmuZhULjB4WFWAa0F9bOf/ew5xjRNC/FOIC0aLnHFrVfAHavWsvX8Tplez6xzhZ3wN0pHuji5Kno2ovpLGOtR/ecaNjoHyc+g8ZjmwWao5yZNi6RjK4hL2PVe1/Xtkvuc+7Zs6n0Vh2dxu9R0Tu9j8oafnbienSTPf9a3S/JAmLkP2w1XGCkr3E6Rcl/v7/ReL5M8A3F7gXnp2Ml8D5/85CfHNrDZefakaKrUglgf/PpAfvnLXx6/ntOV9973vnd45zvfObzjHe8YTj/99OEtb3nLOLB86t797nePbtaxRZw4ONMdiFNYtmf5jYv/pM/y7W9/+7g+yz+X8HM9ljnXMvFa8pfwZ4XFJa3i9VUi/zWcWedw8eO8xJflLP9c/LMYOj/714vHMffs/e9//3he9jtfeqvfRV3SmjTkmqVt6ne7Thql31KcyaOtxuV85+b6LVMOZvnfjkt6E4d9iXPqd1GX8OSBZcJ685vfPC6znXsUl/M34xJX7oH7nHBn+d+qy/3krNsnztynqf9FXM0HS+G96U1vGpfV36JOOAlTPniW6r5lOtctj8VhOc2bZbrUhdkWjzxKeV2Vc51x0iB+12uZa+fiZ6v3cSMnL4T94he/eHjiE594dovY7CR7TjQRRXm7qgq9CiZU0WQSzFe+8pXDc57znPHXKyeffPK4NHfTVa961eGkk04anve85y3ViYM59NrXvvY4nsrcUs997nNn+uWM03rUox413PSmNx3TxX+OCav6jXvRi1403PCGNxzD50f4wnGua815xn9Z2r71rW89/OVf/uU5wq8uaXSOSUTvfe97D9e97nWHl73sZeumX34K8653vesYx4knnjimZb1z+D/hhBOG29/+9qN/2/zXtE8dfxe5yEXWrjF+14tnI5cwXIPwTaD64Ac/eKxoZvnfrrva1a42POIRjxjXpVs8uUdbdbmGl7zkJcNRRx013OMe99iR9CePLnrRi848vhUnD6TdNdh+xjOeMdzpTncan4fc5/iLq+dvxuVc4d/5znfedtmZ5dyD2972tsNtbnObtTIt33IdW3HSmXXhCO9CF7rQtsJ0rmf8/ve//3CXu9xlfMa3Ww5nOWk1RcxVrnKVseG2bf9OxMW5LvfgAQ94wPih0E7U7xu51Ce5RnW1evrggw8envCEJ4zHa9mzXHY5rGXGOpHW7Dx70tIUgTQVTVlO1+u+im67O9zhDufo6lsm+pHvec97Dt/5znfO3rM+BrlrTM8666yz92zM/e53v3GSz0VRaanIF+XUU08d7na3u83Mv1morFQOGW+xEV/4wheGpz/96Qvfgx//+MfjLPCLpmez6MJ90IMeNL6x7hQaKGPzdgq/GHrVq161Y3nkpeWKV7zijnWv+GBDg2Pw6k5BmHE7lUemRPHStFPhw3OwjHtw2mmnjXXCTqbVc0Wo+pJ5VbDqPPKRj1wblrHbmJzZS+Vm6vdm32NPWppUFFx9yGftQ/bpxrOsYwA+8YlPjFYO4zIcm567XYRPcETUbBT+Rz7ykeGv/uqvxt++IGlyDfO4733vO3zzm99c81f95/y6T0XOAjGPeg7e8IY3LCSa0k2q8hUHEbTIWAKTkBJyi94DounP/uzPRn+uab28WRRhJK3f//73hwc+8IHD+973vnF7J/DPxI9+9KNrac/4lK1Q8yzhEa4sq1sNcx7Jc4LYvGnWs28rzEo7NC4sE8ZhIPHkGd4qCQc+DPnbv/3bc6RhmQg/omkZcdS0h0tf+tJbzvt6nmecVXgZ6ZyFuAgXLwuf+cxn1vZtNe3rUcPUBfuQhzxkfKZXjXzMNXK2v/vd747tjRfF6menyP3c6Xiac7JnLU1ZpjBkPcfSCNrOPvCTcz796U8Pf/EXf7GUwayVxOdN+Zhjjhm+8Y1vjNs1HbP4h3/4h7HB/uIXv3j2no3PIZq+9rWvjeu5tjQucckX+3X9MdfOI/FlqUL1dpTtjYhoIm4WgTXOAMXcg43iEa7urWk6LRdN45SUB+f7/c6xxx47jgXYKcxk/8EPfnBc3066Q8LIdehyecUrXrHtcOdBEJuVP+VqO+T8hMWZwFZ3AstrqMdzzmap5/qzAGG21bA2Qpl+zGMesxZnLWNbYdb5JvbN/s1Sw2FN1qWVtO4EnivdlbE0iWeraV+Peg0saPkTxE7EtR7iU99aJm6iSdd5FU1Z7lT6kh+Jq9l59vxA8HlMC4lCmX2Wtr0xm008BTtCKwU4y62Q8L01syQkbCT+mkbrhIOuvFge4tbDg1jTXcO1rPssvXUZ45Wwqx+IO+sgUv7pn/5pXOc35JzsyznC1r2S7RrWLMQnTa5BWLmWGpd1LnG6Z3VfXa5HPZ5zQo3fPahCehr+9NxK9Rs/Wc+2/Mw9qPu3Q41PI5FfBuW6qpPnG8FfvRec8LPMi0D2cSHrObYeU7/i5Fgmcg8cS7nkNqL6F2aNI+d7Lms5neWPy75FiX8igXMtNazNhldxbsLC17/+9XPsS/j1nodsxx9yfz3j6cKq/pCwkfPmUcNNGNlnncXdMfemLmt8qHHOY5qWhAPnqnv9UcJ9nqalnrtRPFsl6alx2ae+zvMXP8t+aW92l31WNM0ihTgPZR4Y+1KQLeNnOwhjuvSQJHyII/HmeNYx9T8Px+PPOcKt++KC9Vwfq0G2a1psJ/7s4xJ+Jcf4jX/keubhePwkDGEn/Byz7RimYeaY5XrjqHI+Ej6ShsRf/QkvYcO666vnT6lh8Cd/q/8aVr329cJcD+fVPElYSUdcyP1eD8eTJ7CevJ2VfseSDktxYKN4wE/CkrfZFk5c0lKPzyP3DFkKw3rSZhlqvDWu6mc9ck5wbuLNes2frZKwEnbSZ1mPVYttdUj8ls6Lw3Q9fq1Pw5lH/KKeU/cL13rug/XENfU7D8fjZ7qs9zdhxdmuceacLJeJMFOukDxH0oBZx5t9m/1KNKUQ54GphTQP7jIQdn1gsgxJQ+K3zeVhmvrfiKQ959frqw2N7cQZqr8cs55GMjhWw44L88LdiJo+OCfnJc5sJ+6K7QiB6bFKjsUfJzwu4WdfliH+a1q5WdRjacBrurONGvd2qEJBGrlZpPGO31k4VvN96lfY9XoqEUuOczVd83A8+QHbnLin+ZNj65HzEsYs/znOTfMq9xizzq3UeCoJe9qALwvxJm7Lin3TMpB8IKisZ3ujNFW/7uU0rgo/cc5JPnJIeuu+wH+9puxbj/izTDpD0pm44jfwm7KZ85eNMKfx2k680ziTlmbfZ78RTSmotXDqFqqF2PYZZ5wxfpqZBmCr5MG1NHbK3BwZkKhCyUNTH/Dg2N///d+PaWFeXg/nJTzdSjGz245zjdln3VeDvixh3kfOF1YqrlR6Bmr7UXJtEJGwwR/3la98ZfzqzJdhaTDiZx7OY0bXZSVtSQeX49O4pEfe6CLK8aR3Ho5VB+flei3lX45ZOm7s0XTgZpazcIyr4fKbLhDrOTd+dNW5fuubpZ7D9F+7tGDgrXuScW8b5ROSbn6hW0V+f+ADHxjTmvIkLgPale2U05wb6vo8dCWad8tzV8t7zlVOlVfX4rrWS3/iTxpt6yZTJo1Ty5dL9iePjLPxEUbKbI4tEhcn/T76kEbPSz3GSY+8co+Tp5vFXHPCl876OygIV94lf8SXY6hpiYO8Tn7LL39OMLePcYYhebBRuUl+xT+X+5BymfsJ+SSu6WD/rFe/UxJ+4F/6XIuy4sMYdYP7GX+69JVfdXAN3/pOIHzPvHRw0pSvqJMm7YJn032r19Ps2+w3oqk+hB6UV7/61cN1rnOdtUpUg28As4HY5ia65S1vORb0rZAHwEN8/PHHj5/amgvlJje5ydqn5tLDX1yQDvEbMOjLD4M01yPXpUL1VZm5VoLrVFmpUFRe4vFl1XHHHTfOYXLYYYcNr3/960e/tRLhz/KUU04Z57K5+93vPjz2sY89hyALWZdXpm8wt468c73irn6n5JgpCsw3ZZI92F/zJg2NCu8+97nPOAeR8N1DSHu9v+uROC1zjsrLF20GySN+xCEux/LFYc6RrlkkzQkDBIu88UVV7kOOazyOOOKI8Z4veg2VhGNw/61udatzCLy//uu/HsuRsG9xi1uMk9wtQk0fQeCrJ+XYNfgoQOXvOnxWb3oGHzso2xp058L503yYhfCf+tSnjlNnuLfyIoPkYUC78qTM+nfWRp9ri5MIF2/i9nGC8LlDDz10nJJB2cTrXve6sYy7xoc+9KHjdUE4uZaNeM1rXjM+455X8wJlKoPkgfLrHpi/bCvTKCgXRx555HgPLJXHiGDpl2cPe9jDxmtTDhJ34q/kWdKQe+aUD37UH+Ymk8/mijOXkP05XxqmYU2J/8QB04mYn4kozvnmTTKPlbLjd1j21/uVe7AR0pRzCN973ete431QRt1rgh7Kpf3ugWNEYdKKhLFM5IEvWOWxaWfks3ou90QZkQfaG3PV7UQamt1hv7M0wddFvsD63d/93bHBhErUp/7eVFQoKlEiaiskHpU/IfPhD394fENPgw9+4i8VODzYhIc3I29o9c17HiwB17ve9YZLXepSa2kWtmtOI50KwrV99atfHQWQykuF600VSYcH3tusuXh8tiuPTNIZAZd0Jw4IjwDQoGrYrnCFK4zWiY1QmboXJhnNV33iTxxIHCoYeegeuebkTY5nOYuklZMnCV9aCQr3yb1JGOY5kqfe8AlLAjOfS6Omr5I4oFJ3D32hefGLX3z80jF5HD/2/fmf//nY2G7VuulLLaLloIMOWvvizFv8la985XHbvSEITGq6SIPk2pJfrkEj4zqUHeVA3kircuReELMEGnHtHOdO7+E8+BMOR3gTHpnighXimte85liOxOGe12dlFs5L3JbSnzLvGXzmM585ijDX495q1Agzx69xjWuMX1zVxngRPKvCUh4Jf/keqzI0nn/8x388TprKIpR7vyj859mSRze4wQ3GMF2PskuYyJc3vvGNwyUveck1CwtXryXxWirrrldaHVcHEB7iMN2GCW2JDTjunPXyxDFxIfF4tomV8573vKO4g/rEj9ZZfVgA81FHzk1614srfpyXuAgkafaseqbV5fIHXia89CkH6hBfxyaOhLNshEnI+lLWNcpb8cMXydIkf5WZrb6cN3uTfVI01Ycg63lA4C1NRXz1q199zRQ9fXA8WD5X3Q4aWYLAm6gH3ZuQt2rMeljPPPPM8U1IZeNBY96tTP0HE2JKrzc3b6OofhNXrj+oyDQgGiPUc/yiwey12adx90akIYL9canwAj+Xu9zlxopxPaTHmzOx5C3crLmVmh6VOmFhWgYVe74Om5eGWYgveZA8UbF6+zcJnvuTOIkzb8FQqRE+scqtR9KTcNxDDZ5P3DVUVbT4rQ/rDdFz+OGH/4ygynIj5IkK+U/+5E/WLJmuSaMozRonoomwWSTMpJ/L/Q7EIwvkNBzX5206DRqSx5vB88GSAuUtLxCe2UXCquWg+s+6tCtz8oSAuda1rjVapsD6SrTxK5xFylRI+BpCIjgvIsQZ4UeYseAQJOtdx6w0Z5nyq8FlPZNu8/5IN6Ekjpvd7GZrZcx5Obdei+fe85aXx9yvQHBMRdMiKCvi41+5Vx5MUiqsvHB5pjIlSRWW0/xeJM7qR1rVD7pgYxEHAVXreaJYnadMYTP3eDPIB3WKFxUvoPW59xyymqp7kgeuZdF8bvY2+5RomlYueYAreUg0Miq3mMv5zfnG/Ji8z9iZ7cKa47cfLCne0lVu8x4O1gFvYaxNKpyjjz76HNaNWQ+4PnHXoVHRnZSGPtc/JXGrtDQeVQg5luPeyDVeCUPDTkjUCinHpkvX7A1eZVHTML1uvxggGog2lbgGDc6ZhmnMiDd1ZndvrwQICx7mXetm8CZKGCYcFbCGCcQMU3qd32qj+Kbpj2iKMFL+XDOLQSryWJrS+LjfG11bjjmHNaPObeR3J3/0R380CgNlL5OmTu9DRXg5bn0q8jSA6QKMPyJWF4yXA+ckjBrWPOIPrFaEunjA4qSMEgVEq99MJI/mUdOedXlOrGisDjnkkDGdMDcRsRp/ts0lZLumaxF0bxEDwicUcq5nhmA195pn2/PqWNKX9fjPM57jWffcmYyT5cIzk0afGDDJJWHwv//3/14LHwm3XosXAN14xLQ0y+8aD3RTE2Yph9mf5SyqPxgmwIrtfrHYuqeuQVeuZ8nStfCX9NV0ZH0eiS/+WMMJSM+UsmKeL8flB6Gfss/671ljxcz5lstGmCYM9ewpU67XmDFi3cuZtCobluqAja632XfY50QTV8WFAdUsRiaaM2A1x1QeTNMZiJj9KjddHfyvR33YUuA1hBoqbxhmuSYGPCAaehYglUcdoxQLhLdpgsEPLf3TywPvDYloUrEkfEtvKMLXgDD5Eif6x8XFf96UodJjUdNYcN7GHFOREVcqD2OoIGz+kw8qaG9JCUt/vO6XiKakKcSft3djxXQV2Fedc+KPGJQf3naZqL0hE2oa6fiFNEG4RIF0yZs0pDHBY5qmzaDBk39JH4Fm/BekSeVGDEIebRRXwok/opNoilXDmBGNKEuEylXFrkw6T/g5H7kn8xCHNGo8I5pUzqyPKmtlWZlWOQu3hj0PYVa/wtUtFEGQNHlTZh2Vd9Uy6vyN0i2c3F/llxj2rGSfBpAYIwyUpwiq9dKfdNc8tO6nqMSAMqx7hD/3s4omIl6Zsh23XlyO5bgfDHsBkQ+xmNrHkiPvCHz3wPPvnMSZ9RpP3c66Z0QZ8scA446IJvuNtVM2xe1aCDTnxNV7YNvLAdFFRLz2ta8d60BlJ/7UQ/KZ9RIRzY47fz2kh1OHEunqMQjPc+7FTneieoeAINxM0OnFNedikXhyfcqK7QwLEIdwTb5qDB+xrG7JhMFEk+dOd57zav4sE+F6nuWzl3DDPdwnbYS6xQuplw9d3SzE9eW42bfZ57rnPEj1QWCh0OAbtFoHIyrQ1dKECCaWHm+nqbxnIZy4POQqMpWDMQbeWr1FefMUF+xjqg/iI36kTUVO4Bg06OGHiouFKt1nrkvFLnyDoFXAKiSNFnGmAjQOyRskpI1Qcv2c7j9hEEwqtXTl5Bocsw7pkdZsa4CJtYgaWGYdKilvvISN8OpxeZl8grENKgvCzDVbZ90hjsBv0gRp14gaOwKVoXuV+xf/W0WDWrvnNK75K7iuFo0p0YFF4kpexp+wNKjyQR56+2S1McaCYLrYxS42DsR1Dj/Oz7WvF1fSK0xj2pR3aEyvf/3rr5WdCAKV9kaIN/dL+N7ilQXiPpYyxwgzjYGGMGU85zovaZtHjstfDTmrUrq14H7k9x6uT1lR9tcLV/xJd5z0BPeQuNDIek4I9wgD3dxEpvNr/s8j4Sc+aAhZqcXpBcfz6L4bbH6JS1xibCwJBiT8mmYk/oQdF+S3lzPXIC6CEl7CWJsyThMJB/KWMPWi5XkmHs5//vOPz6s8kDfG9lVxnXSlPMwj1wDPMDHEUkgEX/CCFxyFCxGpjGewujA9w+rMpDHL9eKC4/HjnOQlhOs+ehHyUqgOjiiRBted52B67rKYhuvlXR3nmdEj4IWMH8+TvNnJGfyb1bLPiSYFj5v30GW/CsdgZY0xdA0ovBrwWC/We3BrAZ8Xn7cIP9XMW44Hw5snks6Khkdj7cEGK5QHPP6m/qVTBUz8eHPS6CT98TutEDTe0pCux/hLw5HrEIaKzxuyvNK46EZC/FjmfAKPaPOFWE1n9Zt1x3XdsfJp5KWddYpwyefU4K+GxdzPGge/wCCivIGHhL8VNHDEZ3CvpAnErLfDfI0zTdcscjwNNiuBLlfbjqnMlT0NHEHLjB/Bk3zlqvVmHvwJlyUuIpIYV/ZYI8GqQCwo5xshvOQlkUoIs2DUrjGVvZcLz4xB1Eiac/4ijZFGRONKRFbhBV+56cJwbcq5+5EvJtfD+cpzrqHmofE8xDkxKd2Ea77a9FxkfVHEk2cHGkdWDi9Qnhv3mPNMy0dWKPkojVzKg7RmHbaTfnmUdXERTYQHKyWxnS87PbMGgmf8TuKAsDkvZNKjnLC0Sau8UFcRYBmwza84pUcYWc7DcWWCH88wAScOItKLnzLuOrw4Eg38qxfrMIjEhyznkePyQ1rlaQQ9QeSlMN28LFsRhnoddMNDGDXOZSIfcp/h+VdfQVr0CMDz7x7Estfs++xTokkBTeWSh6E+/HHwYHkTzxsIE/rlL3/58W3A26GBzEze8xBm4kINO2jQdcmoNFR0rEKEB3/1jV26c67GWqXOKqDR02AjfuJfBTCNjyUgn83nYc058BB7073whS88ChwVlrELGYzIL8efpYaXWDAGwpcg6ZqLv8QhfJapC1zgAmO+eVtVEegSQfwJl1/nui/BPumqUwjYl3RnaXyChlMlaJCzOINzhLtVWPt0+UFYutHcO4N3dUtlPJO01LTPQ1r4TZpUlN6608DmmsBiyBKRfBf+9Pz1SJqUl3Q329Y46N4ippXpaimbR+JNmLozWArcTy8ZlvJd2SY4dCd7bpQllqHc41zDRui6IMhZSIRPBBBKEBbrEmHG0sV6UMfUzUKczkuZk9/yQZnRaCmfrFfg17p6QBlnBfGBgXNSBte7BseUExYN18CK4xrc6ykEmuPTl5XkNYdpOZYW4kP48kKeq0t0Q8lj91TeGyfk/hO3SXvIdvIksNa6dnhpON/5zjfeSy9LrFGZ+kF6UjbXw3EuZTxIbwSMlwX5wLqqDmJphfQ5d9FyI46cA+XI8yUfWJaIkrz8qkPdX3Wq+q6+nGCR+DaLvFaXi49z/2JF9yKiq04eEHcsnM3+wz5pacoy6x6OVIT1AYmf6hd5cOu+WTieCqn6rw8zPCS6BgmlWf6m53vz0/hNvxDLdcBSOnNu9ktP3W87+ypJN3LMdho9ON+bKWuFfTkn60lX/Nbj2RdX/VtPGrOM/+kyxyxtyxOVHqFXz7Oe7c1S47HOJV2uPRYQ2zlmOQ/+XCPkZ8j5NY665AK/1f9G5P6HnO9tniUyg/IXCc/xady2YTvXFH+h3mNuo3xyLPmUc1DjggaRQ+JYD8eFkXA8d6yEKTeQtsTN+sYyMk3LIvGAJcvLl65w1pRQ0yBsccJ5WQc/07jqdVonulixks7qn8UpX9yG6bUg8eT8+KnxJ722rfOT49MyVnE8YSYs1zi9TvBDCMbqmXMRP1nOg3/pSZxQz8ojL8TZB2lQb6hTY4XPNWV9JyDwvYx7/jKWMWnmWPzUrzUtzb7PPjmmKYVvWghr4YzL/izrvuyfRfyFaZiWOT/7ZsUT6rmhhgEPv32pyELOsy+VRfULy2n4wf64ULenx5DtGm6N376kcbo+pe7jr27XSjfXFLKesLfKrHTCdo3Psep3PXJ8ukSNw7pjcajryc/1qOdNqfvW81eRplpu4JyabuTex4Gf+Nsonkr1az1hTONchJyT9FVsJ/waD2qc0/NmMSsMJI5K/MR/jmdpX/UzPT6Peh6m5aXGhbqd9ZxvPS7P3fT8RUgYCRfTOIL1pLnGVf3Mot5byxpX3T8vnPiv5y2Tabg1LfPSNS+tzb7FPieamqZpmqZpdoMWTU3TNE3TNAvQoqlpmqZpmmYBWjQ1TdM0TdMsQIumpmmapmmaBWjR1DRN0zRNswAtmpqmaZqmaRagRVPTNE3TNM0CtGhqmj3Oz/3cz811j3nMY0Y/Bx100No/ynaSVcWzKK6//iS7aZpmJ2nR1DR7nCoKqmh517veNf6v7EBFPhCOLZqaplkVLZqaZo8TaxKmlp567ECkLU1N06ySFk1Nsw8xr3uMxYXlCRESscRwYJWaZZmxHX+zwq7ws1E8U+pxP0hOOrItPOuxms1Lz6z9VTRZz/EaruMHskWuaZrl0aKpafYhZokm+4gDIqEKlAgFx3MeMRG/IDQSXkTGPBaJR3iz4L8KF/6m21nOSs96+yOaLOMH2b/RdTVN0yxK1yRNsw8R8TOFKCAOUIUErEeUoPqNEKoux2ZRj28UTyViLRBM4oZjuaZ56Zm3P2lwfJru9dLTNE2zFVo0Nc0+BHGwTNFU1xdhM/FMcbyeG6HjeggnzEvPvP3CcYybxh2hxlWrVtM0zVZp0dQ0+xDLFk3zwpvHZuKZ4hgXkUTIZF+Yl555+50r3gikWcIqxzZznU3TNLNo0dQ0+xDLFk2Ei+0g7FnCI2wmninOk/74sT09Z1565u2vabAu/FDT5vwWTU3TbJcWTU2zD0AgEA1xRECo+5/0pCetrRMNERtcREW2hQn+sq8KjSnxw20Uzzwcr+Jluo156Znud17dFm+2HavbNZymaZqt0qKpaZqmaZpmAVo0NU3TNE3TLECLpqZpmqZpmgVo0dQ0TdM0TbMALZqapmmapmkWoEVT0zRN0zTNArRoapqmaZqmWYAWTU3TNE3TNAvQomkL/Nd//de4/M///M9xCfuqy7FZfptzkjw6UKnlZVpuptifY3XpvC5jTdM0O0uLpi1QGzgN1n/8x3+sNVywngZteqw5J/InS3n07//+7+P2gUbK0qwyZFnLUfziJz/5ybi0/dOf/nQtH5umaZrl06JpC6ShTyMGjX0astrwZZn1WdRfUOQ/W7tNfkuxU9SGPSJAHiZvp9RfZlQ3/QWHffk9yLKQDzv9Gw7XHcGY/Kh5FFKWan7Fbz22EdP83Ml7vQiryOPtMu+/f3udraR70eefv5ShZT93y2CR60j+LPo8OFb9zquvp/7yk+ppXNU5vlfagGY2LZq2SN7wofH64Q9/OHz/+98fnfUf/OAH45JLwzYLD9D0J6Ment3EAysNi1Sa20FePfjBDx6+/e1vj9uLNPjSlco5lVIahPxXbZmVdyq4VTTo//Zv/zaWq3/9138dl//yL/8yWo+4f/7nf17Ln+TRNK+++tWvjnm5UR5WlplfW63oV5nHm+FAbbgWff4djx/n7LX82ug6iBjHKxs9D8pora8xb9807NRPYVZcyUNp3mvPQ/PftGjaAtNG6SMf+cjwkpe8ZHjhC184vPSlLx1e9rKXDc9//vPHfc961rOGf/zHfzzb588yq7LZC5WPB3ajSnO7vOIVrxiufOUrD095ylPG7XlWpsq0orFd82tWRbRdVlWBvfe97x3uc5/7DHe/+92Ho48+elxy97jHPYZ73eteo4hCLFAph8k3+XjUUUeNQn1RlpVfhM928mivNRLbvZ59nUWe/0X87DbrpZGIIZwq6z0PEfezqPVQ/E3DBj/Zv9GzJ917PX8PRFo0bYFp98lpp502fOpTnxrXp7zzne8cPve5z83sakEeMMtZeKgcj7OdczgPYfzUtx2VRfwkbA+g/fX8iuP28VMrm1lp2C4EwG1uc5vh3e9+9ygKvvSlL4375+VTmMbvmueJpvXS7ZzsrxXTevmW/OEqdX9Ny2Z59rOfPfzWb/3W8Iu/+IvDr/zKrwy/+qu/Orrf+I3fGLdZ5qDspfxFOH3lK18Zrnvd6w6/9Eu/NLzvfe8b9y2CNM+7n/PyL/vlieut11/9zWJeXq2Xx9P4wnr3Ksee+tSnrvnJuZY5Z9Y1zrueuo6NrmXeczaPpIsTBmalD9PrTLqn+1DXkeNc8g25noSRNMwi58dFCCQMblaeJO6HPvSh5zi3XrvtXLf9WY/Ltcy73kWuw3XX9IUazhR1jfBmkfQj8W5Ejcuy3ouQMJu9Q9+RLZBGK2NQ3va2tw2f/vSnx/UprAef+cxnzt6azbTCqHj48jDxl4fRQ1YfuvqQqiRyTvzZThypLFQCqVAcj+jKOTk2Lw3bgQVOg4YXvOAFw9/8zd+M6xtRrzmVY9KGenxeup2XPEi+YFa+IfHU/Khh1fzgL2Fvluc+97nDec973lEk/fZv//Zw7nOfezjXuc41LokpFqQIperAsum8X/u1XxtuetObrpXNjaj5NWVe/mU5zaOaD7NYL6/Wy+N58U3vVe4lV6/Jen2hQI1n1jVO0+r8Gu70uGPOr2nItdXnbB6Ox3/CwKz0zbrOWfswK90Jzz7HYN+8538e0lL9WN8oT2ra7M81o+YBEvaieYBFr6OGWZmGV3Gspq8iDsfV3+v5q/BX3az0zEtns3v89xPTbJo0XmedddYoAHQ1nXHGGeNb/nve857RgvL+979/eN7znje86lWvGr71rW+dfeZs8rBxteKpTCulPKj2VbGVirI6FcH0fOupUJxTK4t6rDINYxHSuGvIX/3qVw/HHHPMcNhhh43dmccee+zwiEc8YuyO0rX0zGc+c11r0/S6pmnMtU6p6Z5ea1g03+xzDM6plZr1HFuUCJ+TTz55FE0EEtFEBBFNccY1heQpvvGNbwzXuMY1hl/+5V8eBZZz3/GOd6wdj99Z3Z+5xo2oeTCrbEzzaBbr5dV6eTwrvkXvVeA/zwh/s665njsrnMSBzVzLrPRPEd6sNFU2St+sfZimO/kV59g0/kXSPPWzmTxB6rxAaAgDjtWwQg1nVpiLXsfUX0h+zMKxZYumxOVaZ12vcBYJq1kd/6/ENpuCANAQfe973xsL+5vf/ObhzDPPHD7+8Y+PVifddbZf/vKXj8cMDF8ED5GHafoAecjtn1YStaIJ9WGsTCuZWqFMz5lV2cxLw3oknzgDnW0zzbMy6W762te+Ng58FtcJJ5ww5ud6zLu2MOv4NN3Wq8gM88Ke5lut7KfnWM+xzcLSdL7znW8UP4TPec5znnGpi856ytBUBL3oRS8afv3Xf310v/mbvzmKrZvc5CbjsfghRLcqmqb5l+vnUqFP82gW07hqXq2Xx7Pim4YV5qXDfi7rU6bXOCucGuc0/vWuxfqsOCvOnVUmwyLpm7UP66U7TPcvkuapn2kY6+VJsC/n8OM6bav/pvmx2XuEaRrD1F+Ytx/in3UNqPXwev4q68UVhJsy3+wNtla7H+BosCpvfetbf2ZMU6wlrE7pupueBw/0tHKoD7oHxsPFz7SSsK1y8ZDWB8v2rLeW6fk1HnHUcxZNw0akgY9lztibBz3oQT/Tnclix+rk+HpsVNHU4/PSPS9/Fs034fMLy+QT6rHNwir5u7/7u6PoSZccEcTK9Du/8zujaJqWISLTYHrn8ENkOe/85z//8KY3vWn0Uy13UyverPy0LR82uu/2O87vIuVivbxaL49Djc+xRe5VcG6NK8y7xlnh1LzazLVYr35nMe96NpO+WfswTfeseJKvYZE0T/1sJk+C/Zy4XaPrzb6w2Xu0yHVIV/KkUvMq2BamcJKOKfXa1/PnWMKfFdcU1841e4cWTVsgDU+Wp59++vgFnU/DDXDWjWL54x//eHjLW96yNqZpnmhKxQIPWn2Y6jq/qSTyEAf+sp1KJvArjHo+aoUyPcc651zLWWnYiAimOPjC64gjjhj+7u/+bnjjG984Ouu6k250oxsNz3nOc0Z/86hpmUU9Pi/drrXmefJnvXyr+4XjGHIsFaQwkqeLkrzRNcnK9P/9f//f8D//5/9cWxoY/vM///PnGAie5d/+7d+Ox37hF35hdPwbDP4//sf/GK53veud44u7RS1N8mZaDmv+1fvveuUFt1G5WC+vcizUPJ4V33r3al467He8Xu+8a5x1PVO/611LPTfxrofzZ5XJeembxoFZ+1DDmJdv0/3WOcfnMb0u685ZJE+CuKvgsD0NV5iL5sGi18HfrGurcYU8DxBfvU+Ytc+2sHIepHfedc1D2Ovdg2b1/L/S1SyMxkeDFdH00Y9+dPyCjnjiPAiWhMApp5yy9mVYGruKh8iDlYebqw9JKgEuD2LdnvrJQ+lhy748eHV71jk1fH6yf1YaHF+EXLO8sm7QvEHfBi4TSAaBn3TSSWPX1Iknnjjm26x8qunnauUT6nF5ul66LXOsXsu8/eLL/mklVuOxvlV8aZkpB3xRmKkGOOtEuLxJ+cPjHve40f+9733vNf+W9pkD64tf/OLoD/W8aX5WN6tc1fyreZE8qmV4mj+V9fJqXh7Pig/Te1WvqfoLwsm1hXnXOL2erHNpCGddyzQN1Y/412N6PZiVvurib961V79J96x4UMO3f730xh9X83SRPJliPz9hur1oHoRFrkP49byaxqmr14daHrlc55Sabi7pmMa1UT43e4u+I1sgAiCiSWNmoLeuJRMMGphrrM7Xv/71cWksD2aJgf0Z15trTp4182GpNL5LeaoTXMalvKXscT/60Y/W/NXzLDllj1iq5zZN89/iaiNLz25CTK0nqJrdoUXTFokgyNv7tDHKdpb1Lf9AwjXXBrvmRxr+HNfAH4h5hOl1J08qGVSf5Sw/U6q/Rfw3zYFCrImxwO0lWKOmFq5mb9CiqWmapjlg2WvihPVrVjdmszdo0dQ0TdM0TbMALZqapmmapmkWoEVT0zRN0zTNArRoapqmaZqmWYAWTU3TNE3TNAvQoqlpmqZpmmYBWjQ1TdM0TdMsQIumpmmapmmaBWjR1DRN0zRNswAtmpqmaZqmaRagRVPTNE3TNM0CtGhqmqZpmqZZgBZNTdM0TdM0C9CiqWmapmmaZgFaNDVN0zRN0yxAi6amaZqmaZoFaNG0D3DNa15z+Lmf+7k19+IXv/jsI//Nu971rnH/Xueggw76mbRvl7/8y78c3ap4zGMes3YfrO8FpEMZORDZ6v3//Oc/P95Dy72KZ8UzsxMso8xsNg/5VVdthu3UbYvmn3zYK89ys/dp0bTHUWFMG4W6LxXXViuWVRHht0zRFAGzKtGkAk9Ds5MN2ka47p1o7FeVj8tiM/dffu1LDWPEwk6UMWVX2NsVTcLgFimLroPfzYim3arb9rXnoFktLZr2MB7eWRVbKtQIkO28ja0SFecyRRPk0aoqOY3udhuaZeBeL1s0uS974do2y6L3n599STRhJ4X5MspyRM2iZZHfzYgmrLpuE99uvQw1+wYtmvYoqZDmVfQe7FR6qViynFZO/NmnEq7haUjiv+7PtmXO5VKZCMd2Gqsa77TCSRyWjs0STYmLy3F+bcuHGj5Xr024SUeO13NqepKncSF+XWvCmlLzgUs6kxc5PyTMXFvN38C//Ql71vlxtqfpT1prHmBemhIfv/VYzX9OXIvkCebFhdzDhBmS3sSbe+R829NrSblJWPIhJKwwKz0JNw65vsDPrLwJ0zC4mo7KvOuu54qrUo8l3Fx70lqPTcl1T/NjWmaC+F1Tza9K8oGbpjXXl/snjqwn7uSX8IPtmh81T6s/ZH/CnUX8pPzUPECuMdQ01WtK+cr5cdM0NQ1ml8Zm10lFOe/BVQGksojfVBC1onEsFYTjWa8VRypWy1SItbJBjodppRNqHJYJJxXSvOvhd1rZx68wss5PTZvtnFevA86paavr9byEl3ycR70ezArf8aSDq/lUEXf8pCGp/udd8/Qa+bdd86CmUZqEU+OznXAS9/Tasr5enjiW65+Gl3hhmWNJL5drtc6/44lPeFnncn2WiRO2N7p22J/4klYOm8mbmr5ZCCvnCStpFUbSmfwIuXaIZ+ovcddrmBI/NU7UtNqf8y0dS1w1ryzjL3mRMGoakm85ZjvhoYYJfmue5ljyNNTzxFePTanxI2lzvmPJF3HkWL2GhJ/4LGv+Nc2U+aWx2VVSkeRhnuJhz8M9rXRg2/5Zx5DKorrEZd15FZVhTcu0cqouFZX1WqFNK9EKf7WySvhT7E/4qBW1MGqc4prmUXU5Jrx58VWmcU/PSxzin5fvlen50/BD3T+9RtQ84DfXF5dj0/gcy32exj31OwvhzvIz69qFl3TU9KKWi/XuIabHa1ibufZpGtfLm1npzbEpNe64eq9Q47Zer68yvfZpOio1D4Ptek8rrrUeq9dvfXoNwpqmdb17gWma+E2+OVbDz7FpmmtezUJ8NY56D+s1rhdOTadlvcammTK/NDa7SiqkWglUPNipoGZVCI6nguLPcS4VXK0opvCXc4PtVEDOSzjTyjdMK1SsFyeEk3hnXbfzhVnjqxX1NM5aAa5XGeY8LmHNYnqt0+up8c+6J1OEVa9TWNO8nF7z9BpR86CuT5nGJ5ya3zXuRfKE/1n3c1Zer5fGmo/T65sVVj2+XriV6bVP7896eWNZ01Djr0zTPgvp4ydxz7rnYXrt611frofLdVjO8z+93/X66/2oTNMzvd5p+qbh8Js8reuVabpyXfNwPP7FVfN+Gpa0CaumGTWd02tsminr1+rNruKBn/UAp7JKpTOrYplWDFBpJLxaSU6pYVecK8x63rxKZppG8Fcr0SmOSaNzq79Udol7WhFySJyWqGmblUdTcv68NE7jtp64kfOxSHzTe2A94c275uk1oubBNI2VaXzCyf2Zd956eVLjreTap2lM3NPzarmYXl+9h8jxUMPazLVP7896eQPH7ePmlQ9MzwvOybk17mk6KtNrn+bbLBKe5fT8yjSv6vVP8yLkGsL0Xk3TV+8rki5MjwXx1jSvlz+Bf2mYpnl6jUEaaxw1LevlWdNg/dLY7DoqjGlFOd1XK0qoLHLcvlQmKpZUCPY5JxUef6k4algV58SFVJx1X+JWYSW++JsXdpiGhXqOY7UiFFfNi+qXP9vxb736rekM9s2qzDGNm79p2hKmfY6th7BqePIqYU3Drf4cy32DOKfx1muo11nztsbBf42jrs/Lk1x/0mKZ8F3LvDTX9ILfhJ9yEr/TOGoeo4a13rVb1muP37Be3tg/6/pnIZyUeThX2mv407it17iTZnHWsOq1Tql5bV0cyctZ+SG+6TlJg6XzkufCShj21/TZ5lDDzDVyyce6LoycB2HVNE/TUvNhCj9xFds1PTkujhpeLX/8rRdX06xfqzd7Ag++iiOuVoLBw57jtWK1v55vO6Ti4lJRWM7yi8SRyjTUuKfnZZ9wa+U0D2mt6cc0nZbxl/2pEOs+67kupEKOS1qcm32pZKdM70HyYNa503jmwX8NN9eAedeMnGM5Kw9cV/Zx0jP1lzA596um2fmL5AmqP65S96dMVP/SVK9/Vrrtk9akt97PRa99uv+lL33p2rrwNsqbaZjcenlSzxc2ahj1OKblhd/6TPE/zbcp9Rrq8RoON72eeWWo7hN/qOHl3iWP63U45jxxIfur/3rva35O02e5HklTwsU0v/ip8dlGvRfZl+3kRdNUWjQ1zS6hEu+KeX00oLXR3g3S8Ffsq4100zQHBi2ammaXaNG0MbstmmI9mVKtOU3THDi0aGqaXWBWl0hzTmpX0G4Kp9rVE9dWpqY5MGnR1DRN0zRNswAtmpqmaZqmaRagRVPTNE3TNM0CtGhqmqZpmqZZgBZNTdM0TdM0C9CiqWmapmmaZgFaNDVN0zRN0yxAi6amaZqmaZoFaNHUNE3TNE2zAC2amqZpmqZpFqBFU9M0TdM0zQK0aGqapmmaplmAFk1N0zRN0zQL0KKpaZqmaZpmAVo0NU3TNE3TbMgw/P8o+FJJGs7V4QAAAABJRU5ErkJggg==" /></p><p>Figure 3 Change from randomisation (week 0) in body weight (%) by time in trial 4</p><p><strong>&nbsp;</strong></p><p>Before week 0 patients were only treated with low-calorie diet and exercise. At week 0 patients were randomised to receive either Saxenda or placebo.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p><em>&nbsp;</em></p><p>Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-liraglutide antibodies following treatment with liraglutide. In clinical trials, 2.5% of patients treated with liraglutide developed anti-liraglutide antibodies. Antibody formation has not been associated with reduced efficacy of liraglutide.</p><p>&nbsp;</p><p><em><u>Cardiovascular evaluation</u></em></p><p><em>&nbsp;</em></p><p>Major adverse cardiovascular events (MACE) were adjudicated by an external independent group of experts and defined as non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. In all the long-term clinical trials with Saxenda, there were 6 MACE for patients treated with liraglutide and 10 MACE for placebo-treated patients. The hazard ratio and 95% CI is 0.33 [0.12; 0.90] for liraglutide versus placebo. A mean increase in heart rate from baseline of 2.5 beats per minute (ranging across trials from 1.6 to 3.6 beats per minute) has been observed with liraglutide in clinical phase 3 trials. The heart rate peaked after approximately 6 weeks. The long-term clinical impact of this mean increase in heart rate has not been established. The change in heart rate was reversible upon discontinuation of liraglutide (see section 4.4).</p><p>&nbsp;</p><p>The Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcomes Results (LEADER) trial included 9,340 patients with insufficiently controlled type 2 diabetes. The vast majority of these had established cardiovascular disease. Patients were randomly allocated to either liraglutide on a daily dose of up to 1.8 mg (4,668) or placebo (4,672), both on a background of standard of care.</p><p>&nbsp;</p><p>The duration of exposure was between 3.5 and 5 years. The mean age was 64 years and the mean BMI was 32.5 kg/m&sup2;. Mean baseline HbA1c was 8.7 and had improved after 3 years by 1.2 % in patients assigned to liraglutide and by 0.8 % in patients assigned to placebo. The primary endpoint was the time from randomisation to first occurrence of any major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.</p><p>&nbsp;</p><p>Liraglutide significantly reduced the rate of major adverse cardiovascular events (primary endpoint events, MACE) vs. placebo (3.41 vs. 3.90 per 100 patient years of observation in the liraglutide and placebo groups, respectively) with a risk reduction of 13%, HR 0.87, [0.78, 0.97] [95% CI]) (p=0.005)</p><p>(see figure 4).</p><p><img alt="" width="510" height="357" src="data:image/png;base64,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" /></p><p>Figure 4 Kaplan Meier plot of time to first MACE &ndash; FAS population</p><p><strong>&nbsp;</strong></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Saxenda in one or more subsets of the paediatric population in the treatment of obesity (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>In a double-blind trial comparing the efficacy and safety of Saxenda versus placebo on weight loss in adolescent patients aged 12 years and above with obesity, Saxenda was superior to placebo in weight reduction (evaluated as BMI Standard Deviation Score) after 56 weeks of treatment (table 9).</p><p>A greater proportion of the patients achieved &ge;5% and &ge;10% reductions in BMI with liraglutide than with placebo, as well as greater reductions in mean BMI and body weight (table 9). After 26 weeks of off-trial product follow-up period, weight regain was observed with liraglutide vs placebo (table 9).</p><p>&nbsp;</p><p>Table 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trial 4180: Changes from baseline in body weight and BMI at week 56 and change in BMI SDS from week 56 to week 82</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Saxenda (N=125)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=126)</strong></p></td><td style="vertical-align:top"><p><strong>Saxenda vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>BMI SDS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline, BMI SDS (SD)</p></td><td style="vertical-align:top"><p>3.14 (0.65)</p></td><td style="vertical-align:top"><p>3.20 (0.77)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56 (95% CI)</p></td><td style="vertical-align:top"><p>-0.23</p></td><td style="vertical-align:top"><p>0.00</p></td><td style="vertical-align:top"><p>-0.22<sup>*</sup> (-0.37; -0.08)</p></td></tr><tr><td style="vertical-align:top"><p>week 56, BMI SDS (SD)</p></td><td style="vertical-align:top"><p>2.88 (0.94)</p></td><td style="vertical-align:top"><p>3.14 (0.98)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean change from week 56 to week 82, BMI SDS (95% CI)</p></td><td style="vertical-align:top"><p>0.22</p></td><td style="vertical-align:top"><p>0.07</p></td><td style="vertical-align:top"><p>0.15<sup>**</sup> (0.07; 0.23)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Body weight</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline, kg (SD)</p></td><td style="vertical-align:top"><p>99.3 (19.7)</p></td><td style="vertical-align:top"><p>102.2 (21.6)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, % (95% CI)</p></td><td style="vertical-align:top"><p>-2.65</p></td><td style="vertical-align:top"><p>2.37</p></td><td style="vertical-align:top"><p>-5.01<sup>**</sup> (-7.63; -2.39)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, kg (95% CI)</p></td><td style="vertical-align:top"><p>-2.26</p></td><td style="vertical-align:top"><p>2.25</p></td><td style="vertical-align:top"><p>-4.50<sup>**</sup> (-7.17; -1.84)</p></td></tr><tr><td style="vertical-align:top"><p><strong>BMI</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline, kg/m<sup>2</sup> (SD)</p></td><td style="vertical-align:top"><p>35.3 (5.1)</p></td><td style="vertical-align:top"><p>35.8 (5.7)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Mean change at week 56, kg/m<sup>2</sup> (95%</p></td><td style="vertical-align:top"><p>-1.39</p></td><td style="vertical-align:top"><p>0.19</p></td><td style="vertical-align:top"><p>-1.58<sup>**</sup> (-2.47; -0.69)</p></td></tr><tr><td style="vertical-align:top"><p>CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients with &ge;5%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>reduction in baseline BMI at week 56,</p></td><td style="vertical-align:top"><p>43.25</p></td><td style="vertical-align:top"><p>18.73</p></td><td style="vertical-align:top"><p>3.31<sup>**</sup> (1.78; 6.16)</p></td></tr><tr><td style="vertical-align:top"><p>% (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Proportion of patients with &ge;10%</p><p>reduction in baseline BMI at week 56,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 26.08&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp;8.11&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 4.00<sup>**</sup> (1.81; 8.83)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p>% (95% CI)</p></td></tr></tbody></table><p>Full Analysis Set. For BMI SDS, body weight and BMI, baseline values are means, changes from baseline at week 56 are estimated means (least-squares) and treatment contrasts at week 56 are estimated treatment differences. For BMI SDS, value at week 56 are means, changes from week 56 to week 82 are estimated means (least-squares) and treatment contrasts at week 82 are estimated treatment differences. For the proportions of patients losing &ge;5%/&ge;10% baseline BMI, estimated odds ratios are presented. Missing observations were imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach.</p><p>*p&lt;0.01, **p&lt;0.001. CI=confidence interval. SD=standard deviation.</p><p>&nbsp;</p><p>Based on tolerability, 103 patients (82.4%) escalated and remained on dose of 3.0 mg, 11 patients (8.8%) escalated and remained on dose of 2.4 mg, 4 patients (3.2%) escalated and remained on dose of</p><p>1.8 mg, 4 patients (3.2%) escalated and remained on dose of 1.2 mg and 3 patients (2.4%) remained on dose of 0.6 mg.</p><p>&nbsp;</p><p>A 16-week double-blind, 36 week open-label study was conducted to evaluate the efficacy and safety of Saxenda in paediatric patients with Prader-Willi Syndrome and obesity. The study included 32 patients between 12 to &lt;18 years of age (part A) and 24 patients between 6 to &lt;12 years of age (part B). Patients were randomized 2:1 to receive Saxenda or placebo. Patients with a body weight less than 45&nbsp;kg started dose escalation at a lower dose; 0.3&nbsp;mg instead of 0.6&nbsp;mg and were escalated to a maximum dose of 2.4&nbsp;mg.</p><p>The estimated treatment difference in mean BMI SDS at 16 weeks (part A: -0.20 vs -0.13, part B: -0.50 vs -0.44) and 52 weeks (part A: -0.31 vs -0.17, part B: -0.73 vs -0.67) were similar with Saxenda and placebo.&nbsp;</p><p>No additional safety concerns were seen in the trial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>The absorption of liraglutide following subcutaneous administration was slow, reaching maximum concentration approximately 11 hours post dosing. The average liraglutide steady state concentration (AUC&tau;/24) reached approximately 31 nmol/L in obese (BMI 30&ndash;40 kg/m<sup>2</sup>) patients following administration of 3 mg liraglutide. Liraglutide exposure increased proportionally with dose. Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean apparent volume of distribution after subcutaneous administration is 20&ndash;25 L (for a person weighing approximately 100 kg). Liraglutide is extensively bound to plasma protein (&gt;98%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>During 24 hours following administration of a single [<sup>3</sup>H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide. Two minor plasma metabolites were detected (&pound;9% and &pound;5% of total plasma radioactivity exposure).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Liraglutide is endogenously metabolised in a similar manner to large proteins without a specific organ as major route of elimination. Following a [<sup>3</sup>H]-liraglutide dose, intact liraglutide was not detected in urine or faeces. Only a minor part of the administered radioactivity was excreted as liraglutide-related metabolites in urine or faeces (6% and 5%, respectively). The urine and faeces radioactivity was mainly excreted during the first 6&ndash;8 days and corresponded to three minor metabolites, respectively.</p><p>&nbsp;</p><p>The mean clearance following subcutaneous administration of liraglutide is approximately 0.9&ndash;1.4 L/h with an elimination half-life of approximately 13 hours.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p><em>&nbsp;</em></p><p>Age had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results from a population pharmacokinetic analysis of data from overweight and obese patients (18 to 82 years). No dosage adjustment is required based on age.</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>&nbsp;</p><p>Based on the results of population pharmacokinetic analysis, females have 24% lower weight adjusted clearance of liraglutide compared to males. Based on the exposure response data, no dose adjustment is necessary based on gender.</p><p>&nbsp;</p><p><em><u>Ethnic origin</u></em></p><p><em>&nbsp;</em></p><p>Ethnic origin had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results of population pharmacokinetic analysis which included overweight and obese patients of White, Black, Asian and Hispanic/non-Hispanic groups.</p><p>&nbsp;</p><p><em><u>Body weight</u></em></p><p><em>&nbsp;</em></p><p>The exposure of liraglutide decreases with an increase in baseline body weight. The 3.0 mg daily dose of liraglutide provided adequate systemic exposures over the body weight range of 60&ndash;234 kg evaluated for exposure response in the clinical trials. Liraglutide exposure was not studied in patients with body weight &gt;234 kg.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p><em>&nbsp;</em></p><p>The pharmacokinetics of liraglutide was evaluated in patients with varying degree of hepatic impairment in a single-dose trial (0.75 mg). Liraglutide exposure was decreased by 13&ndash;23% in patients with mild to moderate hepatic impairment compared to healthy subjects. Exposure was significantly lower (44%) in patients with severe hepatic impairment (Child Pugh score &gt;9).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p><em>&nbsp;</em></p><p>Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function in a single-dose trial (0.75 mg). Liraglutide exposure was lowered by 33%, 14%, 27% and 26%, respectively, in patients with mild (creatinine clearance, CrCl 50&ndash;80 ml/min), moderate (CrCl 30&ndash;50 ml/min) and severe (CrCl &lt;30 ml/min) renal impairment and in end-stage renal disease requiring dialysis.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em>&nbsp;</em></p><p>Pharmacokinetic properties for liraglutide 3.0 mg were assessed in clinical studies for adolescent patients with obesity aged 12 to less than 18 years (134 patients, body weight 62-178 kg). The liraglutide exposure in adolescents (age 12 to less than 18 years) was similar to that in adults with obesity.</p><p>&nbsp;</p><p>Pharmacokinetic properties were also assessed in a clinical pharmacology study in the paediatric population with obesity aged 7-11 years (13 patients, body weight 54-87 kg) respectively.</p><p>Exposure associated with 3.0 mg liraglutide was found to be comparable between the children aged 7 to 11, adolescents and adult patients, after correction for body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity or genotoxicity.</p><p>&nbsp;</p><p>Non-lethal thyroid C-cell tumours were seen in two-year carcinogenicity studies in rats and mice. In rats, a no observed adverse effect level (NOAEL) was not observed. These tumours were not seen in monkeys treated for 20 months. These findings in rodents are caused by a non-genotoxic, specific GLP-1 receptor-mediated mechanism to which rodents are particularly sensitive. The relevance for humans is likely to be low but cannot be completely excluded. No other treatment-related tumours have been found.</p><p>&nbsp;</p><p>Animal studies did not indicate direct harmful effects with respect to fertility but slightly increased early embryonic deaths at the highest dose. Dosing with liraglutide during mid-gestation caused a reduction in maternal weight and foetal growth with equivocal effects on ribs in rats and skeletal variation in the rabbit. Neonatal growth was reduced in rats while exposed to liraglutide and persisted in the post-weaning period in the high dose group. It is unknown whether the reduced pup growth is caused by reduced pup milk intake due to a direct GLP-1 effect or reduced maternal milk production due to decreased caloric intake.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium phosphate dihydrate</p><p>Propylene glycol</p><p>Phenol</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Substances added to Saxenda may cause degradation of liraglutide. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months

After first use: 1 month

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze.</p><p>Store away from the freezer compartment.</p><p>&nbsp;</p><p><em>After first use: </em>Store below 30&deg;C or store in a refrigerator (2&deg;C&ndash;8&deg;C).</p><p>Keep the cap on the pen in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartridge (type 1 glass) with a plunger (bromobutyl) and a laminate rubber sheet (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polyacetal, polycarbonate and acrylonitrile butadiene styrene.</p><p>&nbsp;</p><p>Each pen contains 3 ml solution and is able to deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and</p><p>3.0 mg.</p><p>&nbsp;</p><p>Pack sizes of 1, 3 or 5 pre-filled pens. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution should not be used if it does not appear clear and colourless or almost colourless.</p><p>&nbsp;</p><p>Saxenda should not be used if it has been frozen.</p><p>&nbsp;</p><p>The pen is designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm and as thin as 32G.</p><p>&nbsp;</p><p>Needles are not included.</p><p>&nbsp;</p><p>The patient should be advised to discard the injection needle after each injection and store the pen without an injection needle attached. This prevents contamination, infection and leakage. It also ensures that the dosing is accurate.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S 
Novo Allé
DK-2880 Bagsværd 
Denmark
Saxenda®, NovoFine® and NovoTwist® are trademarks owned by Novo Nordisk A/S, Denmark.

© 2025
Novo Nordisk A/S


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>